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Abbreviations 
 
Abbreviation Full Form 
Ist Gen. AdV First generation adenoviral vector 
IInd Gen. AdV Second generation adenoviral vectors 
Ad2 Human Adenovirus Serotype 2 
Ad5 Human Adenovirus Serotype 5 
Ad12 Human Adenovirus Serotype 12 
AdV Adenoviral vector 
AAV Adeno Associated Virus 
bp Base pairs 
CIP Calf intestinal phosphatase 
Chr Chromosome 
DNA Deoxyribonucleic acid 
ds Double stranded 
DSB Double stranded breaks 
DBP DNA binding protein 
EDTA Ethylenediaminotetraacetic acid 
FAH Fumarylacetoacetate hydrolase 
Fah+ve Fah positive 
Fah-ve Fah negative 
FAA Fumarylacetoacetate 
FCS Fetal calf serum 
HC-Ad vector High capacity adenoviral vector 
HR Homologous recombination 
ITR Inverted terminal repeat of the adenoviral genome 
i.u. Infectious Units 
Kbp Kilo base pairs 
LITR Left ITR of the adenoviral genome 
moi Multiplicity of infection 
NHEJ Non Homologous end joining 
dNTPs  Deoxribonucleotides 
OD Optical density 
p.f.u. Plaque forming units 
PCR Polymerase chain reaction 
pTP Pre terminal protein 
RITR Right ITR of the adenoviral genome 
RV Retro virus 
SDS Sodium dodedcyl sulphate 
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ssDNA Single stranded DNA 
TBS Tris buffered saline 
TP Terminal Protein 
Tris Tris-(hydroxylmethyl)aminomethane 
wt Wild type 
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I Introduction 
I.1 Scope of the work 
“Nothing in life is to be feared; it is only to be understood.” So wrote Prof. Maria 
Sklodowska-Curie in her Diary (Caporale, 2002).  Viruses are greatly feared as 
harbingers of death, with fears that influenza pandemic may cause hundred thousand 
deaths in an outbreak in the USA alone (Lee & Krilov, 2005), and had claimed 20- 40 
million human lives in the past (Perez et al., 2005). Like the impartial death that 
ensnares both kings and the common people, referred to in the famous poem “Death 
the Leveller” by James Shirley (Quiller-Couch, 1919), viruses have often been the 
bane of humans, time and again in the course of our history, have been accused of 
taking millions of paupers and princes, like King Rameses V in 1157 BC, to the grave 
(Mahalingam et al., 2004).  The recent threats of terrorists who may use biological 
warfare as means to achieve their ends, have only added more fuel to these fears 
(Agarwal et al., 2004). However, the idea that these agents can be used for beneficial 
purposes to help humanity has not escaped the notice of science and that has been put 
into action. The fact remains that viruses can also be used for therapeutic purposes for 
humankind and so far offers the best gene delivery system to treat acquired and 
inherited genetic disorders (Verma & Weitzman, 2005). 
Gene therapy, which has been labelled as the “twenty first century medicine”, seems 
to be ideal for the treatment of inherited and acquired diseases.  The fundamental idea 
of gene therapy is to introduce to the target diseased cells a fragment of genetic 
material that will at least slow down the progression of the disease or better still cure 
it outright (Verma & Weitzman, 2005). To deliver the genetic material to the target 
cells, gene transfer systems have been developed that can be classified as non-viral or 
viral gene delivery systems (Kootstra & Verma, 2003).  Non-viral methods used in 
gene therapy include liposomes (Stern et al., 2003), nano particles (Yamada et al., 
2003), plasmid DNA (Liu et al., 1999), chimeric RNA:DNA oligonucleotides (Kren 
et al., 2002) and transposable elements (Montini et al., 2002) [reviewed in (Glover et 
al., 2005, Griesenbach et al., 2004, Li & Huang, 2000)].    
Viral gene delivery systems (except in the case of suicide gene delivery (Campbell & 
Gromeier, 2005) use replication deficient viral vectors, where part or the complete 
coding region of the viral genome is replaced by the genetic material of the 
therapeutic gene.  The cis-acting regulatory sequences essential for the packaging of 
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the vector genomes and, in certain viruses, responsible for the integration into the 
host, are left intact. Non-replicating viral vectors are produced when the viral vector is 
introduced into a producer cell, which by itself, or by the aid of another system, is 
able to provide the viral structural proteins essential for the growth. Currently, the 
viral vectors used for gene therapy are based on retrovirus, adeno-associated virus, 
herpes simplex virus type-1 and adenovirus [reviewed in (Kootstra & Verma, 2003)]. 
Gene therapy was first used in humans subjects in 1989 (Rosenberg et al., 1990) and 
had its first taste of success in the pioneering experiments in 1992 in which two girls 
suffering from a from a type of SCID caused by a deficiency in the enzyme adenosine 
deaminase (ADA) were treated successfully (Anderson, 1992). The first subject used 
in the trial has maintained a circulating level of 20 to 25% gene-corrected T cells and 
a normal life-style with amelioration of her disease symptoms (Anderson, 2000). 
Further successes have been observed in the treatment of a small number of 
individuals with other diseases and clinical trials are going on [reviewed in (Edelstein 
et al., 2004, Selkirk, 2004)].  However, leukaemia induction was observed in an 
animal model of retroviral gene marking following the retroviral vector integration 
into the murine gene ecotropic viral integration site-1 (Evi 1) (Li et al., 2002). Gene 
therapy received a setback at the death of an ornithine transcarbamylase (OTC) 
deficient human subject during the clinical trials (Raper et al., 2003).  The risks of 
insertional mutagenesis were put into the spotlight during the SCID trials conducted 
in France (Hacein-Bey-Abina et al., 2003a), (Fischer et al., 2004) (Hacein-Bey-Abina 
et al., 2003b), (Woods et al., 2003). The recent work on viral vectors seems to suggest 
that an integration pattern exists even in the integration of viruses that were 
previously thought to integrate very randomly into the genome (Bushman, 2003) 
(Mitchell et al., 2004). 
The work done on Adenoviruses and adenoviral vectors suggested that the 
Adenoviruses remain as episomal DNA, albeit with rare integration events which 
were observed since the late 1960s (Doerfler, 1968), (Doerfler, 1970), (Doerfler et al., 
1975), (Doerfler et al., 1989), (Knoblauch et al., 1996), (Muller et al., 2001), 
(McDongall et al., 1975), (Sambrook et al., 1975), (Harui et al., 1999).  In background 
of the recent developments during gene therapy trials, it is imperative that a thorough 
study of the integration patterns of high capacity adenoviral vectors (HC-AdV) be 
carried out before they could be safely used for gene therapy.  In particular, the 
integration of HC-AdV into the genome in vitro and in vivo has to be characterised to 
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allow a prediction of potential insertional mutagenesis of HC-AdV when applied in 
clinical gene therapy trials.  This evaluation of the biosafety of the HC-AdV was the 
aim of the work presented in this thesis.  
 
I.2 Adenovirus  
I.2.1 Adenovirus classification 
Adenoviruses were first isolated from surgically removed adenoidal tissue while 
establishing tissue culture lines and during the investigations into the causative agent 
of respiratory illnesses among military recruits (Rowe et al., 1953),  (Hilleman & 
Werner, 1954), (Huebner et al., 1954).  Adenoviruses are also responsible for 
epidemic keratoconjunctivitis, acute haemorrhagic cystitis and gastroenteritis 
(Garnoff A, 1999).  The Adenoviridae family of viruses are comprised of the genus 
Aviadenovirus, Mastadenovirus, Atadenovirus, Siadenovirus and possibly a yet 
unnamed genus isolated from fish (Davison et al., 2003, Kovacs et al., 2003). Based 
on the resistance to neutralisation by antisera to other known adenovirus serotypes 
and recently on the DNA sequence data, 51 human adenoviral serotypes have been 
identified (Verma & Weitzman, 2005).  Based on their ability to agglutinate red blood 
cells and the resistance to neutralisation to antisera, these serotypes are categorized 
into 6 subgroups (Davison et al., 2003, Kootstra & Verma, 2003) (See Table 1). 
Serotypes 5 and 2 of subgroup C Adenoviruses have been used mainly as the basis for 
the generation of gene transfer vectors. 
 
Species Serotype Haemagglutination groups 
A 12, 18, 31 IV (no or little agglutination) 
B 3, 7, 11, 14, 16, 21, 34, 
35 
I (complete agglutination of monkey erythrocytes) 
C 1, 2, 5, 6 III  (Partial agglutination of rat erythrocytes) 
D 8, 9, 10, 13, 15, 17, 19, 
20, 22-30, 32, 33, 36-
39, 42-49 
II (Complete agglutination of rat erythrocytes) 
E 4 III 
F 40, 41 III 
 
Table 1. The classification of Adenoviruses [based on (Davison et al., 2003, Shenk, 2000)] 
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I.2.2 Adenovirus structure 
Adenovirus is a double stranded DNA virus. The nonenveloped icosahedrally shaped 
virion has 20 triangular facets and 12 vertices and is 60-90 nm in diameter comprising 
of an inner DNA-protein core complex surrounded by an outer protein shell, the 
capsid, which is made up of 240 hexons, 12 pentameric penton bases and 12 trimeric 
fiber  proteins.   
Fig. 1. Structure of Adenovirus obtained from (Volpers & Kochanek, 2004) 
 
Each of the triangular facets is composed of 12 copies of the hexon trimer.  The 
trimeric hexon (polypeptide II) is the most abundant of the structural proteins and 
makes up 63% of the total protein mass (Burnett, 1985, van Oostrum & Burnett, 
1985).  The facets are rounded to bring hexons from adjoining facets into close 
contact at the edges.  The capsid is sealed at each of the 12 virion vertices by the 
Penton complex, composed of the pentameric Penton base (polypeptide III) and the 
trimeric fiber proteins.  The Penton base has a 30- Å diameter filled by the fiber 
protein.  The monomeric polypeptide IIIa acts as a rivet to stabilize the interface 
between two adjacent capsid facets.  The hexameric Polypeptide VI acts as a 
cementing protein that anchors the five peripentonal hexons and connects the capsid 
to the core (Stewart & Burnett, 1995).  It is also a cofactor for the adenovirus 
protease.  Polypeptide VIII is present inside the capsid along the edges where it might 
act as a “measuring rod” to determine the size of the virion.  The trimeric Polypeptide 
IX acts as a cement to hold the central nine hexons in each facet together as a unit.  
The viral genome, composed of a linear double stranded DNA, 30-40 kb long, and 4 
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virus-coded proteins all together comprise the core.  The function of the Polypeptide 
X (μ protein) is yet to be elucidated.  The major core protein, Polypeptide VII acts as 
a histone-like center around which the viral DNA is wrapped.  Polypeptide V binds to 
the penton base and acts as a bridge between the core and the capsid.  The terminal 
protein, which is covalently attached to the ends of the viral DNA, is involved in the 
attachment of the viral genome to the nuclear matrix and acts as the primer for DNA 
replication (See Fig. 1). Ad protease, a cysteine endopeptidase that is involved in the 
maturation of the viral particle, is also present in the virions [reviewed by (McConnell 
& Imperiale, 2004, Nicklin et al., 2005, Rux & Burnett, 2004, San Martin, 2003, 
Shenk, 1995, Volpers & Kochanek, 2004)].  
 
I.2.3 Adenovirus life cycle 
The Ad penton and fiber capsid proteins play an important role in Ad infection.  The 
carboxy terminal part of the fiber folds into a knob that contains a reception-binding 
region and a trimerization domain (Henry et al., 1994).  The coxsackievirus-
adenovirus receptor (CAR) cell surface protein binds with high affinity to the fiber 
protein (Bergelson et al., 1997).  CAR might act as a pathfinder protein during 
embryogenesis directing the organ formation, and also in the formation of cell 
aggregates and in cell adhesion (Fechner et al., 2003), (Noutsias et al., 2001).  The 
permissivity of various cell lines to adenovirus may differ and many factors such as 
the expression of CAR may be responsible for this (Carson et al., 1999, Hidaka et al., 
1999, Kibbe et al., 2000, Leon et al., 1998).  CAR may not be the only receptor 
recognized by the Ad fiber.  The expression levels of other molecules such as heparin 
sulphate proteoglycans (Dechecchi et al., 2000), MHC class I (Hong et al., 1997), the 
αv integrins (Wickham et al., 1993), the actin cytoskeleton (Patterson & Russell, 
1983), phosphatidylinositol –3-OH kinase (Li et al., 1998b), CD46 (Segerman et al., 
2003), the Rho family GTPases (Li et al., 1998a) might also play a part in the 
permissivity of the individual cell lines to Adenovirus.   
  Following the docking of the Adenovirus to the cell membrane, the penton proteins 
bind to αvβ3 and αvβ5 integrins through a Arg-Gly-Asp (RGD) consensus motif 
(Goldman & Wilson, 1995, Karayan et al., 1997, Mathias et al., 1994).  Following 
this, the fiber trimer is released and the penton structure gets altered (Nakano et al., 
2000, Schoehn et al., 1996).  This leads to integrin clustering where up to 5 integrin 
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molecules bind to each homopentamer, and this integrin ligation triggers cytoskeletal 
changes, leading to the local formation of clathrin-coated pits (Chiu et al., 1999).  Ad 
Penton - integrin binding results in the activation of phosphatidylinositol-3-OH kinase 
(PI3K).  PI3K activates Rac and CDC42 GTPases, leading to the polymerization of 
actin and viral endocytosis into the clathrin-coated pits (Lamaze et al., 1997, Li et al., 
1998a).  During this process, all of the fiber proteins get detached.  As the endosome 
matures, the vesicular pH goes down and at pH 6 the virus breaks out of the 
endosome into the cytosol (Greber et al., 1993).  Up to recent times, the mechanism 
by which Ad capsid penetrates the endosomal membrane was not quite clear.  The 
penton was believed to be involved in this process, because at low pH the 
conformation of the protein changes, exposing hydrophobic regions that bind 
nonionic detergents (Seth et al., 1985). The Ad protease too was thought to have been 
responsbile; for though it is inactivated after capsid release from the cell, it is 
reactivated after entry into acidified endosomes (Greber, 1998).  Recent work has 
suggested another model.  According to this, partial disassembly of the capsid is 
triggered by the endosome acidification.  The capsid disassembly liberates 
peripentonal hexons, penton base, IIIa and VI proteins from the structure.  The free 
protein VI associates with the endosomal membrane and ruptures it (Wiethoff et al., 
2005). 
Following the escape from the endosome, Ad capsids are trafficked to the cell nucleus 
periphery via the microtubules by a signaling pathways mediated by the cAMP-
dependent PKA.  The integrin binding activates PKA and the intracellular cAMP 
levels regulate microtubule dependent vesicle transport towards the nucleus (Reese & 
Haimo, 2000, Reilein et al., 1998).  The Penton might still be involved in this too, 
since the fiber-binding site, which matches the sorting signal found in trafficking 
proteins, the dileucine motif, might bind to clathrin-associated adaptor protein 
complexes that mediate endocytic and secretory pathways (Heilker et al., 1999, Hong 
& Boulanger, 1995, Kirchhausen, 1999).  At the nuclear pore complex, the Ad capsids 
are dismantled and the internal protein VI is degraded.  The nuclear pore complex 
glycoproteins themselves might also be involved in the dismantling of the capsid 
(Greber et al., 1997, Greber et al., 1996).  Once this happens, the viral DNA and 
protein VII pass through the nuclear pore into the nucleus (Greber et al., 1993), but 
the method by which this takes places is still unclear [reviewed by (Medina-Kauwe, 
2003, Nemerow, 2002)].  On reaching the nucleus, the Adenovirus manipulates the 
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cell into i. entering the S phase of the cell cycle, so as to enable the optimal viral DNA 
replication; ii. shutting down the anti-viral host response; iii. using the cellular 
proteins together with the viral gene products to carry out the viral DNA replication. 
The Ad genome is a linear double stranded DNA genome of 30 to 40 kb.  At each end 
of the genome are the ≅120 bp inverted terminal repeats (ITR), the first 50 bps of 
which contain the replication origins.  At each 5’ terminus of the genome, the terminal 
protein is covalently attached.  At the left end (the 5’ end in the left to right 
orientation) of the genome, a cis-acting packaging element that enables the polar 
encapsidation of viral genome into capsids is present. The Ad genome contains one 
immediate- early region, the E1A region, four early transcription regions, the E1B, the 
E2, the E3 and the E4 regions, two delayed early regions, the IX and the IVa2 regions 
and one late region that encodes five families of mRNA, the L1, the L2, the L3, the 
L4 and the L5 families (see Table 2).  The early regions have their own individual 
promoters, and the late transcripts are initiated from the major late promoter.  The 
genome is transcribed from both ends.  A ≅ 200-nt leader sequence (tripartite leader), 
that directs efficient specific translation of Ad late mRNAs independent of the host 
cell initiation factor eIF4F, is present in the 5’ ends of all late mRNAs (see Fig. 2). 
 
ITR ψ
E1A  E1B pIX   MLP  L1    L2     L3               L4    E3     L5
Iva2     E2b                         E2a                             E4
ITR
 
Fig. 2: Scheme of the transcription of the Ad genome [adapted from (Evans, 2002)] 
 
Region Function Action 
E1A Transactivates 
 
Modulates host cell 
gene expression and 
proliferation 
Activates transcription from other early promoter regions. 
Interacts with i. Retinoblastoma tumour suppressor pRb and related 
family members ii. Sequesters p300, the transcriptional coactivator for 
p53- dependent gene expression iii. transcription factors such as TATA 
binding protein (TBP), ATF family and the Srb mediator complex iv. 
E2F, resulting in the promotion of G1 and S phase progression  
E1B Inhibits apoptosis 
 
 
Increases viral 
protein production 
Inhibits p53-induced transcription. E1B19K is a functional homolog of 
Bcl-2 and also blocks the oligomerization of death-inducing 
complexes. 
Complexes with E4OFR6 and selectively stabilizes and transports viral 
mRNA, while inhibiting host cell mRNA transport. 
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E2 Ad DNA replication Encodes Ad DNA polymerase (Ad Pol), preterminal protein (pTP) and 
DNA binding protein (DBP). 
E3 Counteracts host 
immune response 
 
Cell death 
E3gp19K tethers MHC I to the Endoplasmic reticulum. 
E3 RID and 14.7K clears Fas and TNFR1 and other proteins involved 
in the apoptotic pathway. 
E3 11.6K promotes cell death later in the life cycle 
E4 Viral DNA 
replication, viral 
mRNA transport and 
splicing, regulation of 
apoptosis. 
E4 ORF 6 inhibits p53 and targets it for degradation and together with 
E4ORF3 inhibits DNA-protein kinase, blocking the formation of viral 
DNA concatomers. 
E4 ORF4 regulates mRNA splicing 
E4 ORF6/7 enhances production of E2 products. 
IV a Packaging IVa2 product is responsible for the recognition of the packaging signal. 
L1-5 Structural proteins. 
Host mRNA 
translation inhibition 
Assembly of viral 
particles 
 
 
100K late protein binds to eIF4, and shuts off translation of any mRNA 
lacking the tripartite leader sequence. 
 
 
Table 2:  Ad viral gene products and their function  [reviewed by (Evans, 2002, Shenk, 2000)]. 
 
In the Ad life cycle, the Ad DNA replication starts after the expression of the Ad early 
genes.  Ad Pol, pTP, and DBP are essential for Ad DNA synthesis. The cellular 
proteins NFI/CTF, NFII and NFIII/Oct-1 increase the replication rate (de Jong & van 
der Vliet, 1999, Hay et al., 1995, Van der Vliet, 1995).  The minimal replication 
origin (core origin) is located in the terminal 18 bp and contains an essential triplet 
repeat at the ends (5’-CATCAT in Ad5).  The next 32 bps constitute the auxiliary 
replication origin region and contain binding sites for NFI/CTF and NFIII/Oct-1.  
Taken together, the first 50 bps constitute the origin of Ad DNA replication. 
The DNA replication can be divided into two phases.  In the first phase, DNA 
synthesis starts at either termini and proceeds to the corresponding end of the genome, 
producing a duplex consisting of a parental and daughter strand, and one single strand 
of DNA.  In the second phase, the complementary strand to the single strand is 
produced.   
The pre-initiation complex consisting of Ad Pol-pTP, DBP, NFI/CTF and Oct-1 form 
at the origin, and the DNA is bound by the DBP.  NFI/CTF and Oct-1 interacts with 
the auxiliary region (enhanced by DBP) and stabilizes the interaction of the Ad Pol-
pTP heterodimer complex with the core origin (Mul et al., 1990, Stuiver & van der 
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Vliet, 1990).  The TP, covalently bound to the genome, enhances this complex.  The 
first dCTP is covalently coupled to the Ser-580 residue of the pTP by the pol, forming 
a pTP-dCMP complex essential for the protein priming.  The conserved Asp-578 and 
Asp-582 are essential to the maintenance of the optimally functioning active site of 
the pol leading to effective initiation (Mysiak et al., 2004).  The origin is unwound by 
the DBP and the Ad Pol-pTP complex forms a pTP trinucleotide intermediate. The 
complementary sequence from bp 4-6 (3’GTA) is used to synthesize the pTP-CAT.  
The NFI/CTF then unbinds from the binding site and the pTP-CAT moves back from 
position 4-6 and binds to the 1-3 GTA.  Ad Pol unbinds from the pTP and the 
elongation starts.  The replication is carried out by the Ad Pol, and the DBP not only 
unwinds the DNA but also binds to ssDNA to protect it from nucleases.  The single 
stranded DNA is used as the template at the next stage.  The left and right ITRs anneal 
to form a loop structure (pan handle) that appears as the terminus of the actual 
genome and contains the covalently linked TP and the cycle continues [reviewed in 
(Evans, 2002)]. 
A cis-acting packaging domain located between ≅ 200 and 400 bp, containing 7 
redundant elements (the A repeats), most of which share a bipartite consensus motif 
5’TTTGN8CG-‘3, packs the Ad DNA in a polar manner from left to right into the 
virus particles (Grable & Hearing, 1990, Grable & Hearing, 1992, Schmid & Hearing, 
1995, Schmid & Hearing, 1997).  Trans acting packaging components too have been 
reported (Schmid & Hearing, 1998).  The empty capsid (light particle) is the first 
stage of the assembly.  The viral DNA and core proteins are packaged into this as they 
mature into heavy intermediate particles.  The protease cleaves numerous proteins 
within the particle and it matures into the infectious virus (Weber, 1995).  The E3-
11K protein, which is synthesized only in low amounts during the early stage from the 
E3 promoter, is expressed in large amounts from the Ad MLP.  The Adenovirus Death 
Protein (ADP) kills and lyses the cell (Doronin et al., 2003, Tollefson et al., 1996).  
The Ad virions are liberated and the life cycle is completed [reviewed in (Evans, 
2002, Shenk, 2000)]. 
 
I.2.4 Gene transfer vectors based on adenovirus 
E1A gene products are not only essential for the expression of the early and late viral 
genes, but also encode the oncogenic transforming functions of the virus and so the 
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first successful adenovirus based vectors for gene therapy had deletions in the E1 
gene.  The E1 gene region was replaced by the transgene and the vector could not 
replicate in its absence (Fig. 3). The E1 functions necessary for the replication were 
provided in trans by cell lines like the 293 cells which contain the left end (bp 1 to 
4344) of the Ad5 genome including the left ITR, packaging signal sequences (Ψ), 
E1A, E1B, IX and a part of the IVa2 regions  (Graham et al., 1977, Morsy & Caskey, 
1999, Rosenfeld et al., 1991, Stratford-Perricaudet et al., 1990, Zabner et al., 1993).  
The sheared Ad5 DNA had, after the transfection, integrated into Chr 19q13.2 into the 
pregnancy specific β-1 glycoprotein 4 (PSG 4 gene) (Louis et al., 1997).  In this 
method, up to 5 kb of transgene could be accommodated in the first generation 
adenoviral vectors (Ist gen AdV) (Bett et al., 1993).  Many of the Ist gen AdV had 
additional deletions in the E3 region and up to 8 kb of foreign DNA can be 
accommodated in these vectors [reviewed by (Shenk, 1995)].  The vector plasmid 
with the deletions in the genome is linearised and transfected into the cell line and an 
agarose overlay is plated over the monolayer.  The successfully generated AdV 
appear as plaques in the plate, which are picked and further seeded and isolated by 
another round of plaque purification.  The AdV is then grown on a larger number of 
cells.  When the cells display a cytopathic effect (CPE), they are collected and 
disrupted by repeated freezing and thawing and the vectors purified by 
ultracentrifugation on a Cesium Chloride (CsCl) density gradient (for the detailed 
protocol, see the Materials and Methods section). These vectors could be produced in 
titers up to 1013 vector particles/ml and can transduce proliferating and quiescent cells 
[reviewed by (Volpers & Kochanek, 2004)].  Nevertheless, Ist gen AdV are not the 
ideal vector for long term gene therapy for inherited diseases.  Recombinant 
replication competent Adenovirus (RCA) can arise as a result of the recombination 
between the adenoviral sequences in the cell line and homologous sequences in the 
vector (Lochmuller et al., 1994).  Furthermore, it was observed that in vitro, the early 
and late AdV genes were expressed, albeit in a low level, from the Ist gen AdV (Christ 
et al., 1997).  Some of the late viral proteins themselves are toxic, and in addition, the 
expression of the viral proteins results in the stimulation of a cellular immune 
response in vivo, leading to the transduced cells being cleared from the body (Yang et 
al., 1995, Yang et al., 1994).  Inflammation reaction to the Ad was observed in in vivo 
experiments involving mice and baboons (Schiedner et al., 1998, Simon et al., 1993, 
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Yang et al., 1994).  Therefore, only a transient transgene expression was observed in 
immuno-competent test animals following gene transfer with Ist gen AdV.  The 
second generation Adenoviral vectors (IInd gen AdV) were developed to 
circumnavigate the immune response generated by the Ist gen AdV.  Deletions in the 
E2 and/or E4 regions were introduced and the functions were provided in trans by cell 
lines stably expressing DBP, pTP, Ad Pol or all the three (Armentano et al., 1995, 
Engelhardt et al., 1994, Gao et al., 1996, Wang et al., 1997).   
 
 
Fig. 3: Schematic representation of the different types of adenoviral vectors used for gene transfer. 
Owing to the ambiguous nature of the efficiency of the IInd gen AdV (McConnell & 
Imperiale, 2004, Volpers & Kochanek, 2004), adenoviral vectors with larger deletions 
in the genome were developed (Clemens et al., 1996, Fisher et al., 1996, Kochanek et 
al., 1996, Mitani et al., 1995a) (see Fig. 3).  The term high capacity adenoviral vectors 
(HC-AdV) is used in this study to describe these vectors.  HC-AdVs contain only the 
cis viral elements essential for propagation and packaging, the Ad ITRS and the Ψ 
signal, with a transgene carrying capacity between 26 to 36 kb.  The necessary viral 
proteins, apart from E1, are provided in trans by a replication deficient Ist gen AdV 
helper Virus (HV).  The Ψ of the helper virus is flanked by two lox P sites (Floxed) 
[reviewed by (Branda & Dymecki, 2004)] and when it is  
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HC-AdV plasmid Ψ      Helper virusΨ
Lox P    Lox P
Transfection Infection
293 Cre cellCre
HC-AdV DNA
Helper virus DNA
Cells are freeze-thawed
 to release the virus
Virus particles
 run on a CsCl 
gradient
HC-AdV
Helper virus
 
Fig. 4 Schematic diagram of the production of HC-AdV 
 
transduced into a cell line that expresses both E1 and Cre like 293 Cre, then, although 
all of the viral proteins are expressed, the Cre mediated excision of the Ψ prevents the 
helper virus itself  from getting packaged into the virions.  For production, the HC-
AdV vector plasmid is linearised and transfected into the cell line, which is then 
infected with the HV.  The cells are collected when they start exhibiting the CPE and 
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the virus is harvested and used to transduce a larger amount of cells, which are co-
infected with the helper virus.  Thus, through successive rounds of transduction, the 
vector is serially amplified and can be finally isolated from any helper virus 
contamination in the preparation by ultracentrifugation in a CsCl density gradient (for 
the detailed protocol, see Materials and Methods) (see Fig. 4).  
Adenoviral vectors have been used in gene therapy trials involving the liver, muscle, 
brain, lungs and eye [reviewed by (Alba et al., 2005, Kochanek, 1999, Morsy & 
Caskey, 1999, Palmer & Ng, 2005, Volpers & Kochanek, 2004)].  As of date (Sept 
2006), of all the viral vector systems, the largest number of clinical trials are carried 
out using vectors based on Adenovirus (n = 305), 26 % of the total number of clinical 
trials worldwide (visit http://www.wiley.co.uk/genmed/clinical/ for more details).  
The advantages that HC-AdV offers to gene therapy of inherited diseases are evident.  
Transgenes up to 37 kb in size can be accommodated in the vector in comparison to 
the 8 kb limit in the size of the transgene that can be delivered using the Ist gen AdV.  
In in vivo experiments, in contrast to the effects observed when Ist gen AdV were 
used, the HC-AdV did not elicit the immune response directed against the production 
of the viral proteins in the cell. Furthermore, the acute and chronic hepatotoxicity, 
which was the hallmark of the in vivo experiments conducted with Ist Gen AdV, was 
absent following injection with HC-AdV (Kim et al., 2001, Morral et al., 1998, 
O'Neal et al., 2000, Schiedner et al., 1998).   
However, the toxicity conferred by the incoming Ad capsid itself, cannot be 
overlooked in a gene therapy trial.  The innate immunity is initiated shortly after 
vector injection, before the viral genes themselves might be expressed, and also even 
when transcriptionally inactive vector had been injected (Muruve et al., 1999, Muruve 
et al., 2004, Zhang et al., 2001).  This was confirmed when baboons were injected 
with HC-AdV. On the injection of 5.6x1012 VP/kg, the immune response subsided 
after 24 hrs, but on the injection of 1.1 x1013 VP/kg, the animal had to be euthanized, 
as a result of the severe toxicity (Brunetti-Pierri et al., 2004).  The amount used in the 
ornithine transcarbamylase (OTC) gene therapy trial using IInd Gen AdV, that resulted 
in the death of one of the participants was 6 x1011 VP/kg (Raper et al., 2003). 
As opposed to the short term expression of the transgene following gene therapy with 
Ist gen AdV, experimental animals injected with HC-AdV displayed long term 
expression of the transgene.  Human α-1 antitrypsin (hAAT) was expressed for more 
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than 1 year in baboons (Morral et al., 1999), transgene expression was maintained for 
about 2 years in baboons (Brunetti-Pierri et al., 2006), and Apolipoprotein E (Apo E) 
was expressed for practically the whole life (2.5 years) in ApoE deficient mice (Kim 
et al., 2001) following injections with HC-AdV.  Phenotypical correction was 
demonstrated in the hemophilia B dog model for about 2 years (Brunetti-Pierri et al., 
2005), and for about a year in a mouse model of glycogen storage disease type II 
(Kiang et al., 2006).  A life term correction of hyperbilirubinemia in a rat model, with 
negligible levels of toxicity was also reported (Toietta et al., 2005) and long term 
correction coupled with similar levels of toxicity was observed in the mouse model of 
the disorder (Mian et al., 2004).  These results suffice to demonstrate the promise that 
HC-AdV offer in the field of gene therapy. 
 
I.3 Vector DNA –chromosomal DNA recombination during gene 
transfer with viral vectors 
I.3.1 Recombination and DNA repair mechanism 
The ancient Greek myths spoke of terrible monsters like the Chimera whose body was 
composed of parts of 3 different animals, or the Hydra that had many heads grafted on 
to a single body.  Myths apart, the various methods of recombination and DNA repair 
are present to protect the cellular DNA that gets continuously damaged by external 
sources such as mutagens, ultraviolet rays and internal reactions such as methylation, 
oxidation and hydrolysis. According to the current model, DNA recombination and 
DNA repair are no longer considered as two separate systems but as components of a 
single system that maintains the DNA integrity (Volodin et al., 2005).  
Repair via Homologous Recombination (HR) occurs more frequently in the lower 
forms of life, whereas the repair of DNA by non homologous end joining (NHEJ) 
repair is preferred by the cells of the higher forms of life. It has been proposed that 
two protein family complexes, the Rad52 and Ku compete for the broken ends of the 
DNA and based on the protein that binds first, the repair would take place via HR or 
NEHJ (Van Dyck et al., 1999).  The latest model suggests that in mammals, repair by 
HR involves an array of gene products from the RAD family.  ATM kinase acts as a 
sensor of the broken ends leading to the binding of the MRE11-RAD50-NBS1 (MRN) 
complex to the DNA ends. Single stranded overhangs are obtained by the resection of 
the DNA, either by the MRN complex or replication protein A (RPA). If the double 
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strand breaks (DSB) had occurred in between repeats, and the cell is in G1 phase of 
the cell cycle, then the Single Strand Annealing (SSA) of DNA takes place.  RAD52 
binds the complementary single strands together, and the ssDNA overhangs are 
removed by ERCC1/XPF, resulting in the deletion of the region between the 
complementary ssDNA.  In the case of the classical HR, which occurs when the cell is 
in S or G2 phase of the cell cycle, the RPA are replaced by BRCA2, which in turn, 
recruits RAD51 to the site as the XRCC3/RAD51C complex.  RAD51 binds to 
ssDNA, and crosses over and pairs with the homologous sequences with the aid of 
RAD54.  The break is repaired either by using the intact DNA as a donor or with a 
classical crossing over of the strands. 
Fig. 5: The various DNA repair pathways present in mammalian cells [from (Vasileva & Jessberger, 
2005)} 
However, in mammalian cells, the non mutagenic effects of rate of repair via HR is 
masked by the rate of repair by NHEJ, which occurs predominantly in the G1 phase, 
by a 1000 to 10000 fold (Wurtele et al., 2003).  Inositol 6 Phosphate (IP6) binds to the 
KU70/KU86 complex, which in turn envelopes the end of the DNA, and recruits 
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protein kinase, DNA-activated, catalytic polypeptide PRKDC (DNA-PKCS) which 
bridge the DNA ends.  There is evidence to believe that short homologous sequences 
of 1-4 bps at or near the site of break influence the alignment of the broken ends.  
DNA-PKCS recruits the nuclease Arthemis that processes the DNA ends.  Pol X 
family members Pol µ and Pol λ fills in the small gaps in the DNA generated during 
the alignment and nucleolytic processing of the DNA ends. DNA-PKCS also forms a 
complex with DNA ligase IV/ XRCC4 complex that ligates the broken ends.  
When ds DNA breaks are repaired via HR, no mutations take place in the DNA.  
During SSA, the region between the repeats involved in the repair will be deleted and 
during NHEJ, massive mutations can take place [reviewed by (Haber, 1999, Hefferin 
& Tomkinson, 2005, Helleday, 2003, Jeggo, 1998, O'Driscoll & Jeggo, 2006, Taylor 
& Lehmann, 1998, Valerie & Povirk, 2003, Vasileva & Jessberger, 2005, West, 
2003)] (see Fig. 5). 
 
I.3.2 Recombination between chromosomal and viral/viral vector DNA derived 
from wt Ad and AdVs 
Within just 9 years of the first publication about adenoviruses, it was demonstrated 
that adenoviruses could induce tumour formation in hamsters (Yabe et al., 1962).  Six 
years later, it was proved that adenovirus DNA could integrate into the host genome 
in semi and non permissive cells where the lytic part of the Ad life cycle could not 
take place.  Infact it, along with a paper on SV40 DNA integration published in the 
same year, were the first instances of viral DNA integration into the genome 
(Doerfler, 1968, Sambrook et al., 1968).  Ad2 was observed to integrate as simple 
copies or in a rearranged form, where the viral sequences of the junction site could be 
amplified.  The integrations into the genome appeared to have taken place in a 
random manner (Sambrook et al., 1980a, Sambrook et al., 1980b).  It was observed 
that the integrated Ad2 DNA could undergo rearrangements and deletions after 
integration in 8617 rat embryo fibroblasts (Sharp et al., 1974).  In hamster cells, Ad7 
was observed to integrate as multiple (≅25) copies, which had undergone 
rearrangements and fragmentation (Fujinaga et al., 1975).  Deletions were also 
observed in the viral genome in Ad5 and Ad2 infected hamster cells (Vardimon & 
Doerfler, 1981, Visser et al., 1980).  In contrast, Ad12 genome had integrated into 
mouse and hamster genome without the internal deletions (Fanning & Doerfler, 1976, 
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Stabel et al., 1980, Starzinski-Powitz et al., 1982).  Three types of patterns of 
integration of AdV into the genome were proposed.  i. Multiple integrations in 
different locations.  ii. Multiple integrations present in a single site as a tandem, which 
could arise from repeated replication of a single monomer, or integrated directly as a 
multimer.  iii. A single integrated copy that had undergone multiple rounds of 
initiation of DNA replication to form a railroad structure (Sambrook et al., 1975).  
Ad2 and Ad12 were observed to cause chromosomal aberrations in rat and 
mouse/human hybrid cells (McDongall et al., 1975).   
Data on the detailed analysis of Ad integration junction sites in the genome were 
available from the early 1980s.  In the Ad2 transformed rat embryo brain line F4, the 
virus had integrated with deletion of the last 2 (5’-CA) bps of the viral right terminus.  
In the Ad12 induced hamster tumour line CLAC3, where 4-5 viral genomic molecules 
had integrated into the cellular genome, a 45 bp deletion of the viral left terminus was 
observed.  In the Ad2 transformed hamster cell line HE5, two copies of the viral 
genome were present.  No mutations were introduced in the cellular sequence, but 10 
and 8 bps deletions were observed in the left and right termini respectively.  The site 
of linkage between the two Ad2 DNA fragments was analysed, a novel dinucleotide 
was observed to be present between the two recombining molecules.  The Ad12 
induced tumour cell line CLAC1 had 10-13 copies of integrated viral genomes and on 
analysis of a left terminus, the first 174 bps of the terminus were absent.  A much 
larger deletion of 572 bps was observed in the Ad5-DNA transformed hamster cell 
line BHK268-C31.  A direct linkage of the 108th bp of the right terminus and the 63rd 
bp of the left terminus was seen in site of linkage between the left and right termini of 
the Ad5 DNA transformed rat line 5RK20.  In the hamster based Ad12- induced 
tumour T1111(2), which had 10-11 copies of the Ad genome, a deletion of the 
terminal 64 bps of the LITR was observed.  The 135 bps of cellular DNA was 
sandwiched by another left terminus, with a deletion of 1296 bps, suggesting that 
complicated rearrangements of sequences can also take place during the integration of 
Ad DNA into the cellular genome.  A deletion of the first 9 bps was observed in the 
left terminus sequence obtained from the mouse based Ad12 tumour CBA-12-1-T, 
which had 20-30 adenovirus genomes.  Limited homology (patchy 
homology/microhomology) extending up to 18 bps between the virus and cellular 
DNA was observed in almost all cases.  The analysis of all of these cell lines and 
tumours demonstrated that the Ad integrates through the termini, and that deletions in 
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the termini do occur during the process, which seems to be influenced by the limited 
homology between the cellular and viral DNAs [reviewed by (Doerfler et al., 1984)].  
The data presented in that paper agreed with those already published about the 
integrations sites of the cell-Ad2 DNA junction where rearrangements of the viral 
DNA was observed (Sambrook et al., 1980a).  The integrations could occur without 
modifying the cellular DNA (Gahlmann & Doerfler, 1983) or with deletions in the 
cellular genome of up to 1.6 kb (Schulz & Doerfler, 1984).  Sequence data from the 
“os2” RITR of the Ad in the cell line T637 showed that the terminus was present with 
a deletion of the first 2 bps and the first 6 bps of the junction were the same in both 
the cellular DNA and the Ad terminus.  In the “os3” junction of the same clone, the 
LITR with a deletion of 7 bps was joined to a RITR with a 14bp deletion via cellular 
DNA bridge suggesting that Ad12 genome can integrate in a non true tandem manner, 
but interspersed with cellular DNA.  In the Ad12 induced tumor T191, the left 
terminus of one Ad genome recombined with the left terminus of another with cellular 
and internal Ad12 DNA in between (Knoblauch et al., 1996).  In a cell free system, 
using a fragment of Ad12, it was demonstrated that the recombination took place 
between two short stretches of homology, with the first partner being at or near the 
site of recombination and the second partner could be remote from the site of the first 
cross over in a recombination that may not be conservative (Wronka et al., 2002).   
The rates of transformation of rat CREF cells by wt Ad5 and of the temperature 
sensitive mutant H5ts125 were calculated to be around 2x10-4 for wt Ad and 2 x10-3 
for the mutant.  Almost all the isolated clones of the cell line had the complete Ad5 
genome integrated in the cellular genome (Fisher et al., 1982).  Fowl Adenovirus type 
1 also did not have any specificity towards any particular chromosome in a rat cell 
line during integration into the genome, but nevertheless, integrations were observed 
in regions where genomic rearrangement had taken place.  These mutations might 
have been responsible for the transformation (Ishibashi et al., 1987). 
Some of the cellular sites at or around the junction of integration between the viral 
and the cellular genome were observed to be transcriptionally active (Doerfler et al., 
1984, Schulz et al., 1987), with significant alterations in the patterns of cellular 
methylation.  In certain cases, not only some neighboring genes, but also ones located 
remote from the integration site had alterations in the methylation pattern, which were 
caused by factors other than transgene transcripts from the integrated virus 
(Lichtenberg et al., 1988, Remus et al., 1999), [reviewed by (Hohlweg et al., 2004)].  
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Ad DNA was found to be associated with chromosomal DNA within 2 hrs post 
infection.  When Ad12 DNA covalently linked to the TP was added to the medium, it 
was 20 fold more efficient in reaching the nucleus as apposed to the naked Ad12 
DNA (Schroer et al., 1997).        
To summarize, the wt Ad genome does integrate at a low rate, in a random manner 
(Wronka et al., 2004), through the termini, with deletions occurring in the termini.  
Multiple copies of the virus may be present in the cellular genome, but not necessarily 
in a truly tandem manner. Rearrangements and deletions of the viral and cellular DNA 
too can occur.  Short sequences of homology between the viral and cellular DNA are 
present in and around the site of recombination.  Many of the integrations had taken 
place into transcriptionally active regions of the cellular genome [reviewed by 
(Fechteler et al., 1995)].    
The first study of the rates of integration of a adenoviral vector involved the 
transduction of simian CV1 and Rat2 cells with a Ist Gen AdV carrying a neo-R gene. 
The vector DNA was shown to integrate at rates of 2x10-6 to 8.5x10-5 in Rat2 cells 
and 5x10-5 to 2x10-4 in CV1 cells at mois between 1 to 20 per pfu of virus.  At a 
higher moi of 200, the vector DNA integrated at 4x10-3 and 7.5x10-3 in Rat2 and CV1 
cells, respectively.  The CV1 cells contained single copies of full length viral 
genomes and the Rat2 cells contained also tandemly repeated viral DNA where the 
left and the right termini were joined together (Van Doren et al., 1984).  A Ist Gen 
AdV encoding a β-gal marker gene was found to integrate at rates of 1.5x10-1, when 
ionizing radiation was used, in mouse NIH3, human A549 and primary human cells 
(Zeng et al., 1997). 
Stable integration into the genome into zona free eggs by a Ist Gen, Ad5 based AdV, 
was demonstrated in mice.  Expression of a LacZ gene tagged with a nuclear 
localization signal under the control of a CAG (chicken β-actin and CMV-IE) 
promoter was demonstrated even in the F1 progeny.  Almost the entire vector DNA 
had integrated as single copies, randomly throughout the genome, though the terminal 
fragments at both ends were missing in the integrants (Tsukui et al., 1996).  
Integration by a Ist Gen AdV expressing β-gal, into the genome in vivo, was also 
demonstrated using immunocompromised  B6D2F1 mice transplanted with congenic 
splenocytes and bone marrow cells.  When 2x109 to 1x1010 viral particles were 
injected, transgene expression was observed for over 6 months in colonic epithelial 
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cells, but not in the liver, lung, kidney or spleen (Brown et al., 1997).  When Ist Gen 
AdV was injected with doses of 1x108 to 2x1010 viral particles into 14-15 day’s 
gestation Balb/c mice fetuses, integration was observed at the site of injection and in 
the liver.  Integration was also observed in the lung, bone marrow, and spinal nerves 
(Yang et al., 1999).  The fumarylacetoacetate hydrolase (FAH) knockout mice were 
injected a Ist gen AdV encoding the FAH cDNA at mois of 5x109 pfu, and integration 
of the vector was observed in the liver (Overturf et al., 1997).  In an in vivo study 
using Ist Gen AdV on a transgenic mouse system, the rate of gene targeting via 
homologous recombination was observed to be less than 1/20,000, and not 
significantly different from the controls (Ino et al., 2005). 
When a Chinese hamster ovary (CHO) cell line deficient for the adenine 
phosphoribosyl transferase (aprt) was transduced with a moi of 10 by a Ist Gen AdV, 
gene correction via homologous recombination of the vector into the genome, 
resulting in the regeneration of the APRT phenotype, was observed in the range of  
10-6 to 10-7.  The correction was of a classical replacement type homologous 
recombination with no sequences derived from the viral vector or the Moloney 
Murine Sarcoma Virus (MoMSV) promoter present in the region of correction (Wang 
& Taylor, 1993).  An inserted mutant neo gene in a self replicating extrachromosomal 
plasmid DNA in the mouse cell line C127 was targeted with a Ist gen AdV carrying 
the correct copy.  At a moi of 400, the rate of homologous recombination was as high 
as 8.3x10-4 with respect to the number of cells used. At a moi of 4, the rate of G418 
resistant colony formation was 7.3x10-5.  The gene was corrected in all of the clones; 
however in 25 % of the cases, non homologous recombination was observed outside 
the region of homology.  The rate of homologous recombination with AdV was 3 logs 
higher than that with calcium phosphate transfection and electroporation.  It was 
suggested that a part of the nonhomologous recombination observed might have been 
mediated by homologous recombination between the DNA partners (Fujita et al., 
1995).  The rate of homologous recombination of Ist gen AdV on mouse embryonic 
stem cells at the fgr locus ranged from 1.4x10-6 to 1.2x10-5 at mois of 100 and 1000 
respectively.  The rates of integration ranged from 5.2x10-6 to 2.1x10-4 under the same 
mois.  Each of the recombination event analysed by Southern Blot had only one copy 
of integrated vector.  In 7/12 clones analysed, Ad sequences too were present.  In 
certain experiments, the targeting efficiency (homologous recombination 
rate/integration rate) percentage was up to 40 % (Mitani et al., 1995b).   
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The rates of integration of HC-AdV and Ist Gen AdV into the host genome, analysed 
on the human cell lines HeLa, HT1080, and KB, the simian cell lines CV-1 and Vero 
and the rodent cell lines BHK, CHO and NIH 3T3 with a fusion β-geo marker (fusion 
of β-galactosidase and the neo genes) infected at a moi of 10, were in the range of 10-3 
to 10-5 per cell, depending on the cell line, with slightly higher rates for the HC-AdV. 
In HT1080 cells, the Ist Gen AdV integrated at rates between 3.3 x10-4 to 2.4 x10-3 
and the HC-AdV integrated at rates between 2.9x10-4 to 1.8x10-3.  The rates of 
integration in HeLa cell for the Ist gen AdV ranged from 3x10-5 to 3.1x10-4 and those 
for the HC-AdV ranged from 5.5x10-5 to 9.3x10-4.  In the clones analysed by Southern 
Blot, multiple integrations of the right terminus, and possibly one case of a rearranged 
right terminus, were observed.  These were observed in clones where only one copy 
of transgene was detected.  Interestingly, in a clone (clone 4) where 2 copies of the 
transgene were observed, only one terminus was seen.  No internal deletion was 
observed in the majority of the clones generated via HC-AdV integration, but in one 
(clone 5), rearrangement of the vector was detected (Harui et al., 1999).  
HC-AdV and Ist Gen AdV carrying a neo transgene showed rates of integration of 
1.7x10-4/ cell and 2.6x10-5/cell respectively, in the human glioblastoma cell line U87-
MG when infected at a moi of 0.1.  Integration had taken place randomly with the 
vector integrating as a monomer through the termini.  In 50 % (n=16) of the clones, 
both the termini were present, and in 81 %, the integration had taken place with little 
or no loss of termini sequences.  The HC-AdV contained a 27 kb stuffer DNA from 
the X chromosome and no event of homologous recombination was observed in the 
200 clones analysed (Hillgenberg et al., 2001). 
During the preparation of this thesis, two new papers on the rates of recombination of 
HC-AdV into the genome, have been published.  In the first paper, Ist gen AdV and 
HC-AdVs, carrying varying lengths of hprt stuffer DNA (from 1.7 kb to 18.6 kb) 
were used to transduce male mouse ES cells with a known mutation in the hprt exon 
3.  In the HC-AdV carrying the 18.6 kb hprt stuffer, the rate of homologous 
recombination was 2 x10-4/cell at a moi of 1000.   The rate of random integration was 
in the range of 10-3 to 10-4/cell at mois of 10, 100 and 1000.  Of the 20 clones 
analysed, 3 junction sites from both termini were obtained, the other gave sequences 
from only one of the terminus. 72 % of the integrations took place in non coding 
regions.  Deletions ranging from 1-99 bps in the termini and a case of inversion of the 
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chromosomal DNA were reported.  Limited homologies between the termini and the 
chromosomal DNA and insertions of novel sequences up to 30 bp were also observed 
in the junction sites (Ohbayashi et al., 2005).   
In the second paper, HC-AdV-AAV hybrids were used in human MO7e cells and in 
cord derived human CD34+ cells.  Two of the hybrid vectors contained the β-globin 
locus control region, derived from Chr 11.  Most of the clones had multiple integrants.  
33 % (11/33) of the integrations had taken place in the chr 11, out of which 4 were in 
the LCR.  30 % (10/33) of the integrations had occurred in active genes.  Deletions 
from 2 to 205 bps were observed in the integration events that had integrated through 
the Ad terminus. In 3 clones, both the 5’ and 3’ junctions of the clones were 
sequenced and deletions of 14, 24 and 567 bps were observed in the chromosomal 
DNA of the junction sites.  Transposition of the chromosomal DNA was observed in 
many of the integrants with the AAV terminus.  A HC-AdV-AAV hybrid vector with 
a 18.1 kb X chr stuffer DNA was also used.  41.6 % (10/24) of the integrations were 
in active genes, including one in the vav2 oncogene.  One integration had taken place 
in the X chr.  Deletions were observed in the terminal sequences (Wang et al., 2005).    
The gist of all of these publications is that it can be concluded that adenoviral vectors 
can recombine into the host genome via homologous or random recombination at low 
frequencies, and the structure of the junction sites between the vector and the cellular 
DNA are very similar to those observed during wt Ad integration.  The integrations 
seem to occur through the termini, though deletions in the termini are also observed.  
The vectors use limited homology between the termini and the chromosomal target to 
guide the process and deletions and rearrangements also may occur in the host 
genome during the process.  
 
I.3.3 Recombination between chromosomal and vector DNA during gene 
transfer with vectors derived from the family Retroviridae  
The family Retroviridae consists of enveloped RNA viruses in whose life cycles an 
obligatory integration of the provirus into the genome takes place.  Integration takes 
place through the termini and they are left intact, apart from the last 2 bps of each 
terminus, which gets deleted.  The only modification to the cellular DNA involves the 
first 5 bps of the junction site.  The first 5 bps of the cellular DNA from the 5’ LTR 
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junction site is duplicated at the 3’ LTR junction site, and thus serves as a marker to 
identify the validity of the junction site (Vincent et al., 1990).   
Though it was earlier believed that viral vectors based on the Retroviridae family 
integrate randomly into the genome, it was demonstrated that the integration pattern 
of retroviral gene transfer vectors (RVV) into human stem cell genome was not as 
random as expected (Laufs et al., 2003).  The partiality of a hybrid RVV to integrate 
into transcription start regions was observed in the 186 integration sites analysed 
(Laufs et al., 2004).  When 903 murine leukemia virus (MLV) and 379 human 
immunodeficiency virus (HIV) integration sites were studied, it was observed that the 
region near the transcriptional start was preferentially targeted by the MLV, whereas 
the HIV integrated throughout active genes, but not upstream of the transcriptional 
start (Wu et al., 2003).  After analyzing 3127 integration sites from vectors based on 
HIV, MLV and avian sarcoma-leukosis virus (ASLV), it was reported that the pattern 
of integration of HIV based gene transfer vectors displayed a bias towards active 
genes. MLV based gene transfer vectors (MLVV) displayed a preference for 
integrating into the transcription start sites, while ASLV based gene transfer vectors 
showed a weak preference for active genes and no preference for the transcriptional 
start site (Mitchell et al., 2004).  This was reconfirmed in a study where 491 MLVV 
and 501 Simian immunodeficiency virus (SIV) vector integration sites were analysed.  
MLVV integrations were observed more around the transcription start sites and SIV 
based gene transfer vector integration sites were observed in active genes and gene 
rich areas of the genome (Hematti et al., 2004).  The correlation between the retroviral 
based gene transfer vector integration sites and the active genes was published 
(Wagner et al., 2005).  Analysis of foamy viral (FV) vector integration sites showed 
that the virus preferred not to integrate in active genes.  Nevertheless, integrations in 
active genes too were observed near transcription start sites and in CpG islands 
(Trobridge et al., 2006). 
To summarize, retrovirus based gene transfer vectors display a strong tendency to 
integrate into active genes, with no rearrangement of the vector and cellular sequences 
apart from the deletion of the first 2 bps of each terminus and the duplication of the 5 
bps of the cellular DNA.     
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I.3.4 Recombination between chromosomal and vector DNA during gene 
transfer with vectors derived from the family Parvoviridae  
Parvoviruses consist of non enveloped small viruses with linear single stranded DNA 
packaged into a 18-25 nm icosahedral capsid.  Wt Adeno Associated virus (AAV) 
integrates preferentially into a specific locus in Chr 19q13.3 (AAVS1) into the slow 
skeletal troponin T gene.  Studies with gene transfer vectors derived from AAV 
(AAVV) demonstrated intregration frequencies of 0.2-1x10-3 per vector genome.  The 
integrations seem to take place through the termini, with small deletions in the termini 
(Rutledge & Russell, 1997).  Limited homology of 2-5 bps between the cellular and 
viral DNA were observed at the junction.  During the analysis of  977 AAVV 
integration sites, it was noticed that a larger number of integrations took place in 
active genes.  A significantly higher proportion of integrations took place in CpG 
islands, within the first 1 kb of genes and in ribosomal DNA repeats.  Deletions of up 
to 2 kb of the cellular DNA, and insertions of novel sequences of up to 13 bps were 
observed at the junction sites (Miller et al., 2005).  Chromosomal translocations at the 
junction sites too have been reported [reviewed in (McCarty et al., 2004)].  In vivo 
data suggested a much more higher percentage (72.5 %) of AAVV integration into 
genes, which were active in the liver (Nakai et al., 2003).  Concatomerisation of the 
vector and deletions and amplifications of viral and cellular DNA were also observed 
(Miller et al., 2002, Nakai et al., 1999).  The preference of AAVV for integration into 
CpG islands in the genome was observed in 347 AAV1 junction sites analysed.  3.5 % 
of the integrations took place in cancer related genes (Nakai et al., 2005). AAV 
integrations had occured around chromosome breakage sites (Miller et al., 2004). 
The rate of gene targeting via homologous recombination of AAVV into the cellular 
genome was reported as 8x10-3 at an moi of 40,000 and 2.7x10-2 at mois of 400,000 
(Russell & Hirata, 1998).  Ten individual mutations (up to around 20 bps) were 
corrected by gene targeting using AAVV in a different experiment.  However, 
rearrangements at the 5’ end of the homology was reported in one of the events (Inoue 
et al., 1999). Transgenes of up to 1 kb was introduced via homologous recombination 
of AAVV with rates of gene targeting going up to 7x10-3 at mois of 20,000 (Hirata et 
al., 2002).  The effects of random integration of the vector into the genome at these 
mois were not discussed in these papers.  
Vectors based on Parvo Minute Virus of Mice recombine via homologous 
recombination and random integration at the same rates as AAVV (Hendrie et al., 
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2003).  It has also been reported that the invertebrate parvovirus Junonia coenia 
Desnovirus (JcDNV) based vectors integrate in a similar manner as AAVV into the 
genome, with concatomerization and rearrangements of the vector (Bossin et al., 
2003). 
 When the recombination potential of parvovirus based vectors is studied, it can be 
concluded that they integrate at frequencies of up to 1x10-3 into the genome.  A higher 
proportion of the integrations takes place in active genes and rearrangements and 
modifications of the genomic DNA may accompany such events.  Under certain 
conditions, AAVV genome can undergo homologous recombination with the cellular 
genome at rates of 2.7x10-2. 
 
I.3.5 Recombination between chromosomal and vector DNA during gene 
transfer with vectors derived from the family Papillomaviridae 
Papilloma viruses are non enveloped DNA viruses with a dsDNA genome of 8 kb and 
an icosahedral capsid. Vectors based on bovine papilloma virus (BPV), which can be 
grown in vitro, were tested as early as 1987 (Elbrecht et al., 1987).  It has been 
reported that wt BPV and BPV vector remain as episomes (Amtmann et al., 1980, 
Tammur et al., 2002), nevertheless, integrations of BPV into the genome with small 
deletions in the termini of the viral DNA has been reported (Agrawal et al., 1992). In 
fact, an equine skin tumor has been associated with BPV (Chambers et al., 2003).  
Though there is not a lot of published data regarding the integration of Papilloma 
vectors, wt human papilloma virus (HPV) was associated with cervical cancer and 
was observed to integrate frequently into the genome (Gilles et al., 1996).  During 
integration into the genome, the E1 and the E2 regions, which span 4 kb of the 
genome from the 5’ side, were found to be frequently deleted (reviewd in 
(Yoshinouchi et al., 1999).  Random integration of the HPV genome into the cellular 
DNA with minor deletions in the viral DNA was observed (Kalantari et al., 2001, Luft 
et al., 2001).  It was observed that HPV integrates into active genes, especially genes 
involved in cellular growth and differentiation (Klimov et al., 2002).  HPV16 
integrations were observed near fragile sites in the genome (Thorland et al., 2003), 
whereas HPV18 not only displayed a similar preference for the fragile sites, but 30% 
of the integrations took place in a specific location at Chr 8q24 (Ferber et al., 2003b).   
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To summarize, papilloma viruses display a tendency to integrate non randomly into 
active genes, near protooncogenes or at fragile sites in the genome. Parts of the 
terminal sequences of the virus might get deleted during the process. 
 
I.3.6 Recombination between chromosomal and vector DNA during gene 
transfer with vectors derived from the family Herpesviridae  
Herpesviridae are large enveloped viruses with an icosahedral capsid that is located in 
the tegument inside the envelope and a ds DNA genome of about 150 to 230 kbps.  
Vectors based on Herpes Simplex Virus (HSV) and Epstein Barr Virus (EBV) are 
currently in use in in vitro and in vivo studies (Basu & Banerjee, 2004, Glorioso & 
Fink, 2004, Hellebrand et al., 2006, Ren et al., 2006, Tomiyasu et al., 1998).  During 
the latent infection in the life cycle of the virus, the genome remains as a circular 
episome through the joining of the termini.  Nevertheless, integration of the virus into 
the host genome through intact termini has been observed [reviewed in (Chang et al., 
2002)].  Translocation of a chromosome at the integration site of the viral DNA into 
human genome (Debiec-Rychter et al., 2003) and integration via intact termini at a 
fragile site near a protooncogene and the subsequent expression of that gene (Luo et 
al., 2004) has been reported during integration of EBV into the genome.  The virus 
was present as tandem repeats (Takakuwa et al., 2005).  Site specific integration into 
chr 19 was achieved using hybrid HSV-AAV vectors (Bakowska et al., 2003, Liu et 
al., 2006, Wang et al., 2002). 
Though in the latent infection most of the Herpesviridae viral genomes remain as 
episomes, there is a possibility that integration of the virus in a random manner into 
the host genome, possibly as concatamers, can occur through the termini sequences. 
 
I.3.7 Recombination between chromosomal and vector DNA during gene 
transfer with vectors derived from the family Hepadnaviridae  
Hepadnaviridae are small enveloped viruses with an icosahedral capsid and a circular 
dsDNA genome of 3.5 kb.  15-20% of one of the strands of the Hepatitis B virus 
(HBV) DNA is single stranded.  Vectors based on HBV have been developed 
(Untergasser & Protzer, 2004).  During the life cycle, the viral DNA remains as a 
covalently closed circular duplex DNA.  However, integration of the viral genome 
with rearrangements such as deletions, chromosomal translocations and duplication in 
the cellular DNA, and activation of cellular genes has been observed [reviewed in     
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(Wang et al., 2001)].  The integration was observed throughout the genome, with a 
number of integrations near protooncogenes [reviewed in (Ferber et al., 2003a)].  It 
was suggested that HBV DNA integration takes place in regions of chromosomal 
DNA breaks via non homologous end joining (Bill & Summers, 2004).  Deletion of 
viral DNA during integration was reported (Kimbi et al., 2005).  Analysis of junction 
sites of viral integration showed that 90 % of integrations took place into cellular 
genes that could confer growth advantage.  Mutations in the viral DNA (Koike et al., 
1983, Mizusawa et al., 1985) and chromosomal DNA (Tokino et al., 1987) have been 
reported. Integration was also mapped into tumour supressors and apoptosis genes 
(Murakami et al., 2005). 
It can be concluded that HBV viral DNA can integrate into the genome and the events 
are marked with mutations in the cellular DNA. The data published so far suggests 
that the viral DNA can integrate in genes that may have oncogenic potential.  
 
I.3.8 Recombination between chromosomal and vector DNA during gene 
transfer with vectors derived from the family Polyomaviridae  
Polyomaviridae are small non-enveloped viruses with an icosahedral capsid and a 
circular ds DNA genome of around 5 kb, that lacks terminal repeats.  During the life 
cycle of wt Simian Virus 40 (SV40), the virus may exist either as a minichromosome 
or in an integrated form. Wt SV40 DNA integrates randomly into the genome, with no 
apparent hotspot within the viral DNA for integration. Vectors based on SV40 have 
been developed (Zern et al., 1999), used in in vitro and in vivo experiments [reviewed 
by (Vera & Fortes, 2004)] and were found to integrate randomly into the genome with 
loss of viral DNA (Strayer et al., 2002, Strayer, 1999). During the integration of a 
vector based on polyoma virus integrated into the rat genome deletions of the cellular 
DNA was reported (Wallenburg et al., 1987).  The upregulation of gene expression 
due to polyomaviral integration in mouse tumors was also reported (Hollanderova et 
al., 2003).  Integration of wt SV40 has also been recorded in human tumors 
(Shivapurkar et al., 2002, Vilchez et al., 2003).  Polyoma JC virus was linked to 
colorectal cancer and was shown to induce chromosomal mutations in colonic cells 
(Ricciardiello et al., 2003).   
From the available data, it may be concluded that polyoma viruses integrates 
randomly into the host genome, with deletions observed in the viral DNA, and 
mutations in the host genome.  
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Some viruses used as gene thransfer vectors integrate into the genome as a part of 
their life cycle.  Though it was once thought to occur in a random manner into the 
chromosomal DNA, the data compiled here display a strong bias displayed towards 
integration into active genes.  In the case of viral vectors that may not necessarily 
integrate into the genome as a part of the viral life cycle, integrations have been 
observed, and they display all the hallmarks of the canonical NHEJ pathway.  
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II Objectives  
Gene transfer with adenoviral vectors has now been well established and currently 
clinical trials using this vector type are ongoing. Adenoviral vectors are currently 
perceived as non-integrating vectors, although earlier work demonstrated that 
adenovirus DNA can integrate into chromosomal DNA under certain circumstances. 
HC-AdVs represent a more recent adenovirus-based vector version with several 
advantages over earlier generation adenoviral vectors and have, therefore, 
considerable potential for clinical application. However, very little information on the 
fate of adenoviral vector genomes following gene transfer is available. Very limited 
work with Ist Gen AdV pointed to rare chromosomal integration events. However, 
when this thesis work was started, there were no data available on the recombination 
potential of HC-AdVs.  
The development of leukaemia in several subjects during a clinical trial using a 
retroviral vector reiterated the importance of studies on the insertional mutagenesis 
potential of gene transfer vectors used in the clinic. Therefore, the overall aim of this 
thesis project was to gain scientific information on the recombination potential of HC-
AdV DNA with the chromosomal DNA. The first specific aim was to determine the 
rates of heterologous and homologous recombination of the HC-AdV DNA with the 
chromosomal DNA in vitro in primary cells and in established cell lines. To address 
this question, two well established models were chosen. The hprt model, which has 
been extensively used in DNA recombination studies, was used to study homologous 
recombination of HC-AdV DNA with the chromosomal DNA. The second model 
involved the use of a selection marker expressed from the vector, which allowed for 
the investigation of random integration events into the chromosomal DNA.  
The second specific aim of this project was to investigate heterologous and 
homologous recombination events of HC-AdV DNA with chromosomal DNA in vivo. 
Here, the Fah∆ exon 5 knockout mouse was chosen as an excellent model that allows to 
monitor recombination events in hepatocytes in vivo. The final aim of this project was 
to analyse integration events of HC-AdV DNA at the molecular level, so that precise 
information on the integrity of the vector genomes and the junctions between vector 
DNA and the chromosomal DNA was obtained. This would then also allow the 
analysis of potential integration preferences of HC-Ad vector genomes.  
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Taken together, these studies were designed to provide detailed safety-related 
information on rates of recombination of HC-AdV DNA with chromosomal DNA, the 
insertional mutagenesis potential of HC-AdVs, and the integration patterns of the 
vector DNA. 
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III Materials and Methods 
III.1 Materials and Instruments 
III.1.1 Materials 
All chemicals, unless specially mentioned, were purchased from the company 
Applichem GmbH (Germany). The solutions were prepared using water obtained 
from EASY pure instrument (Werner Water Purification System, (Germany). The 
bacterial media and agar was purchased from Invitrogen (Germany). The Enzymes 
were purchased from NEB (Germany). Oligonucleotides were purchased from 
Invitrogen, Qiagen or MWG Biotech (Germany). Cell culture media when not 
specially mentioned were purchased from Invitrogen (Germany). All cell culture 
materials (cell culture dishes, pipettes etc.) were purchased from Renner (Germany).  
 
III.1.2 Instruments and equipment 
Autoclave     Systec (Wettenberg)  
Cell culture hood    Clean Air Technique. (Netherlands) 
Cell culture Incubator    Forma Scientific, (U.S.A) 
Centrifuges     Biofuge fresco (Germany) 
      Eppendorf 5417C (Germany) 
      Sigma 6K15 (Germany) 
Heating block      VWR (Germany) 
Incubator (Bacterial culture, 
enzyme reactions, pipette sterilization) VWR (Germany) 
Mini hybridization oven   Biometra Biomedizinische Analytik          
                                                                        GmbH (Germany) 
PCR thermocycler Uno II   Biometra Biomedizinische Analytik  
                                                                        GmbH (Germany) 
pH-meter pH526    WTW GmbH (Germany) 
Spectrophotometer    Pharmacia Biotech (Germany) 
Ultracentrifuge     Beckman, L7-65 with SW41- Rotor  
                                                                        (USA) 
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III.1.3 Buffer and Solutions 
 
DNA-loading buffer (6x) 
30%       Glycerin 
60 mM       EDTA 
0.1%      Bromophenol Blue 
0.1%       Xylene cyanol Blue 
 
HBS-Buffer (2x) 
50 mM      HEPES 
280 mM     NaCl 
1.5 mM     Na2HPO4 
pH      7.13 
 
Hybridization buffer for slot blot and Southern blot 
2x      SSC 
10 %      Milk powder solution 
0.5 mg/ml     Herring sperm 
10 %      Dextran sulfate  
 
Transfer buffer for Southern blot analysis 
0.4 N        NaOH 
 
Wash Buffer I for Southern blot 
2x                                                                    SSC 
0.1 %                                                               SDS  
 
Wash Buffer II for Southen blot 
0.1x                                                                 SSC 
0.1 %                                                               SDS 
 
Milk powder solution for the above work 
5.0 %       Milk powder 
10 %      SDS 
 42
PCR-Mix 
DNA      Plasmid DNA at 1-10 ng concentration 
       Genomic DNA at 1-2 µg concentration 
Taq polymerase buffer    1x 
Taq polymerase    1.25 units [Stratagene (Netherland)] 
dNTP-Mix     40 nmol [( La Roche (Germany)] 
dH20         up to a volume of 50 µl 
 
Sodium phosphate-buffer pH 8.0 (100 mM) 
46.6 ml     1M Na2HPO4 
3.4   ml     1M  NaH2PO4 
8.8   gm      NaCl 
500  ml     dH2O 
 
SSC Solution (20x) 
3 M      NaCl (sodium chloride) 
0.3 M      C6H507 Na3 2H2O  (tri-sodium citrate) 
pH       7.0 (adjusted with NaOH) 
 
TAE-Buffer (50x) 
2.0 M      Tris-Base 
0.05 M       Acetic acid 
0.05 M      EDTA 
0.225 M     Tris base  
0.225 M     Boric acid 
0.02 M      EDTA 
 
TBS-Buffer (1x) for resuspension of virus 
137 mM      NaCl 
2.7 mM     KCl 
25 mM       Tris-Base 
pH      7.4 (adjusted with HCl) 
(The solution was sterilized by autoclaving)  
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TE Buffer (1x) 
10 mM      Tris-HCl, pH 7.5 
1 mM      EDTA 
 
TELT Buffer 
50 mM      Tris-HCl, pH 8.0 
62.5 mM     EDTA 
2.5 M      LiCl 
0.6 %      Triton X-100 
One spatula of Lysozyme 
 
Lysis Buffer for DNA isolation 
10mM                                                              Tris.Cl (pH 7.4) 
10mM                                                              EDTA 
10mM                                                               NaCl   
0.5 %                                                                Saodium Lauryl Sarcosinate 
1mg/ml                                                              Proteinase K 
 
Suspension medium (S.M.) for Lambda DNA isolation 
1.5 mM                                                               NaCl 
2 gm                                                                   MgSO4.H2O 
50 ml                                                                 1 M Tris.HCl pH. 7.5 
5 ml                                                                   2% Gelatin Solution 
To 1 lit                                                              H2O  
 
Soln I for hepatocyte isolation 
Earles basic Salt Solution (EBSS) without Ca and Mg, [Gibco 310-4150 AJ]  
0.5 mM                                                           EGTA [Sigma 4378] 
 
 Soln II for hepatocyte isolation  
EBSS with Ca and Mg [Gibco 310-4010 G]  
10mM                                                            Hepes, pH 7.4  
 
 
 44
Soln III for hepatocyte isolation  
High Glucose DMEM [Gibco 320-1960 AJ] complete 
0.3 mg/ml                                                  Collagenase [Boehringer, grade D] soln 
0.04 mg/ml                                                Soybean trypsin inhibitor [Sigma T9128] 
10mM                                                        Hepes and Mg,  
 
III.1.4 Oligodeoxyribonucleotides 
The oligodeoxyribonucleotides were purchased from Invitrogen, Qiagen and MWG 
Biotech. The lyophilized oligonucleotides were dissolved in 1xTE buffer and were 
stored at –20οC.  Oligodeoxyribonucleotides used for ligation were dissolved in 10 
mM Tris buffer.  The details are given in Table 3. 
 
Name Sequence 5’- ‘3 Binds to/Comments 
Fiber I ATGAAGCGCGCAAGACCGTCTG 31042-31063, Ad 5  
Fiber II CCAGATATTGGAGCCAAACTGCC 32368-32390, Ad 5 
ITR I AACGCCAACTTTGACCCGGAACGCGG 438-413, Ad 5 
ITR II CATCATCAATAATATACCTTATTTTG 1-26, Ad 5 
SamStephenI CAGTATCACCAGGTTATGACCTTTGAT
ATCTTTTGCATACCTAATCATTATGC 
13480-13525, SLS 11 
T nucleotide + Eco RV site 
SamStephen II ATTCAATACCAGGTAAGGTTT 13977-13957, SLS 11 
InvPCR LITR1 CGCCCAGGTGTTTTTCTCAGGT 399-420, SLS 11 
InvPCR LITR2 GCAACATCACACTTCCGCCAC 141-121, SLS 11 
InvPCR RITR1 CATCACTCCGCCCTAAAACCTA 30224-30247, SLS 11 
InvPCR RITR2 TTGATTTAATTAAGGCCGGCCC 30191-30170, SLS 11 
AdRITR new GCTTATCGATACCGTCGAGACCTCG 30192-30216, SLS 11 
AdRITR2 CGTCACCCGCCCCGTTCCCACGC 30247-30269, SLS 11 
AdLITR new CCGTCGCTTACATGTGTTCCGC 170-149, SLS 11 
AdLTR2 CTACTACGTCACCCGCCCCGT 119-99, SLS 11 
Ad11LITRnew CGTCGCTTACATGTGTTCCGCCAC 169-146, SLS 11 
LITRnested TACTACGTCACCCGCCCCGT 117 to 99, SLS 11 
Inv LITR new CGCCCAGGTGTTTTTCTCAGGT 399-420, SLS 11 
InvPCRLITR2nest CCGCGTTCCGGGTCAAAGTTGGC 426-449, SLS 11 
InvLITR1new GCAACATCACACTTCCGCCAC 141-121, SLS 11 
SLS16RsvFah1 GACAGGTCTGACATGGATTGG 484-504, FAH cDNA cassette 
SLS16RsvFah2 CTCCTTCCATGCAGCTTGACC 881-861, FAH cDNA cassette 
RITR1 CATCACTCCGCCCTAAAACCT 30225-30245, SLS 11 
RITR1nest TAAAACCTACGTCACCCGCC 30238-30258, SLS 11 
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RITR2 GGTCTCGACGGTATCGATAAGC 30211-30192, SLS 11 
RITR2 nest TTGATTTAATTAAGGCCGGCCC 30190-30170, SLS 11 
RITR4Tsp CCCTCGAGGTCTCGACGGTAT 30220-30200, SLS 11 
RITR4nestTsp CGACGGTATCGATAAGCTTGA 30208-30188, SLS 11 
LITRx TCCGTCGCTTACATGTGTTCC 171-151, SLS 11 
LITR1 GCAACATCACACTTCCGCCAC 140-129, SLS 11 
LITR1nest TACTACGTCACCCGCCCCGT 118-99, SLS 11 
LITR2 CGCCCAGGTGTTTTTCTCAGGT 398-420, SLS 11 
LITR2nest GCGTTCCGGGTCAAAGTTGG 428-446, SLS 11 
LITR4Tsp TGACGTTTTTGGTGTGCGCCG 183-203, SLS 11 
LITR4nestTsp GCCGGTGTACACAGGAAGTGA 200-220, SLS 11 
SSHPRT1 GTATCCTGTAATGCTCTCATTG 13421-13442, SLS 11 
SSHPRT2 AGCATTCAATACCAGGTAAGG 13979-13960, SLS 11 
Fah A CTAGGTCAATGGCTGTTTGG 6571-6590, m FAH gene 
Fah B GGACATACCAATTTGGCAAC 6705-6686, m FAH gene 
Fah C TAAAATGAGGAAATTGCATCG 3911-3931 pcDNA3 
  
Table 3: List of oligonucleotides used in this study   
 
III.2 Bacterial Methods 
III.2.1 Bacterial culture techniques 
a) Culture of bacteria in Luria Broth Base 
E.coli was cultured in Luria Broth Base in the presence of the antibiotic ampicillin at 
a concentration of 100 μg/ml.  For small-scale preparation (1.5 ml) eppendorf tubes 
with a capacity of 2.0 ml were used. For large scale preparation (200 ml), Erlenmeyer 
flask with a capacity of 500 ml were used.  The cultures were incubated for 12h with 
shaking at 250-300 rpm at 37οC.   
b) Culture of bacteria in Luria Broth Agar 
E.coli was cultured in 10 cm plates containing 20 ml of Luria Broth Agar containing 
ampicillin at a concentration of 100 μg/ml.   
c) Culture of Bacteria in NZYCM medium 
E.Coli XL1 Blue MRA P2 [Stratagene] was cultured in 50 ml NCYZM + 0.1 gm 
Maltose 
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III.2.2 Transformation of E.Coli 
Transformation with plasmid DNA 
Transformation of E.coli with plasmid DNA was performed by incubating 20 μl of 
XL-2 blue ultra competent bacteria (Stratagene, Germany) with 10-100 ng of plasmid 
in a 1.5 ml Eppendorf reaction tube for 5 min in ice. After five minutes incubation in 
ice, the bacteria were placed in a water bath at a temperature of 42ο C for 45 seconds. 
The bacteria were then immediately placed in ice for 2 min and SOC medium was 
added. The bacteria were incubated for 1h at 37°C. After 1h the bacteria were 
transferred to LBA plates containing antibiotic ampicillin and were incubated for 12h. 
Transformation with plasmid DNA from ligation 
To transform bacteria using a ligation mix, 50 μl of XL-2 blue ultra competent 
bacteria (Stratagene, Heidelberg) were incubated with 0.5 μl of 2-Mercaptoethanol 
(1.42 M) for 10 minutes on ice. After 10 minutes, 2 μl of ligation mix was added and 
the bacteria were further incubated for 30 min in ice. The bacteria were placed in a 
water bath having a temperature of 42ο C for 45 seconds. The bacteria were then 
immediately placed in ice for 2 min and 200 μl of SOC medium was added. The 
bacteria were incubated for 1h at 37° C before being transferred to LBA plates 
containing antibiotic and were incubated for 12h 
 
III.2.3 Isolation of plasmid DNA 
Analytical plasmid isolation (“Mini prep”) 
Mini prep of DNA was performed to analyze the integrity of DNA by restriction 
digestion. Isolated bacterial clones picked from Luria Broth Agar plates were grown 
over night (12-14h) in 1.5 ml of LB shaker culture containing ampicillin at 100 μg 
/ml. The bacteria were pelleted by centrifuging at 5000 RPM for 3 minutes at RT. The 
bacterial pellet was re-suspended in a volume of 200 μl of TELT buffer. The re-
suspended bacterial pellet was incubated at 96ºC for 3 min followed by incubation in 
ice for 5 minutes. The supernatant containing DNA was collected by centrifugation at 
14,000 RPM for 10 minutes. The DNA present in the collected supernatant was 
precipitated by mixing the supernatant with equal volume of isopropanol and 
centrifuging at 20000 g for 10 minutes. The precipitated DNA was washed once with 
300 μl of 70 % ethanol. The DNA was finally suspended in a volume of 30 μl of TE 
and was stored at 4ºC until further use.  3 μl of the re-suspended DNA was used for 
restriction digestion.  
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Preparative plasmid Isolation. (“Maxi prep”) 
Maxi prep of DNA was performed to obtain large quantities of DNA for transfection, 
cloning etc. The DNA was prepared using the Qiagen Maxi Plasmid Kit (Qiagen). 
The protocol prescribed by the manufacturer was followed. 
 
III.3 Molecular Biology Methods 
III.3.1 Purification of the DNA cloned into Lambda Phage Vectors 
a. Preparation of the plating bacteria. 
The bacterial host XL1 Blue MRA P2 [Stratagene] was streaked on to a LB plate and 
incubated at 370C overnight.  A colony was inoculated on to 50 ml of sterile LB 
medium, supplemented by 0.2 % maltose and incubated overnight.  The bacteria was 
centrifuged down and resuspended in 20 ml 0.01 M MgSO4 and store at 40C. 
b. Plating the bacteria onto the LB plates with the phage. 
0.7% LB agar was made in suspension medium and incubated at 470C water bath. 
Ten fold serial dilutions of the λ stock in SM was made.  100 ml of plating bacteria 
was added to each of the dilutions and incubated at 370C for 20 mins.  3 ml of the agar 
was poured into each tube, and the plate was incubated at 370C overnight. 
c. Picking of the λ plaques: 
A drop of chloroform was added in 1 ml of SM.  The plaques were jabbed with a 
micopipette tip, the agar in the region was pipetted into an eppendorf tube.  1 ml of 
SM was added to it and the tube was stored at  40C. 
d. Preparation of plate lysate stock. 
Dilutions of the picked plaque were made and mixed with 100 ml of plating bacteria 
each and incubated 370C for 20 mins.  3 ml of molten top agar was added and the 
plate incubated at RT for 5 mins before incubating it at 370C for 10 hrs.  5 ml of SM 
was added on to the plate and was store at 40C overnight with intermittent shaking.  
The SM was harvested and 0.1 ml of CHCL3 added and the centrifuged.  The 
supernatant was collected and stored at 40C with a 1 drop of CHCL3.  
e. Large scale preparation of the λ vector. 
A starter culture of the bacterial host in 50 ml of NCYZM + 0.1 gm maltose was 
produced till the O.D.600 nm reached 5 (approx. 2.5 hrs).  Different diluations of the 
starter culture was added to 50 ml of NCYZM + 0.1 gm maltose and incubated at 
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370C till the medium cleared and fine splintery precipitate or stringy clumps was 
observed.  A drop of CHCL3 was added and the supernatent were harvested and 
stored at 40C. 
f. Preparation of the Lambda DNA using Qiagen Lambda Kit. 
100µl of Buffer L1 was added to the pellet and mixed 10 ml of Buffer L2 was added 
and the reaction and the pellet resupended in 3 ml of Buffer L3.  3 ml of Buffer L4 
was added and the reaction incubated at 700C water bath for 10 mins.  3 ml of L5 was 
added, the reaction centrigufed and the supernatnat poured into a Qiagen tip 100 
equilibrated with buffer QBT.  The tip was washed with Buffer QC and the DNA 
eluted with Buffer QF.  DNA precipitation was carried out as in a standard Mediprep. 
 
III.3.2 Isolation of DNA from mammalian cell lines 
1x107 cells were spun down and resuspended in 500 μl of Lysis Buffer and incubated 
overnight at 600C.  1250 μl of precipitation buffer (3 μl 2.5 M NaCl / 100 μl Ethanol) 
was added and centrifuged to obtain the DNA pellet that was washed three times with 
70% ethanol before being resuspended in TE. 
 
III.3.3 Determination of the concentration of DNA 
The concentration of DNA was determined using spectrophotometry. The 
concentration of the DNA present in the solution was calculated using Lambert Beers 
Law which states concentration of double stranded DNA in mg/ml= A260 x 50 x 
dilution factor, whereby A is the adsorption coefficient of DNA at 260 nm. The 
solution was also measured to determine the absorption at 280 nm for proteins. DNA 
samples containing A260/A280 values of 1.7-2.0 were used for experiments. 
 
III.3.4 Storage of DNA 
For routine use, plasmid DNA was stored in TE buffer, pH 8 at 4οC.  For long-term 
storage, plasmid DNA was dissolved in 70% ethanol and was stored at –20οC. 
Oligodeoxynucleotides and vector inserts used for ligation were stored in 10 mM Tris 
buffer.   
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III.3.5 Precipitation of DNA 
Ethanol precipitation 
Ethanol precipitation of solution containing DNA was performed by mixing 0.1 
volume of sodium acetate solution (3 M, pH 5.2) and 2 volumes of 100 % ethanol.  
After mixing, DNA was collected by centrifuging at 20,000 g for 30 min at 4οC.  The 
supernatant was discarded and the pellet was washed with 70 % ethanol by 
centrifuging at 20,000g for 30 min at 4οC.  The supernatant was discarded and the 
pellet was air dried at RT for 5-10 min. The pellet was dissolved in TE buffer. Vector 
inserts and oligodeoxynucleotides were dissolved in 10 mM Tris buffer. 
Isopropanol precipitation 
Isopropanol precipitation of solution containing DNA was performed by mixing the 
DNA solution with 0.5 volume of isopropanol. After mixing, the DNA was pelleted 
by centrifuging at 20.000 g for 20 min at RT.  After discarding the supernatant, the 
pellet was washed with 70 % ethanol for 30 min at 4 οC. The supernatant was 
discarded and the DNA was air dried at RT for 5 min before being resuspended in TE 
buffer. 
 
III.3.6 Phenol chloroform extraction of DNA 
Phenol-chloroform extraction of DNA was performed when DNA was used for 
ligation or for transfection of cells. 200 μl of DNA containing solution was mixed 
with an equal volume of TE equilibrated phenol (Invitrogen, Germany). After mixing 
the aqueous and organic phase were separated by centrifugation at 20,000 g for 4 min 
at RT and the organic phase was discarded. The aqueous phase was once again mixed 
with equal volume of chloroform/isoamyl alcohol (24:1) and the aqueous phase was 
separated by centrifuging at 20.000 g for 4 min at RT. The DNA present in the 
aqueous phase was finally precipitated by using ethanol.  
 
III.3.7 Restriction digestion of DNA and agarose gel electrophoresis  
The restriction analysis was performed with 10 μg or 200 ng of DNA for preparative 
or analytical digest respectively. DNA was digested with restriction enzyme (5 IU/μg 
of DNA) in the prescribed buffer for 2h.  DNA was digested in a total volume of 20 µl 
or 200 μl.  In the case of double digestion of DNA with enzymes having different 
prescribed buffers, the digested DNA was precipitated with ethanol and was re-
suspended in Tris-HCl (pH 8.5), before being re-digested. The digested DNA 
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fragments were dissolved in DNA loading buffer, and were separated in a 0.8 % 
agarose gel. The agarose gel used for the separation of DNA bands contains ethidium 
bromide for visualizing the DNA. TBE running buffer was used for analytical 
preparation of DNA. TAE running buffer was used for preparative digests of DNA. 
 
III.3.8 Isolation of DNA fragments from agarose gels 
Digested DNA for preparative analysis was separated by agarose gel electrophoresis. 
The separated DNA was visualized under U.V. light. The desired DNA band was cut 
out using a sharp scalpel. DNA bands having a size of less than 5 kb were isolated 
using QIAEX II Gel extraction kit. DNA bands having a size of more than 5 kb were 
isolated by electroelution using the Elu trap electrophoretic system (Schleicher & 
Schuell, Germany). The isolated DNA was precipitated using ethanol and was re-
suspended in 20 of μl 1x TE buffer. 
 
III.3.9 Filling up of 5´ends (Klenowing) 
Filling up of 5´ends of DNA fragments was performed to ligate non-cohesive ends. 
Klenowing of DNA was done by incubating DNA (50 ng/ μl) with 2 units of Klenow 
enzyme for 15 minutes in Klenow buffer. After 15 min, the Klenow enzyme was 
inactivated by the addition of 5 mM EDTA and incubation at 75ºC for 10 min. The 
dephosphorylated DNA was extracted with an equal volume of phenol followed by 
chloroform: isoamylalcohol mix (24:1). The DNA was finally extracted with 
chloroform and was precipitated with twice the volume of 100 % ethanol and 1/10 
amount of 3 M sodium acetate (pH 5.2). The precipitated DNA was re-suspended 
with 20 μl of 10 mM Tris-HCl (pH 8.5).  
 
III.3.10 Dephosphorylation of DNA fragments 
Dephosphorylation of the digested vector DNA was performed to prevent self-
ligation.  Dephosphorylation was done by incubating 1-2 μg of DNA with 1U of calf 
intestinal phosphatase (CIP) at 37ºC for 1h at 50 ng/µl concentration.  CIP was 
inactivated by the addition of 5 mM EDTA and incubation at 75 ºC for 10 min. The 
dephosphorylated DNA was extracted with an equal volume of phenol followed by 
chloroform: isoamylalcohol (24:1). The DNA was finally extracted with chloroform 
and was precipitated with twice the volume of 100 % ethanol and 1/10 amount of 3 M 
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sodium acetate. The precipitated DNA was re-suspended with 20 μl of 10 mM Tris-
HCl (pH 8.5).  
 
III.3.11 Ligation of DNA fragments 
Ligation of DNA fragments and dephosphorylated vector DNA was performed in 1x 
T4 ligase buffer overnight at room temperature in the presence of T4 DNA ligase (6 
Weiss units). The amount of vector DNA and DNA fragments were in a molar ratio of 
1:1 and 1: 3.   The entire reaction was assembled on ice untill the ligase was mixed 
into the solution.  The total volume of the ligation mix was 10 μl. The specific ligation 
conditions for inverse PCR is given separately.  
 
III.3.12 Polymerase chain reaction 
Construction of primers for PCR 
The primers used for PCR had generally 18-21 nucleotides. The melting temperature 
for the oligonucleotide primer used in PCR was determined using the formula used by 
MWG biotech, Germany Tm[C] = 69.3 + 41 [(nG + nC)/n ]– (650/5n) 
T represents thymine base, G represents guanine base, C represent cytosine base and 
A represent adenine base. 
a. Standard PCR 
Polymerase chain reaction was performed in a total volume of 100 μl. The equipment 
used for PCR was a PCR – Automat Uno II (Biometra, Götingen). The dNTPs were 
used in a concentration of 200 μM, primers at a concentration of 300 nM and MgCl2 
at an end concentration of 1.5 mM. When not specially mentioned Hot Star Taq 
polymerase (Quiagen, Germany) was used for preparation of probes and pfu 
polymerase (Stratagene, Germany) was used for sequencing and for cloning purposes. 
Genomic DNA was used at a concentration of 1-2 μg and plasmid DNA was used at a 
concentration of 1-10 ng. The denaturing temperature was set at 95°C for 15 min. The 
annealing temperature was set at 5°C below the melting temperature of the primers. In 
general 25 –31 cycles were used for amplification of desired fragments. 
b. Inverse PCR 
1μg of DNA was digested with the enzyme and purified using Qiagen PCR 
purification kit as per manufactarer’s protocol.  200 μg of the digested DNA was used 
for ligation in 500μl volume on the thermocycler with 800 rounds of 30 seconds each 
at 12 and 19 degree celsius.  The product was purified using YM-30 Microcon 
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columns, and ½ of the product was used for the PCR, which was run uder standard 
conditions. 1/100 of the product was used for the nested PCR and 1/20 of the product 
was used for analysis.  30 μl of the nested PCR product was run on a 2% gel TAE 
agorose gel and the band of interest was excised and purified on a Qiagen Gel 
purification kit column as per manufacterer’s protocol and cloned into TOPO Cloning 
kit (Invitrogen) and transformed on TOP-10 E.coli (Invitrogen) as per their protocol.  
The miniprep of the clones was carried out using Qiagen Mini prep kit as per their 
protocol and 1/10 of the product was sent for sequencing. 
 
III.3.13 Purification of PCR product 
PCR products were purified using a PCR purification kit (Qiagen). The PCR product 
was checked using agarose gel electrophoresis.  
 
III.3.14 Southern blot analysis of DNA 
15µg of the cellular DNA and the controls, (+ve has spiked plasmid at 1, 2 and 4 
copies/cell), were digested in 50 μl and loaded on to a TAE agarose gel of appropriate 
concentration and run on a low voltage.  The gel was stained with ethidium bromide 
and photographed with a fluorescent ruler for noting the position of the marker bands.  
The gel was shaken in 0.25 N HCl to depurinate the DNA.  Then the gel was washed 
with water followed by shaking in 0.4 N NaOH to denature the DNA.  The blotting 
apparatus was preapared using a tray filled with 0.4 N NaOH and plastic plates placed 
horizontally across it. The bridge of wartman paper was placed on the plate and the 
gel and the membrane (Hybond N+ from Amersham) were sandwiched between two 
strips of wartman paper soaked in 0.4 N NaOH.  The bale of absorbent paper towels 
was placed on the top and the sides were insulated with Saran wrap.  Another plastic 
plate along with a small weight was placed on the top.  Transfer of the DNA to the 
membrane was carried out overnight and the membrane was neutralised in 2X SSC 
prior to baking at 800C for 45 minutes to complete the cross linking.  The 
prehybridisation mix was made with 3 ml 20X SSC, 3 ml 10X milk powder mix, 1 ml 
salmon sperm DNA, 6 ml of 50 % dextran sulphate solution and filled up with water 
to 30 ml, and boiled for 15 minutes and snap cooled on ice-water mix.  The membrane 
was pre-hybridised at 680C overnight.  The probe was radioactively labeled with 50 
μCi 32[P] dCTP (Amersham Pharmacia, Germany) using the Ready to go DNA 
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Labeling Kit (Amersham Pharmacia, Germany).  The membrane was hybridized using 
the radioactive probe overnight at 68 ºC and washed at 680C with buffer I for 15 
minutes followed by a second wash with wash buffer II for 20 minutes.  The 
membrane was dried on Whartmann paper and exposed to a Kodak film at –800C and 
the film was exposed as per standard conditions. 
 
III.3.15 Generation of DNA probes for slot blot and Southern blot analysis 
The probes for slot blot analysis namely the ITR and the fiber probes were prepared 
using PCR. The 438 bp long ITR probe binds to the Ad-ITR (nucleotide 1 to 438). 
The primers used for the generation of ITR probe were the ITR and ITR II. The 1348 
bp long fiber probe binds to the Ad–fiber DNA (nucleotide 31042 to 32390). The 
primers used for the generation of the fiber probe were fiber I and fiber II. PCR 
amplification was carried out for 2 min at 94ºC followed by 20 cycles of 1 minute at 
940C, 1 minute at 550C, 1 minute at 72ºC and a final extension of 10 minutes at 720C. 
The probes for the different Southern blot experiments were generated by digesting 
the target DNA with the appropriate enzyme.  The probes generated by PCR were 
purified using the QIA quick PCR purification Kit (Qiagen). The probes were stored 
at –20 ºC. The concentration of the probes was determined spectroscopically and by 
agarose gel electrophoresis.  
 
III.4 Cell culture techniques 
III.4.1 Cell lines and media 
The cell culture media and foetal calf serum (FCS), when not otherwise mentioned, 
were purchased from Invitrogen (Germany). Hygromycin B (10687-010) and HAT 
(21060-017) supplement were purchased from Invitrogen and 6TG (A4882) was 
purchased from Sigma Aldrich.  Minimum essential medium (MEM) and α-MEM 
powder were dissolved at room temperature in 4.5 L of water. 11 g of NaHCO3 was 
added to the prepared media and the medium was adjusted to pH 7.1 with 1 N HCl. 
The media was made up to a volume of 5L and was filtered through a 0.2 μm filter. 
All cell culture and viral techniques were performed in the S2 laboratory facility. The 
cells were harvested by centrifugation at 250g. The cell lines were passaged once or 
twice per week. For passaging of cells plated in 15 cm cell culture dishes, the medium 
was aspirated, and the cells were washed once with 10 ml of PBS. After washing, the 
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PBS was aspirated and the cells were detached using 3.0 ml of Trypsin-EDTA 
solution. After detachment, the trypsin was neutralized with 10 ml of medium 
containing 10% FCS. The cells were centrifuged and were resuspended in new 
medium for passaging. 
 
293 : This cell line is a hypotriploid embryonic kidney cell line with a integrated 4.34 
kb of adenoviral DNA (Graham et al., 1977) located in chromosome 19q-30.  The cell 
line was cultured in αMEM/10 % FCS/ 1x penicillin-streptomycin and was passaged 
1:3, twice every week. 
 
293 Cre 66:  The cell line was based on HEK 293.  293 Cre 66 expresses the Cre 
recombinase constitutively. The cell line was used for the amplification of high 
capacity adenoviral vectors. It was a kind gift of Dr. G. Schiedner. The cell line was 
cultured in MEM/10 % FCS/ 1x penicillin-streptomycin and was passaged 1:3, twice 
every week. 
 
HeLa: The cell line is a cervical carcinoma cell line derived from a female patient 
(Gey et. al., 1952). The cell line was purchased from Cell line services, Heidelberg. 
The cell line was used for transduction with HC-Ad vector to estimate the levels of 
transgene expression in vitro. The cell line was cultured in αMEM/10 % FCS/ 1x 
penicillin-streptomycin and was passaged 1:3 once every week. 
 
HT1080: The cell line is a fibrosarcoma cell line derived from a male, containing a 
single X chromosome (Rasheed et al., 1974). The cell line was cultured in αMEM/10 
% FCS/ 1x penicillin-streptomycin and was passaged 1:6 twice every week. 
 
C-32: The cell line is a melanoma cell line, derived from a male, containing a single 
X chromosome (Chen & Shaw, 1973), (Chen, 1983).  The cell line was cultured in 
αMEM/10 % FCS/ 1x penicillin-streptomycin and was passaged 1:3 twice every 
week. 
 
FF-95: These cells are primary human fibroblasts derived from a male patient in the 
Department of Dermatology, Universität zu Köln and is a generous gift of Prof. K. 
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Scharffetter-Kochanek.  These cells were cultured in αMEM/10 % FCS/ 1x 
penicillin-streptomycin and were passaged 1:3 twice every week. 
 
 Human Retinal Pigmented Epithelium (HRPE): These cells are primary human 
cells derived from the eye and are a generous gift of Dr. I. Semkova, Augenklinik, 
Universität zu Köln.  These cells were cultured in αMEM/10 % FCS/ 1x penicillin-
streptomycin and were passaged 1:3 twice every week. 
 
III.4.2 Freezing of eukaryotic cells for long term storage 
For freezing, early passages of cells were used. The cells were washed twice with 
PBS and were detached using trypsin-EDTA solution. The cells were pelleted and 
resuspended using freezing mix. The freezing mix was aliquoted in 2 ml cryotubes 
(Nunc, Wiesbaden). The cryotubes were placed at RT for 15 min and were placed in a 
isopropanol bath, which was frozen at –80οC for overnight. The cryotubes were 
placed in a liquid nitrogen container until further use. The freezing mix used was 90 
% FCS, 10 % DMSO (Sigma-Aldrich, Germany). 
 
III.4.3 Transfection of eukaryotic cells 
The transfection of eucaryotic cells was performed using Fugene transfection reagent 
(Roche, Germany) as described by manufacturer. The cell lines were plated at a 
density of 50 – 80% confluency for 24h before transfection. The DNA used for 
transfection was purified using phenol-chloroform extraction method (Chapter 
III.3.6). For transfecting cells in 6 well plates, 1.5 μg of DNA was added to 
transfection solution containing 6 μl of Fugene transfection reagent diluted in 100 μl 
of serum free medium. The transfection solution was incubated at RT for 15 min for 
complex formation. The transfection solution was added drop wise on the cells and 
the cells were swirled to equally distribute the DNA complex. The volume of the 
culture supernatant was made to 1 ml.  The medium containing the expressed 
transgene was collected at 48 h post transfection.  
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III.5 Adenovirus methods 
III.5.1 Storage of virus 
Adenoviral vectors were purified using PD10 Sepahdex 25 columns (Amersham) after 
double cesium chloride centrifugation.  The viral vectors were eluted in TBS and 
mixed with 10 % glycerol. The vectors were stored at –80οC deep freezer until further 
use.  
 
III.5.2 Agarose overlay and isolation of plaques 
Agarose overlay medium 
0.5    %  autoclaved agarose (FMC products, USA) 
1x   MEM 
0.5    %  penicillin/streptomycin 
0.05 %   yeast extract 
5.0    %  FCS 
Isolation of the plaques 
293 cells were plated at 60-70 % confluency in a 6 well plate. 24 h after seeding, the 
cells were either transfected with a plasmid used for the generation of first generation 
virus or infected with the first generation vector.  After 16 h, the transfected or 
infected cells were overlaid with agarose and were incubated at 37 ºC in a cell 
incubator containing 5 % CO2 for a maximum period of two weeks. The cells were 
observed for two weeks under a light microscope for focal areas of lysed cells called 
plaques. Individual plaques representing single rescue events of vector are caused by 
a single clone of virus and were picked using sterile Pasteur pipettes The plaques were 
re-suspended in 1 ml of TBS and were frozen at –80οC. 
 
III.5.3 Generation of high capacity adenoviral (HC-Ad) vectors 
 Cre 66 cells were used for the generation of HC-Ad vectors. The plasmid used for the 
generation of the HC-Ad vector was digested with Pme I to release the ITRs. For the 
first amplification, the Cre66 cells (2x106 cells in a 6 cm plate) were transfected with 
the plasmid using effectene reagent (Qiagen). 16 h after transfection, the cells were 
infected with 5 moi of helper virus. The infected cells showing CPE at 48 h were 
harvested. The harvested Cre 66 cells were re-suspended in 2 ml of TBS followed by 
three times freeze thawing to release the vector particles.  During the second and the 
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third amplification, Cre 66 cells (3x106 cells in 6 cm plate) were infected with half the 
supernatant from the cell lysate of the earlier amplification, and 5 moi of helper virus.  
During the fourth and fifth amplifications, Cre 66 cells were plated at a density of 
3x107 cells in 15 cm plates were infected with half the supernatant (from the cell 
lysate of the earlier amplifications) and 5 moi of helper virus. For a large-scale 
preparation, Cre66 (ten 15 cm plates, each with 3x107 cells) were infected with the 
supernatant (containing the virus) from the fifth amplification or 10 MOI of HC-Ad 
vector (if the titre has been previously determined) and 5 moi of helper virus. The 
infected cells were harvested after 48 h and were re-suspended in TBS containing 
glycerol. 
 
III.5.4 Purification of adenoviral vectors using CSCl density gradient 
ultracentrifuation 
 The re-suspended cells were freeze thawed for vector release. The vector containing 
supernatant was collected by centrifugation at 200g to remove the cell debris. The 
supernatant was made up to a volume of 20 ml and CsCl was added at a concentration 
of 0.5 gm/ml. The virus was centrifuged twice at 32,000 RPM at 4ºC for 22 h in an 
ultracentrifuge (Ultracentrifuge L7-65 with SW41- Rotor, Beckman, USA) The 
adenoviral vector floats as a ring in the CsCl gradient at a density of 1.34 gm/cm3. 
The virus was aspirated using a 2 ml syringe fitted to a needle. After the second 
gradient, the virus was desalted in PD 100 columns using TBS buffer. Glycerol was 
added to the eluted vector at a concentration of 10 %. The virus was stored at -800C. 
 
III.5.5 Titration of helper virus or first generation adenoviral vectors 
HeLa cells were used for determining the titer of first generation vectors and helper 
virus vectors. The cells were plated at a density of 2x106 in 6 cm plates. The plated 
cells were infected with different dilutions of the vector. 16h after infection the cells 
were overlaid with 10 ml of agarose overlay medium for 15 minutes at room 
temperature. The cells were incubated at 370C in cell incubator containing 5 % CO2 
for 5-14 days. The plates were observed under light microscope for plaques. The 
average number of plaques at a given dilution represents the plaque forming units 
(pfu) of the virus.    
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III.5.6 Titration of HC-Ad vector using slot blot analysis 
 The slot blot method was used to determine the infectious units, total particle and the 
helper virus contamination titers. HeLa cells were used for the determination of 
infectious units of the HC-Ad vectors. The cells were plated for overnight at a density 
of 1x105 cells in a 24 well plate before infection with HC-Ad vector. HC-Ad vectors 
were diluted at 1:20 in TBS, and 4 to 20 μl of the diluted HC-Ad vector was used to 
infect HeLa cells in duplicates. 16 h after infection, the cells were washed intensively 
with PBS and were incubated with 200 μl of PBS/5mM EDTA for 15 minutes to 
detach the cells from the plate. The detached cells were incubated with 200 μl of 0.8 
N NaOH for 30 minutes to lyse the cells. The plasmid p GS46, added to the 
uninfected cells at copy numbers ranging from 1x106 to 1x108, acted as the standard. 
The total particle titre of HC-Ad vectors was determined using a cell free system. The 
HC-Ad vector was diluted 1: 400 in TBS buffer.  Four to 20 µl of the diluted HC-Ad 
vector was made up to a volume of 200 μl of TBS and was lysed with 200 μl of 0.8 N 
NaOH for 30 min at room temperature. The plasmid p GS46 was used as the standard 
and, was diluted in TBS (to a volume of 200 μl) to represent copy numbers ranging 
from 1x106 to and 1x108. The diluted standards were mixed with 200 μl of 0.8 N 
NaOH and were incubated for 30 min at room temperature.   
The helper viral contamination was determined using a cell free system. The HC-Ad 
vector was diluted 1: 200 in TBS. Four 20 μls of the diluted virus was made up to a 
volume of 200 μl of TBS and was lysed with 200 μl of 0.8 NaOH for 30 min at room 
temperature. The plasmid pGS 46 was used as the standard and, was diluted in TBS 
(to a volume of 200 μl) to represent the copy numbers ranging from 1x106 to and 
1x108. The diluted standards were mixed with 200 μl of 0.8 N NaOH and were 
incubated for 30 min at room temperature.    
300 μl of cell or particle lysate was transferred to a nylon membrane Bio Dyne 
membrane (PALL Corporation, USA) using the slot blot apparatus (Hoefer PR 648, 
Bio-Rad Laboratories, Munich). After transfer, the membrane was washed with 2 x 
SSC buffer followed by baking at 1200C for 30 minutes. The baked membrane was 
pre-hybridized with hybridization buffer for 4h at 680C.  The probe used for the 
determination of infectious units and total particle binds to the left ITR of the 
adenovirus (nucleotide 1- 438).  The probe used for the determination of the helper 
virus particle binds to the fiber (nucleotide 31042 to 32390) The PCR probe was 
radioactively labeled with 50 μCi 32[P] dCTP (Amersham Pharmacia, Germany) using 
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the Ready to go DNA Labeling Kit (Amersham Pharmacia,Germany).  The membrane 
was hybridized using the radioactive probe for 16 h at 680C. The membrane was 
washed at 680C with buffer I followed by a second wash with wash buffer II for 20 
minutes. The membrane was transferred to a phospho-imager cassette and the signal 
was read using a Phospho imager 445SSI (Molecular Dynamics,USA). The titer of the 
HC-Ad vector was estimated by comparing the signal intensity between the HC-Ad 
vector and the plasmid standards.  
 
III.6 Animal handling techniques  
129SvJ Fah Δexon5 (5-8 week old) mice were used for all the experiments. The animals 
were maintained under pathogen free conditions at the animal facility of the Oregon 
Health Sciences University. The mice were fed with standard diet (B&K universal) 
and sterilized water with or without the recommended dosage of NTBC. All mice 
were cared for in compliance with the guidance prescribed by OSHU.  
 
III.6.1 Harvesting of the mouse liver 
The animal was anaesthetised and then killed by cervical dislocation. Four limb 
immobilization was carried out using tape on a moisture absorbing surface.  The 
abdomen was opened, the liver removed and placed on a glass slide.  The smaller 
lobes 4, 5 and 6 (behind the gall bladder) were identified, and each was cut 
individually and placed along with the larger lobes 1, 2 and 3 on glass slides. Each 
lobe was sliced lengthwise into 3 pieces.  The middle piece was stored in the solution 
for histology.  The bottom piece for was used for DNA extraction and the top piece 
was quick frozen and stored. 
 
III.6.2 Isolation and serial transplantation of hepatocytes into recipient livers 
The peristaltic pump tubing was rinsed with 70 % ETOH and then with PBS, and all 
the solutions were prewarmed to 370C.  The i.v. infusion set was attached and Soln I 
was run through it. The donor mouse was anaesthetised, and four limb immobilization 
carried out using tape on a moisture absorbing surface inside a tissue culture hood.  
The abdomen was cut open and the inferior vena cava and the portal vessels located 
under the liver were located.  The i.v. catheter was rinsed with Soln I and then the 
inferior vena cava was cannulated.  The i.v. tubing was attached to the catheter and 
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the pump was started.  When the liver filled up with the solution, the portal vein was 
cut.  The chest of the mouse was opened and the superior vena cava was clamped.  
The peristaltic pump was run at a rate of 5 ml/minute.  After 3 minutes of perfusion 
with Soln I, the liver was perfused with Soln II for 2 minutes and then with Soln II.  
When the liver was digested, the catheter was removed, and the liver was transferred 
to a petri dish in a second tissue culture hood.  The liver capsule was disrupted with 
forceps in 5 ml of Soln III and the hepatocytes washed out.  The cells were filtered 
through the nylon mesh into a 50 ml tube that contained 10 ml prewarmed DMEM 
with serum.  Cells were pelleted and resuspended in 50 ml high glucose DMEM plus 
serum.  The washes were repeated three times and the cells resuspended in plating 
medium (high glucose DMEM with serum).  The recipient mouse was anaesthetised 
and had the abdominal fur shaved off, and the region sterilized with 70% ETOH.  The 
abdomen was cut, the spleen located, and the syringe needle containing the 
hepatocytes was inserted into the spleen and the region above the point of entry of the 
needle was clamped and the hepatocytes injected.  The peritoneum and the skin were 
sewn back, and the mouse was allowed to recover. 
 
III.6. 3 Calculation of the rates of recombination HC AdV in vivo 
The histology slides containing the liver samples were scanned on a Canon Flat bed 
scanner along with a size standard.  The software NIH Image was used to determine 
the size of the liver samples and the cell numbers as described in (Wang et al., 2002), 
from which the correction factor was also used.  The number of vector molecules 
reaching the hepatocytes were calculated as described in pg 137.  The slides were 
checked for brown (Fah+ve) cells and nodules.  Photos were taken using a Zeiss 
PVCAM Inverted Microscope and a PCIAIA camera from Hamamatsu (Open lab 
3.03 software).  
 
For example, in mouse 301, the rate of recombination was calculated as follows. 
Total amount of cells (obtained by calculating the total surface area in the liver 
sections using NIH Image J) = 9.4 x105  
Amount of virus reaching these cells after the injection (for 1x1010 inf.units, see pg 
138) = 10 viruses/cell 
∴, total number of virus in the hepatocytes analysed from mouse 301 = 9.4 x106 
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Number of nodules observed in the liver sections from mouse 301 = 30 
∴, rate of recombination = 1/313333 
Correction factor (Wang et al., 2002) = 5 
∴, actual rate of recombination = 1/1566666.7 
                                                       = 6.4x 10-7 
 
Ensembl Version 
Human and mouse genome releases 38, April 2006 were used in this study. 
 
III.7 Hprt model 
Nucleotides are synthesized either totally from the beginning from amino acids, 
tetrahydofolates, CO2 and NH4
+ (de novo synthesis pathway) or are reused from 
existing nucleotides (salvage pathway).  The central molecule in both pathways is 5-
phosphoribosyl-1-pyrophosphate (PRPP) (see Fig. 6). 
Fig. 6:  Fig.ure of PRPP (from http://www-medlib.med.utah.edu/NetBiochem/pupyr/pp.htm) 
 
In the de novo pathway, the first stage is the synthesis of a closed ring 5-
Aminoimidazole ribonucleotide from PRPP.  The gist of the pathway is as follows: 
The amino group from a glutamine replaces the Ppi, and a glycine is added to it. A 
formyl group is added to the α-amino terminal of glycine by N10-
formyltetrahydrofolate. A glycine donor converts the amide group of the compound 
into an amidine group and the ring is closed to form the 5 membered ring of the 
purine skeleton, 5-aminoimidazoleribonucleotide.  Following carboxylation, an 
aspartate is added to the ring.  The fumarate part of the moiety is removed leaving 
only the amino group.  Another formyl group is donated by the N10-
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formyltetrahydrofolate, a water molecule is removed and the ring is closed to generate 
inosinate (IMP), from which adenylate (AMP) and guanylate (GMP) are synthesised 
(see Fig. 9).  
In the purine salvage pathway, the ribose phosphate moiety of PRPP is transferred on 
to the free purine bases obtained during the degradation of nucleic acids and 
nucleotides.  The formation of adenylate from adenine is catalysed by Adenine 
phosphoribosyl transferase (APRT), and the conversion of hypoxanthine and guanine 
to inosinate and guanylate are catalysed by hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT) (See Fig. 7). 
 
Fig. 7.  Schematic diagram of purine salvage pathway based on (Nyhan, 2005) 
 
 
Fig. 8.  Schematic diagram of the human Hprt gene based on (Stout & Caskey, 1985) 
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Fig. 9. Diagram of the Purine de novo synthesis, based on (Stryer, 1998) 
 
The enzyme dihydrofolate reductase (DHFR) converts 7,8-Dihydrofolate to 5,6,7,8,-
Tetrahydrate folate.  The drug aminopterin is an analogue of Dihydrofolate and 
competitively inhibits DHFR.  When combined with hypoxanthine and  
thymidine, the drug (HAT) is used to select for cells that are HPRT positive 
(Szybalski & Szybalska, 1962).  HPRT itself can bind and ribosylate toxic purine 
analogues such as 6-Thioguanine (6TG) with toxic results for the cell.  So HPRT- 
cells can be selected for by the addition of 6TG to the medium (Stutts & Brockman, 
1963). 
HPRT is a housekeeping gene.  In humans, the gene encoding HPRT is 44 kb long, 
consists of 9 exons and is located on the q arm of the X chromosome between bps 
133421923 to 133462354 [reviewed in (Caskey & Stout, 1989, Stout & Caskey, 
1985)] (see Fig. 8).  Deficiency of HPRT leads to Lesh Nyhan Syndrome in humans 
(Nyhan, 2005, Schepis et al., 1996).  Of the various mutations in the HPRT gene that 
result in the syndrome, HPRT CHICAGO, where the insertion of a single T nucleotide 
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resulted in the formation of a stop codon (Davidson et al., 1989) was of particular 
interest in this study. 
The HPRT locus has been used extensively for studies on gene targeting.  In 
pioneering studies using plasmids, the rates of homologous recombination was 
observed to be in the range of 10-6 and the rate of random integration in the range of 
10-3 with respect to the number of cells.  The rate of homologous recombination was 
also observed to increase in proportion to the amount of homology between the DNA 
fragments (Capecchi, 1989, Deng & Capecchi, 1992, Doetschman et al., 1987, Hasty 
et al., 1991, Manivasakam et al., 2001, Thomas & Capecchi, 1987, Wade-Martins et 
al., 2000, Yun et al., 2004, Zheng et al., 1991).  The results published with work using 
viral vectors on the HPRT locus have been mentioned earlier.  
  
III.8 Fumarylacetoacetate hydrolase (Fah) mouse model 
In the pioneering work that linked metabolic disorders to genetics, Archibald Garrod 
postulated the relationship between genes and enzymes when he published his 
findings on alcaptonuria, a condition caused by the absence of homogentisate oxidase.   
It is a part of the phenylalanie and tyrosine degradation pathways, where an aromatic 
ring is broken by molecular oxygen and the products are passed on into the citric acid 
cycle.  Phenylalanine is hydroxylated into tyrosine, which is converted into 4-
hydroxyphenylpyruvic acid, which reacts with O2 to form homogentisic acid.  O2 
cleaves the aromtic ring producing maleylacetoacetic acid.  It is converted into its 
isomer fumarylacetoacetic acid (FAA) by fumarylacetoacetate hydrolase (FAH), 
which is hydrolysed into fumaric acid and acetoacetic acid, which are passed on into 
the citric acid cycle [reviewed in (Tanguay et al., 1996)] (see Fig. 10). 
Deficiency of the enzymes in the pathway results in various forms of 
hypertyrosinemia. The loss of FAH enzyme results in tyrosinemia type 1, 
characterized by progressive liver and renal damage.  The compartmentalization of 
FAA, and its subsequent reaction to glutathione and protein thiol groups lead to 
mutagenic, cytostatic, and apoptogenic activites in cells (Endo & Sun, 2002, Jorquera 
& Tanguay, 1997, Jorquera & Tanguay, 1999, Kubo et al., 1998, Tanguay et al., 
1996).  FAA was proven to induce mitotic abnormality and genomic instability by 
activating the extracellular signal-regulated protein kinase (ERK) pathway, and this 
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was postulated to be responsible for the hepatic cancer developing in 37 % of the 
human cases (Jorquera & Tanguay, 2001).  
In competing with other plants, certain members of the Myrtaceae family and the 
symbionts, the lichens, produce diketone and triketone alkaloids that specifically 
inhibit the 4-hydroxyphenylpyruvate dioxygenase (HPPD) of the neighbouring plants.  
One such competitive inhibitor of HPPD, triketone, 2-[2-nitro-4-
(trifluromethyl)benzoyl]-1,3-cyclohexanedione (NTBC), that binds strongly to the 
HPPD and FeII complex, was used to treat the patients (Holme & Lindstedt, 1998, 
Kavana & Moran, 2003).  Tyrosinemic livers were found to be not only FAH-ve 
tissue, but mosaics with FAH+ve tissues where the actual reversion of the original 
mutation had occurred.  The nodular growth of the FAH+ve cells pointed out to the 
selective advantage those cells have in a FAH-ve liver (Kvittingen et al., 1993). 
 
 
 
Fig. 10. Diagram of the Tyrosine metabolism pathway adapted from (Grompe et al., 1995) 
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Fig. 11.  Schematic diagram of the murine FAH gene 
 
In the mouse, the FAH gene, consisting of 14 exons, is located in Chr 7 between bps 
80506746- 80527407 (see Fig. 11).  The C14CoS albino mouse, with a large deletion in 
Chr 7, including the Fah gene (Klebig et al., 1992), displays neonatal death 
(Gluecksohn-Waelsch, 1979).  This phenotype was shown to arise from the lack of 
FAH (Kelsey et al., 1993).  Knockout mice (FAH-/- mice) with a targeted insertion of 
a neo cassette into the exon 5 of the FAH gene, displayed the same phenotype 
(Grompe et al., 1993).  The use of NTBC alleviated the neonatal lethal phenotype in 
the mice for up to 2 years (Al-Dhalimy et al., 2002, Grompe et al., 1995).  Correction 
of the phenotype was observed when liver cells transduced with a retroviral vector 
carrying the FAH cDNA were injected on recipient mice (Overturf et al., 1998).  As 
expected, given the regeneration capacity of the liver [reviewed by (Michalopoulos & 
Khan, 2005)], as few as 1000 transplanted wt FAH +ve cells were able to repopulate a 
FAH-ve liver in knockout mice, with normal liver function (Grompe et al., 1998, 
Overturf et al., 1996).  The work done on the model using a Ist gen AdV carrying the 
FAH cDNA under the control of a RSV promoter, and an AAV vector carrying the 
cDNA, have been mentioned in the introduction.          
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III.9 Plasmids 
III.9.1 Construction of plasmid p SLS 11 
The aim of generating this plasmid was to generate a high capacity adenoviral vector 
capable of both disrupting exon 2 of the human hprt gene in the event of the vector 
DNA undergoing homologous recombination in the genome, and also inserting a 
selection cassette into the genome in the event of random recombination.  To disrupt 
the hprt gene, the clinical mutation hprt Chicago (Davidson et al., 1989) was utilised. 
A T nucleotide was incorporated at the 30th bp of exon 2 (nucleotide 13162 of hprt 
gene), resulting in the generation of a stop codon and an unique Eco RV site was 
engineered downstream of the mutation by substituting the T at nucleotide 4 and A at 
nucleotide 6 with A and C nucleotides respectively (Fig. 23). 
The plasmid p SLS 1 was constructed to introduce a Swa I site into the multiple 
cloning site of plasmid pBluescript II KS (p BSIIKS). p BSIIKS (Stratagene) was cut 
with Eco RV and the oligonucleotide 24129/24130, carrying a Swa I site (donated by 
Dr. Schiedner) was cloned into the site to generate p SLS 1.  
The plasmid p SLS 2 was constructed to sublone the 11.5 kb of the Hprt fragment 
from p STK 129.  p STK 129 was digested with Swa I and Not I and the fragment 
(base pairs 8913 –20424 of pSTK129) was purified. p SLS 1 was digested with Swa I 
and Not I and the electroeluted insert was cloned in to generate p SLS 2. 
The plasmid p SLS 3 was constructed to remove the exon 2 of the hprt from p SLS 2. 
Plasmid p SLS 2 was grown in a dcm- strain (GM 2163, NEB), digested with Sex AI 
to excise out the 484 base pair Sex AI fragment containing the exon 2 (base pairs 
133,435,071- 133,434,587 of the hprt gene) and was religated to generate p SLS 3. 
The plasmid p SLS 4 was constructed to generate a stop codon within the exon 2 of 
the hprt and to alter its reading frame. PCR was performed on p SLS 2 template using 
the primers Sam Stephen I and Sam Stephen II to generate a 493 base pair fragment 
containing an insertion of a T nucleotide and an Eco RV site into the exon 2 of the 
hprt gene. p BSIIKS was digested with Eco RV and this pfu PCR generated product 
was cloned into the site to generate p SLS 4. 
The plasmid p SLS 5 was constructed to generate a stop codon within the exon 2 and 
to alter its reading frame of the hprt fragment contained in p SLS 3. p SLS 4 was 
digested with Sex AI, and the electroeluted fragment was cloned into the Sex AI site of 
p SLS 3 to generate p SLS5. 
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The plasmid p SLS 6 was constructed to introduce the stop codon and the altered 
reading frame of the hprt into the stuffer DNA of p STK129.  p STK 129 was digested 
with Swa I and Not I and CIPed.  p SLS5 was double digested with Swa I and Not I 
and the 11.5 kb fragment was cloned into the above mentioned p STK 129 to generate 
p SLS 6. 
The plasmid p SLS 11 was constructed to include a Hygromycin-EGFP (Enhanced 
Green Fluorescent Protein) fusion cassette into the p SLS 6 so as to generate a vector 
plasmid capable of introducing the stop codon into the exon 2 of the hprt gene as well 
as inserting a Hyg-EGFP cassette into the genome. p SLS 6 was digested with Not I 
and klenowed. p HygEGFP (Clontech) was double digested with Bgl II and Cla I.  
The 3.1 kb fragment containing the expression cassette including the promoter and the 
poly A signal was cloned into the above mentioned vector.   
The cloning scheme for the construction of the plasmid is shown in Fig. 12.   
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Fig. 12: Scheme showing the construction of p SLS 11 
 
III.9.2 Construction of plasmid p SLS 14 
This plasmid was generated to produce a HC-AdV capable of replacing the mutated 
exon 5 of the fah gene in the Fah-/- mouse with the wild type Fah exon 5, thereby 
restoring the gene function.  The exons 2 to 9 were cloned into the plasmid. 
p SLS 13 was generated to create a viral vector plasmid that can be rescued using Sna 
BI instead of the standard Pme I, due to the presence of a Pme I site in the intron 5-6 
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of the murine fah gene.  p STK 68  and p STK 5 were digested with Pme I and the 16 
kb fragment of p STK 68 was cloned into the digested p STK 5 to generate p SLS 13. 
p SLS 9 was created to subclone the 16.4 kb fragment from the murine fah gene 
including the exons 1-5 from the λ Dash II phage vector.  λmFAH6 was digested with 
Not I and Cla I and the 12.3 kb fragment of the fah gene containing exons 2, 3, 4 and 
5 was ligated onto p BKRSV (Stratagene) cut with the same enzymes to generate p 
SLS 9.  
p SLS 14 was generated to create the vector plasmid.  p SLS13 was cut with Eco RV 
and p SLS 9 was cut with Cla I and Not I, and the 12.3 kb fah fragment was cloned 
into the vector to generate p SLS 14.   
The cloning scheme for the construction of the plasmid is shown in Fig. 13. 
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Fig. 13: Scheme showing the construction of p SLS 14 
 
III.9.3 Construction of plasmid p SLS 16 
This plasmid was generated to produce a HC-AdV carrying a murine fah cDNA under 
the control of a RSV promoter, to restore the fah gene function in Fah-ve cells. 
p SLS 15 was generated to clone the murine FAH cDNA into the MCS of the p 
Rc/RSV so as to enable it to be expressed from the RSV promoter.  p mFAH4AR1 
(donated by Prof. Grompe) was digested with Eco RI, ends blunted using Klenow 
enzyme and purified by gel electoelution and cloned into the Hind III site of p 
Rc/RSV that had been made blunt using the Klenow enzyme to generate p SLS15. 
The vector plasmid p SLS 16 was produced by cloning in the RSV-mFAH cDNA-
BGH polyA cassette into p STK 120.  p SLS 15 was digested with Nru I and Pvu II, 
and the DNA termini were made blunt using Klenow enzyme.  The cassette was 
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purified using electroelution and cloned into p STK120 that had been digested with 
Swa I and the ends made blunt with Klenow enzyme to generate p SLS 16. 
The cloning scheme for the construction of the plasmid is shown in Fig. 14. 
 
 
Fig. 14: Scheme showing the construction of p SLS 16 
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IV Results 
IV.1 Calculation of the amount of Hygromycin B required to select 
out untransduced cells 
Hygromycin B (C20H37N3O13) is an aminoglycoside antibiotic, produced by 
Streptomyces hygroscopicus, and inhibits the growth of prokaryotic and eukaryotic 
cells by inducing the mistranslation of the mRNA (Moazed & Noller, 1987, Spahn & 
Prescott, 1996), the mistranslocation of the mRNA (Cabanas et al., 1978, Hausner et 
al., 1988) and the inhibition of 75-80 % of the ATPase activity of the 70S ribosomes 
(Ganoza & Kiel, 2001).  The E.coli hph gene encodes Hygromycin 
phosphotransferase (Gritz & Davies, 1983).  The phosphorylation of the 4-OH group 
results in the alteration of the stereostructure of Hygromycin B (Hyg B), resulting in a 
loss of its ability to bind to the ribosome.     
 
Experimental setup: 
 
Fig. 16: Scheme of the vitality curve experiments. Cells were plated on to 6 well plates and grown on 
medium supplemented with varying amounts of Hyg B, and the number of living cells, based on 
Trypan Blue exclusion was calculated. 
 
To determine the optimal amount of Hygromycin B to be used in the experiments for 
the determination of the rates of random integration in vitro, vitality curves of the 
different cell lines were plotted in different concentrations of Hygromycin B (see Fig. 
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16).  1x105 cells of each cell line were plated in 6 well plates and were maintained in 
one of the following mediums with α-MEM as the base (see Table 4). 
 
Code number Amount of Hygromycin B (mg/ml) in α-MEM 
a 0 
b 0.1 
c 0.15 
d 0.2 
e 0.25 
f 0.3 
g 0.5 
 
Table 4: List of the amount of Hygromycin B (mg/ml) used in the experiment 
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Fig. 17: Vitality Curve of 293 cells in medium supplemented with varying amounts of Hyg B.  Cells 
were grown in 6 well plates and were selected in Hyg B containing medium. The number of cells was 
counted with a haemocytometer on Trypan Blue exclusion, and the data was mapped on to the graph 
above. 
 
Cell count using Trypan Blue staining was taken once in three days and the number of 
the viable cells, counted using a Haemocytometer, was plotted in a graph which was 
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used to determine the optimal amount of Hygromycin B to be used.  Six cell lines 
were used in the study.  The vitality curve of 293 cells in Hyg B is shown here as an 
example (See Fig. 17).  The following cell lines were used:   
1.  293 cells 
2.  HT1080 cells 
3.  C-32 cells 
4.  FF-95 cells 
5.  HeLa cells 
6.  Human Retinal Pigmented Epithelium (HRPE) cells 
 
The aim of the experiment was to optimise the amount of Hygromycin B to be added 
to the medium for selection. In all of the cell lines used, a concentration of 0.25 
mg/ml of Hygromycin B was sufficient to kill all of the non-resistant cells by day 12 
of the experiment and this concentration was used in the in vitro experiments. 
 
IV.2 Determination of the permissivity of different cell lines to 
transduction with HC-AdV 
 
Before the rates of integration and homologous recombination of HC-AdVs in vitro 
could be determined accurately, it was imperative that a calculation on the 
permissivity of the cell lines used in the study was carried out so that the number of 
recombination events per infection unit of the vector could be accurately calculated. 
The permissivity of various cell lines to adenovirus may differ and many factors such 
as the expression of CAR may be responsible for this (Carson et al., 1999, Hidaka et 
al., 1999, Kibbe et al., 2000, Leon et al., 1998).  The expression levels of other 
molecules such as heparin sulphate proteoglycans (Dechecchi et al., 2000), MHC 
class I (Hong et al., 1997), the αv integrins (Wickham et al., 1993), the actin 
cytoskeleton (Patterson & Russell, 1983), phosphatidylinositol –3-OH kinase (Li et 
al., 1998b), the Rho family GTPases (Li et al., 1998a) might also play a part in the 
permissivity of the individual cell lines to adenovirus.  To determine the permissivity 
of the cell lines used in the in vitro experiments, a modification of the slot blot 
experiment (Kreppel et al., 2002), the same that is used in the titration of the stocks of 
the HC-AdVs produced, was carried out.  Cells of each of the cell lines were plated at 
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1x105 cells per well of a 24 well tissue culture plate.  A HC-AdV of characterised 
titre, was used to infect the cell lines at various multiplicities of infection (moi) and 
the infectivity on the various cells was calculated using the above mentioned method, 
against that measured for HeLa cells (Fig. 18).  The moi of HC-AdV in a given cell 
line, that gave a radioactive signal that corresponded to the moi 1 in Hela was taken as 
moi 1 for that particular cell line.  
 
Experimental Setup 
 
Fig. 18: Scheme of the experiment to determine the permissivity of the cell lines to AdV.  Cells were 
plated on 24 well plates and infected with different dilutions of the vector and the viral load was 
calculated as per slot blot procedure.  The left terminus of Ad5 was used as the probe. 
 
The results obtained from the experiment are summarised in the following table (Fig. 
19).  
The aim of the experiment was to calculate the amount of viral vector needed to infect 
the various cell lines used the experiment at such an moi so as to obtain one vector 
copy per cell. During the experiment, it was found out that different cell lines needed 
different mois, summarised above, so as to obtain a single vector copy per cell. 
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Fig. 19: Graph showing the permissivity of the different cell lines to adenovirus.  Cells were transduced 
with varying mois with an AdV of a known titer and the copy load of vector DNA per cell was 
calculated using the slot blot method and plotted as the graph above. 
 
IV.3 Determination of the rate of integration of HC-AdV in vitro 
This series of experiments were carried out to determine the rate of integration of HC-
AdVs in vitro.  The vector used was Ad SLS 11, based on the plasmid p SLS 11.  The 
structure of the vector is shown in Fig. 20 and the full details of the cloning procedure 
have been given on pg 65.  In Ad SLS11, the exon 2 of the Hprt gene has been 
mutated to generate a stop codon.  This mutation was designed to mimic the mutation 
that has been observed in a patient with Lesh Nyhan Syndrome (Davidson et al., 
1989).  A novel Eco RV site was designed downstream of the above mentioned 
mutation by substituting two nucleotides.  In addition, a Hyg-EGFP expression 
cassette was cloned into the plasmid outside the Hprt fragment. 
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ITR ψ Hprt fragment              CMV HygEGFP   c346           ITR
1st Intron   Exon 2      Exon 3 3rd Intron
                  mutation  
Fig. 20: Diagram of the HC-AdV vector Ad SLS 11, detailing the location of the various components. 
 
The vector was designed to generate Hprt negative clones on the event of the vector 
DNA undergoing homologous recombination into the genome of normal Hprt positive 
cells.  The vector was also designed to confer resistance to Hygromycin B in all of the 
transduced cells, and to form hygromycin resistant colonies in the event of the 
integration of the vector DNA into the cellular genome. 
The plasmid was rescued with helper virus and serially amplified and purified using a 
CsCl gradient. The titre of the vector was determined using Slot Blot procedure. 
 
Experimental setup: 
HT1080, C-32, FF 95, HRPE and HeLa cells were infected at a moi of 1 with Ad SLS 
11 on day 0 in 6 cm tissue culture dishes.  On day 2, the cells were trypsinised, diluted 
and replated on to 15 cm tissue culture dishes. Cells infected with Ad SLS21 (that 
does not carry the EGFP-Hyg fusion cassette, and used in another project) and TBS 
treated cells were used as controls.  On day 3, the cells were grown in medium 
containing 0.25 mg/ml of Hygromycin B, and were selected untill all the cells in the 
controls died out (Fig. 21). The number of hygromycin resistant colonies from each 
experiment was counted and is summarised in Table 5. 
 
Cell line Number of experiments Mean of the frequencies SD 
HT 1080 n = 9 5.43 x 10-3 4.6 x10-4 
C 32 n = 12 1.47 x10-3 7.3 x10-5 
FF 95 n =10 3.51 x10-3 3.4 x10-4 
HRPE n = 8 1.1 x10-4 2 x10-5 
HeLa n = 7 4.66 x10-3 3.01 x10-4 
Table 5: The data obtained from the experiment for calculating the rate of random integration of the 
HC-AdV into the cellular genome. 
 
The results obtained from all of the experiments were plotted as a graph in Fig. 22. 
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Ad SLS 11Ad SLS 21/TBS
Cells replated and 
grown in medium 
supplemented with
Hyg
Any Chromosome in the cells
Hyg R gene integrates into the genome following random integration
Ad SLS 11
No Hyg R.
Cells die
Cells where the integration has 
taken place form Hyg R colonies
Cells
Hyg EGP fusion cassette
 
 
Fig. 21: Scheme of the experiment used to calculate the rate of random integration of the HC-AdV in 
vitro.  Cells were infected at 1 moi either with Ad SLS 11, raised in medium supplemented with Hyg 
B, and the number of Hyg resistant colonies was taken when the control cells (1X TBS treated or 
infected with Ad SLS 21) had died out. 
 
Significant differences in the rates of integration of the HC-AdV in between different 
cell lines were observed when One-way Analysis of Variance (ANOVA) was carried 
out on the means.  The P value obtained was < 0.0001, which is considered highly 
significant, indicating that the variation among column means is significantly greater 
than expected by chance.  
To summarise, the rate of integration of the HC-AdV DNA into the genome varied in 
different established and primary cell lines and was found to be between 5.43x10-3 to 
1.1x10-4 events per vector that enters the cell. 
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Fig. 22: Graph showing the rate of random integration of HC-AdV into the genome in vitro.  The 
results from Table 5 were plotted on to the graph. 
 
IV.4 Determination of the rate of homologous recombination of HC-
AdV DNA in vitro 
This series of experiments were carried out to determine the rate of integration of HC-
AdVs in vitro.  Ad SLS 11 was designed to carry a T insertion (nucleotide 13162 of 
hprt gene) in the exon 2 of the HPRT fragment resulting in the formation of a stop 
codon mimicking the published mutation HPRT CHICAGO (Davidson et al., 1989) 
observed in a human subject. A novel Eco RV restriction site was also engineered into 
the region by two substitutions (Fig. 23). 
The rationale of the experiment was that the vector, on undergoing homologous 
recombination in a cell carrying a single X chromosome, would introduce a stop 
codon in the hprt gene, thereby shutting it off. This in turn would shut off the purine 
salvage pathway, thereby preventing the incorporation of the toxic purine analogue 6-
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Thioguanine (6TG). Thus a successful homologous recombination event would lead 
to the formation of a 6TG resistant clone (Fig. 24). 
 
 
 
 
Fig. 23 A. Diagram comparing the mutations introduced into the mutant Hprt gene via Ad SLS 11 to 
the sequence in the wt Hprt gene 
Fig. 23 B. Diagram showing the translation of the Hprt gene at the site of the introduced mutation and 
the introduction of the stop codon. 
 
Ad SLS 11
ITR Hprt Ex2* Ex3 Hprt  HygEGFP c346 ITR
X X
Hprt gene 
on 
Chr X q26
Mutated Hprt
 gene on 
Chr X q26
Ex1            E2   E3            E4  E5     E6        E7 E8   E9 
Ex1            E2*  E3            E4  E5     E6        E7 E8   E9 
HR
Stop codon introduced in Hprt exon 2 as a result of HR
 with Ad SLS 11
19.5 kb homology
 
Fig. 24 : Scheme showing the formation of 6TG resistant cells following HR with Ad SLS 11 DNA. 
 
Experimental set up: 
HT1080, C-32 and FF 95 were infected at 1 moi with Ad SLS 11 on day 0 in 6 cm 
tissue culture dishes.  On day 2, the cells were trypsinised, diluted and replated onto 
15 cm tissue culture dishes. Cells infected with AdSLS 21 that does not posses the 
A 
B 
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Hprt fragment, and TBS treated cells were used as controls. From day 3 onwards, the 
cells were grown on medium containing 0.2 mg/ml of 6TG, and were selected till all 
the cells in the controls died out (Fig. 25). The number of 6TG resistant colonies from 
each experiment was counted, the mean was calculated and the experiment is 
summarised in Table 6. 
Ad SLS 11
6 TG
S
Ad SLS 21/TBS
Cells replated and 
grown in medium 
supplemented with
6TG
Ex1   2  3  4  5  6  7   8   9
Ex1  2* 3  4  5   6  7  8   9
Ex1   2  3  4  5  6   7  8   9
Ex1   2  3  4  5  6  7   8   9
Hprt gene in the cells
Hprt gene structure resulting from HR of the vector
Ad SLS 11
2* 3
Hprt gene intact
Cells die
Cells where the HR has 
taken place disrupting
the Hprt gene form colonies
Cells
 
Fig. 25: Scheme of the experiment to determine the rate of HR of HC-AdV DNA with the 
chromosomal DNA in vitro.  
 
Cell line Number of experiments Mean of the frequencies SD 
HT 1080 n =9 1.197 x10-6 6.7 x10-7 
C 32 n = 9 2.02 x10-5 3.2 x10-6 
FF 95 n = 10 1.05 x10-5 1.18 x10-6 
 
Table 6: The data obtained from the experiment for calculating the rate of homologous recombination 
of the HC-AdV into the cellular genome in vitro.  Cells were infected at 1 moi, raised in medium 
supplemented with 6TG, and the number of 6TG resistant colonies was taken when the control cells 
(1X TBS treated or infected with Ad SLS 21) had died out. 
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The means obtained from all of the experiments were plotted on to a graph below. 
Fig. 26: Graph showing the rate of homologous recombination of HC-AdV DNA with the 
chromosomal DNA in vitro.  The results from Table 6 were plotted on to the graph. 
 
Significant differences in the rates of homologous recombination of the HC-AdV in 
between different cell lines were observed when One-way Analysis of Variance 
(ANOVA) was carried out on the means.  The P value obtained was < 0.0001, which 
is considered highly significant, indicating that the variation among column means is 
significantly greater than expected by chance.  
Taken together, the rate of homologous recombination of HC-AdV DNA into the 
chromosomal DNA varied in different cell lines and primary cells and was calculated 
to be between 2.02x10-5 to 1.197x10-6 events per vector that enters the cell, depending 
on the cell line. 
 
IV.5 Molecular analysis of the DNA from the isolated clones 
To analyse the molecular structure of the integrated HC-AdV DNA, individual clones 
from the experiments described above were isolated and propagated. DNA was 
isolated from 2 x107 cells. Southern blot experiments and PCR reactions were 
performed on the DNA, as described in the materials and methods section.  In the 
Southern blot photos, -c refers to the negative control (cellular DNA), +c1 refers to 
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the positive control of the cellular DNA spiked with 1 copy of vector plasmid per 6 pg 
of DNA, +c2 refers to the positive control of the cellular DNA spiked with 2 copies of 
vector plasmid per 6 pg of DNA, +c4 refers to the positive control of the cellular 
DNA spiked with 4 copies of vector plasmid per 6 pg of DNA, +c5 refers to the 
positive control of the cellular DNA spiked with 5 copies of vector plasmid per 6 pg 
of DNA, cp refers to the positive control of the plasmid DNA. 
 
IV.5.1 Randomness of integration 
To ascertain whether the HC-AdV DNA integrated in a random manner during the 
events that conferred the individual cell lines their resistance to Hygromycin B, this 
series of Southern blots were performed on the DNA obtained from the clones 
isolated after the experiments described above. The DNA from the 6TG resistant 
clones was also used in the experiment to determine whether the homologous 
recombination that had taken place was of a replacement type or an insertion event. 
 
IV.5.1.A Southern blot of the HT 1080 based clones, digested with Sac I  
The DNA was extracted from the clones derived from the cell line HT 1080 followed 
by digestion with the restriction endonuclease Sac I. The vector DNA does not posses 
a Sac I site downstream of the HygEGFP cassette. The digested DNA was run in a 0.8 
% TBE gel, blotted onto a nitrocellulose membrane and hybridized with a 2.3 kb 
probe derived from pHygEGFP and containing the whole of the Hygromycin EGFP 
fusion cassette, including the promoter (Fig. 27).  Since the right terminus was 9 kb 
downstream of the Sac I site that was located upstream of the hygromycin EGFP 
cassette, following an event of random integration, the size of the DNA fragment 
which would cross hybridize with the probe, was expected to be above 9 kb of size, 
dependent on the location of the next Sac I restriction site downstream of the 
integration site in the genomic locus. However, the sizes of the individual bands were 
expected to be different from one another in the event of random integration.  And no 
hybridization with the probe, to the DNA extracted from the 6TG resistant clones, 
was expected in the case of events of a classic replacement homologous 
recombination. 
 
 86
ITR ψ Hprt fragment              CMV HygEGFP   c346        ITR Chromosomal 
                                                                                                     DNA
Sac I                    9 kb +
Hyg EGFP probe
 
 
Fig. 27: Scheme and the Southern blots of the HT 1080 derived clones.   DNA was digested with Sac I, 
run on a 0.8 % 1X TBE gel, blotted on to a nitrocellulose membrane and hybridized with the 2.3 Hyg 
EGFP probe. 1a to 9a denote the 6TG resistant clones. M stands for marker, -c denotes 20 µg of 
HT1080 DNA, +c1 stands for 20 µg of HT1080 DNA spiked with 1 copy/cell of p SLS 11 digested 
with Pme I, +c2 stands for 20 µg of HT1080 DNA spiked with 2 copies/cell of p SLS 11 digested with 
Pme I, +c4 stands for 20 µg of HT1080 DNA spiked with 4 copies/cell of p SLS 11 digested with Pme 
I.   
From these Southern blots, it was evident that the integration of the vector in the 
genome had taken place in a random manner.  Integrations of multiple Ad SLS 11 
copies were observed in some clones and no evidence of random integration was 
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observed in the 6TG resistant cell lines.  More details of the data have been 
summarised on pg 92. 
 
IV.5.1.B Southern blot of the HT 1080 based clones, digested with Kpn I  
To reconfirm the above result, the DNA extracted from the clones derived from the 
cell line HT 1080, was digested with the restriction endonuclease Kpn I.  The digested 
DNA was run for a longer period in a 0.6 % TBE gel, blotted onto a nitrocellulose 
membrane and hybridized with a 1.8 kb probe derived from pHygEGFP and 
containing the just the whole of the Hygromycin EGFP fusion cassette (without the 
promoter).  The sizes of the hybridised bands were expected to be greater than 9 kb, 
since the Kpn I upstream of the cassette was 9 kb away from the right terminus. 
Following an event of random integration, the size of the DNA fragment which would 
cross hybridize with the probe, was expected to be above 9 kb of size, dependent on 
the location of the next Kpn I restriction site downstream of the integration site in the 
genomic locus (Fig. 28). However, the sizes of the individual bands were expected to 
be different from one another in the event of random integration. And no 
hybridization with the probe, to the DNA extracted from the 6TG resistant clones, 
was expected in the case of events of actual homologous recombination. 
From these two Southern blots, and those described on pg 83 it was observed 
integration of the vector in the genome had taken place in a random manner and no 
evidence of random integration was observed in the 6TG resistant cell lines.  More 
details of the data have been summarised on pg 92. 
 
IV.5.1.C Southern Blot of the C 32 based clones, digested with Kpn I 
The DNA extracted from the clones derived from the cell line C 32, was digested with 
the restriction endonuclease Kpn I.  The digested DNA was run for a longer period in 
a 0.6 % TBE gel, blotted onto a nitrocellulose membrane and hybridized with a 1.8 kb 
probe derived from pHygEGFP and containing the just the whole of the Hygromycin 
EGFP fusion cassette (without the promoter).  The sizes of the hybridised bands were 
expected to be greater than 9 kb, since the Kpn I upstream of the cassette was 9 kb 
away from the right terminus.  Following an event of random integration, the size of 
the DNA fragment which would cross hybridize with the probe, was expected to be 
above 9 kb of size, dependent on the location of the next Kpn I restriction site 
downstream of the integration site in the genomic locus (Fig. 29). However, the sizes 
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of the individual bands were expected to be different from one another in the event of 
random integration. And no hybridization with the probe, to the DNA extracted from 
the 6TG resistant clones, was expected in the case of events of actual homologous 
recombination. 
The presence of the smaller second band was not expected.  It can also be visualised 
in the controls in Fig. 28.  This might be due to star activity.  Though the enzyme 
supplier, New England Biolabs, does not report any star activity for Kpn I, the 
supplier Fermentas has reported it. http://www.fermentas.com/catalog/re/kpni.htm 
From these Southern blots, it was evident that the integration of the vector in the 
genome had taken place in a random manner.  Integrations of multiple Ad SLS 11 
copies were observed in some clones and no evidence of random integration was 
observed in the 6TG resistant cell lines.  More details of the data have been 
summarised in pg 92. 
 
IV.5.2 Presence of the terminus in the clones  
This series of Southern Blots were performed on the DNA obtained from the isolated 
from the isolated colonies, to determine whether the termini of the vector were present 
in the molecules that underwent integration or homologous recombination into the 
cellular genome.  
The DNA extracted from the clones derived from the cell lines HT1080 and C 32, was 
digested with the restriction endonuclease Sau 3A1.  The digested DNA was run for a 
longer period in a 1 % TBE gel, blotted onto a nitrocellulose membrane and labeled 
with a   PCR fragment of the Adenoviral vector, which produces a 350 bp probe 
containing the whole of the terminus of the Adenovirus type 5.  The sizes of the bands 
expected were greater than 457 bp and 190 bp on the left and right termini 
respectively, since a Sau 3 AI site was 457 bp downstream of bp1 of the left terminus, 
and a Sau 3 AI site was present 190 bps upstream of the last bp of the right terminus. 
Following an event of random integration, the sizes of the DNA fragment which 
would cross hybridize with the probe, was expected to be above 457 bp and 190 bp of 
size, dependent on the location of the next Sau 3 AI restriction site upstream or 
downstream of the integration site in the genomic locus (Fig. 30). As in the 
experiment described in earlier, the sizes of the individual bands would be different 
from one another in the event of random integration. The DNA extracted from the 
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6TG resistant clones, would not be expected to hybridize with the probes in the case 
of an event of a classical replacement homologous recombination. 
 
ITR ψ Hprt fragment              CMV HygEGFP   c346        ITR Chromosomal 
                                                                                                     DNA
Kpn  I                    9 kb +
Hyg EGFP probe
 
 
Fig. 28: Scheme and the Southern blots of the HT 1080 derived clones.   DNA was digested with Kpn I, 
run on a 0.6 % 1X TBE gel, blotted on to a nitrocellulose membrane and hybridized with the 2.3 Hyg 
EGFP probe. 1a to 9a denote the 6TG resistant clones. M stands for marker, -c denotes 20 µg of 
HT1080 DNA, +c1 stands for 20 µg of HT1080 DNA spiked with 1 copy/cell of p SLS 11 digested 
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with Pme I, +c2 stands for 20 µg of HT1080 DNA spiked with 2 copies/cell of p SLS 11 digested with 
Pme I, +c3 stands for 20 µg of HT1080 DNA spiked with 3 copies/cell of p SLS 11 digested with Pme 
I.  +cp stands for plasmid DNA 
 
ITR ψ Hprt fragment              CMV HygEGFP   c346        ITR Chromosomal 
                                                                                                     DNA
Kpn  I                    9 kb +
Hyg EGFP probe
 
 
 
Fig. 29: Scheme and the Southern blots of the C 32 derived clones.   DNA was digested with Kpn I, run 
on a 0.6 % 1X TBE gel, blotted on to a nitrocellulose membrane and hybridized with the 1.8 Hyg 
EGFP probe. 10a to 13c denote the 6TG resistant clones. M stands for marker, -c denotes 20 µg of C32 
DNA, +c1 stands for 20 µg of C32 DNA spiked with 1 copy/cell of p SLS 11 digested with Pme I, +c2 
stands for 20 µg of C32 DNA spiked with 2 copies/cell of p SLS 11 digested with Pme I, +c3 stands for 
20 µg of C32 DNA spiked with 3 copies/cell of p SLS 11 digested with Pme I.  +cp stands for plasmid 
DNA. 
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ITR ψ Hprt fragment              CMV HygEGFP   c346        ITR Chromosomal 
                                                                                                     DNA
Sau 3AI                                                                             Sau 3AI
457 bp + 190 bp +
Ad 5 terminus probe                                            Ad 5 terminus probe
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Fig. 30: Scheme and the Southern blots of the C 32 and HT 1080 derived clones.   DNA was digested 
with Sau 3A I, run on a 1 % 1X TBE gel, blotted on to a nitrocellulose membrane and hybridized with 
the Ad5 terminus probe. 1a to 9a and 10a to 12e denote the 6TG resistant clones. M stands for marker, 
-c denotes 20 µg of HT1080/ C32 DNA, +c1 stands for 20 µg of HT1080/ C32 DNA spiked with 1 
copy/cell of p SLS 11 digested with Pme I, +c2 stands for 20 µg of HT1080/ C32 DNA spiked with 2 
copies/cell of p SLS 11 digested with Pme I, +c4 stands for 20 µg of HT1080/ C32 DNA spiked with 4 
copies/cell of p SLS 11 digested with Pme I. 
 
From these Southern blots, it was evident that the integration of the vector in the 
genome had taken place in a random manner.  Integrations of multiple Ad SLS 11 
copies were observed in some clones and no evidence of random integration was 
observed in the 6TG resistant cell lines.  More details of the data have been 
summarised on pg 92. 
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IV.5.3 Structural integrity of the integrated vector  
This Southern Blot was carried out to ascertain whether during the process of 
integration, the structural integrity of the vector had been compromised.  
The DNA extracted from the clones derived from the cell line HT 1080, was digested 
with the restriction endonuclease Pac I.  The digested DNA was run for a longer 
period in a 0.6 % 1X TBE gel, blotted onto a nitrocellulose membrane and hybridized 
with the 1.8 kb probe containing the whole of the Hygromycin EGFP fusion cassette.  
If the vector had integrated as an intact molecule, then the band size expected would 
be 22.5 kb, and if deletions had been present in the genome, the size would be less 
(Fig. 31). 
 
ITR ψ Hprt fragment              CMV HygEGFP   c346        ITR Chromosomal 
                                                                                                     DNA
Pac  I Pac I                              22.5 kb                           
Hyg EGFP probe
 
 
Fig. 31: Scheme and the Southern blots of HT1080 derived clones.   DNA was digested with Pac I, run 
on a 0.6 % 1X TBE gel, blotted on to a nitrocellulose membrane and hybridized with the 1.8 Hyg 
EGFP probe. M stands for marker, -c denotes 20 µg of HT1080 DNA, +c1 stands for 20 µg of HT1080 
DNA spiked with 1 copy/cell of p SLS 11 digested with Pme I, +c2 stands for 20 µg of HT1080 DNA 
spiked with 2 copies/cell of p SLS 11 digested with Pme I. 
 
From this Southern blot, it was evident that in most of the clones, the internal 22.5 kb 
fragment was intact.  More details of the data have been summarised on pg 92. 
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IV.5.4 Summary of the results obtained from the Southern blot experiments on 
the isolated clones 
The results from the Southern blot have been summarized in the following tables.  
Details are given only from the Hyg resistant clones, since the 6TG resistant clones 
did not give any bands, as expected. 
 
Name of  
clone 
Sac I digest 
9 kb + 
Kpn I digest 
9 kb + 
Sau 3AI  
0.5 kb + and 0.2 kb + 
Pac I digest 
22.5 kb 
Probe Hyg  Hyg Terminus Hyg 
3a 1 1 1 strong band at 0.45 kb 1 
3b 0 1 - 1 
3c 2 2 1 weak band 500 bp;  
1 weak band 0.7 kp;  
1 weak band 0.8 kb 
1 
3d 1 2 (1 strong, 
1 weak 
1 strong band 0.45 kp;  
1 weak band about 1.2 kb 
1 
3e 1 1 1 strong band close to 1 kb;  
1 weak band about 0.65 kb;  
1 weak band at 0.45 kb 
2? 
4a 1 1 1 weak band at 0.6 kb;  
1 weak band at 0.8 kb 
- 
4b 1 1 1 very weak band at 0.5 kb - 
4c 1 1 1 strong band at 0.6 kbs;  
1 weak band about 1 kb 
- 
4d 2? 1 1 weak band at 0.6 kb;  
1 very weak band at 0.65 kb;  
1 very weak band at 0.8 kb. 
- 
6a 1 2 1 strong band above 0.5 kp; 
1 weak band at 0.4 kb;  
1 weak band at 0.7 kb;  
1 very weak band at1.2 kb 
- 
6b - 1 1 weak band at 0.6 kb,  
1 very weak band at 1 kb;  
1 very weak band at 0.7 kb 
1  
6c 1 2 1 strong band at 0.6 kb;  
1 very weak at 0.5 kb 
1 (smaller) 
6d 1 1 1 strong band at 0.5 kb;  
1 very weak band at 1 kb;  
1 
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1 weak band at 1.5 kb 
6e 1 2 1 weak band at 0.65 kb;  
1 weak band at 0.55 kb 
1 
6f 1? 1 - 1 
7a 1 1 1 strong band at 0.55 kb 1 
7b 1 1 1 strong band at 0.55 kb;  
1 weaker band at 0.6 kb 
1 
7c 1 1 1 strong band at 0.5 kb;  
1 strong band > 2 kb 
1 
7d 1 1 1 weak band at 0.6 kb;  
1 strong band at 1.2 kb;  
1 weak band at 1.5 kb 
- 
7e 1 1 1 weak band at 0.5 kb 1 
7g 1? 1 - 2? 
 
 
Name of 
the clone 
Kpn I digest 
9 kb + 
Sau 3AI  
0.5 kb + and 0.2 kb + 
Probe Hyg Terminus 
8a 1 1 strong band, 0.6 kb 
17b 1 1 strong band, 0.6 kb 
17c 2-3 1 strong band, 0.6 kb; 1 weak band 0.5 kb   
17d 1 1 strong band, 0.5 kb; 1 strong band 1.2 kb 
17e 1 1 strong band, 0.6 kb; I very weak band at 0.3 kb 
17f 1 - 
22a 1 1 weak band, 2 kb; 1 weak band 2.5 kb 
22b 1-2 1 strong band 1.3 kb; 1 weak band 0.5 kb; 1 v.weak band, 
0.7 kb; 1 veryweak band 1.2 kb 
22c 2 1 weak band 0.5 kb, 1 very weak band ,1 kb (?) 
22d - - 
22e 1 1 very weak band, 1 kb? 
22f 2 0 
22g 2 1 weak band 1.1 kb; 1 weak band 1.2 kb 
22h ? 1 strong band, 1.9 kb; 1 weak band 1.4 kb; 1 weak band 0.7 
kb 
22i 2 1 weak band, 0.6 kb; 1 weak band 1 kb 
22k 1-2 1 strong band, 0.7 kb; 1 weak band 0.4 kb; 1 weak band 1.1 
kb 
Tables 7: Data regarding the number and size of bands, obtained from the Southern Blot experiments 
on C 32 and HT 1080 derived clones 
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From the Southern blot experiments carried out the following results can be inferred: 
i. The integration of the vector took place in a random manner 
(difference in sizes of the bands.) 
ii. In all of the 16 6TG resistant clones analysed, no presence of the 
adenovirus terminus was detected, as was expected in the case of 
homologous recombination between the vector and the genomic 
DNA. 
iii. In all of the 18 6TG resistant clones analysed, no presence of the 
HygEGFP cassette was observed as was expected in the case of 
homologous recombination between the vector and the genomic 
DNA. 
iv. In 9 confirmed and 14 possible (very weak bands) clones out of the 
37 Hyg resistant clones (24 – 38%), more than one copy of the 
transgene was present, suggesting multiple integration events. 
v. In only one of the 15 Hyg resistant clones analysed does the vector 
molecule seem to have undergone an internal deletion. 
vi. At least in 8 out of the 37 (21 %) Hyg resistant clones analysed, there 
were more number of Ad termini than expected for the number of 
transgenes detected in the clone. 
 
IV.5.5 Analysis of the junction sites of integration of HC-AdV DNA 
These series of experiments were conducted to determine the sites within the human 
genome where the Ad SLS 11 DNA had integrated.   Three methods, viz the LAM 
PCR method (Schmidt et al., 2001), Splinkerette PCR (Mikkers et al., 2002), (Devon 
et al., 1995), Inverse PCR (Triglia et al., 1988) was tested on the DNA that was 
extracted.  The best results were obtained with the modified inverse PCR as described 
in the materials and methods section.  Basically, the DNA was digested with a 4 base 
pair cutting enzyme and religated to form circular molecules. A modification of the 
ligation reaction (Lund et al., 1996) was used. wt DNA and wt DNA spiked with 
varying amounts of the plasmid were used as controls. 0.5 % of the product was used 
as a template in the nested PCR. The products were separated on a high percentage (2 
%) TAE agarose gel, and the bands were cut out, cleaned and subcloned into the 
TOPO TA cloning vector (Invitrogen). The DNA was sequenced. The sequences were 
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analysed for the TOPO TA vector DNA sequences and they, the primers, the termini 
sequences and restriction site that were used were marked and separated. The flanking 
sequences were subjected to NCBI BLAST search and the locations of high 
percentage matches were plotted. Holding the mouse over the plot in the map viewer, 
over the component master map (CMM), the co-ordinates of the genomic DNA clone 
identified uying the BLAST search was located at the chromosomal level.  The co-
ordinates were used to confirm the results obtained when the DNA sequences were 
subjected to ENSMBL BLAST search, and the exact location of the integrated Ad 
SLS 11 was determined, right up to the exact nucleotide. Possible locations of the 
sequences involved in the actual recombination event (patchy homologies) were also 
identified.  Chromosomal locations were denoted by the exact words used in the 
databases. 
 
Inverse PCR 
A modification of the inverse PCR protocol reported in (Silver & Keerikatte, 1989, 
Triglia et al., 1988) was re-adapted to fit in with the conditions of amplification of the 
adenoviral terminus junction sites.  A modification of the ligation procedure reported 
in (Lund et al., 1996) was used for the ligation experiment. The full details of the 
protocol are given in the materials and methods section of the thesis (Fig. 32).  
Inverse PCR using a different enzyme Tsp 509L was carried out on 18 of the junction 
sites to reconfirm the sites. 
 
Junction sites obtained: 
Due to space constraints, the sequences obtained from one clones, clone 17e is 
exhibited as an example to demonstrate how the full calculation was carried out.  
Only the processed data from all the remaining clones is given.  
By convention, when the same nucleotides were found in the junction that 
corresponded to the Ad5 and the genomic DNA, it was taken as having originated 
from the AdV terminus.  In the sequences that are presented, the Ad5 ITR sequences 
are given in the first line, the junction site sequences in the second line and the 
genomic DNA sequence where the integration had taken place is given in the third 
line. The junction site sequences with homology to the Ad5 ITR sequence and their 
counterpart in the Ad5 terminus, is denoted by a gray box; whereas the junction site 
sequences with homology to the genomic DNA sequences, and their counterparts in 
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the genomic DNA, are marked by a yellow box.  In the junction sequences, (-) refers 
to positions in the sequences derived from viral temius and (+) to the positions 
derived from chromosomal DNA. 
 
Sau 3 AI                      Sau 3 AI
Chromosomal DNA  Integrated Ad SLS 11
Total cellular DNA 
digested with enzyme
P3    P1             P2  P4 Digested DNA
purified
P2P1 DNA ligated to form
intramolecular
circle.  PCR with 
primer pair P1 and 
P2
P3 P4
AdV DNA                   AdV DNA
    chromosomal DNAunknown
Nested PCR with 
primer pairs P3
and P4
Product sequenced  
Fig. 32: Scheme of the Inverse PCR carried out on the clones derived from C 32 and HT 1080 cells to 
determine the sequence of the junction sites of integration of the HC-AdV and the cellular DNA. 
 
In the sequence from the two clones given below, underlined text denotes the primers, 
bold text denotes the ITR sequence, plain text denotes the genomic sequence, and the 
text in bold and italic characters denotes the restriction endonuclease recognition site. 
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Analysis of clone 17e 
Clone 17e is a C32 derived Hyg resistant cell line. The Southern blot data 
(summarized in pg 92) revealed the presence of one single copy of the vector, with a 
size between 10 and 12 kb.  On analysis of the clone following Inverse PCR, a single 
Kpn I site was found at 1397 bps downstream of the integration site.  This would give 
rise to a 11.3 kb band on the above mentioned Southern blot, validating the result.  
Hybridisation with the terminus probe revealed the presence of one strong band less 
than 600 bps, and a very weak band less than 300 bps in size.  This correlates with the 
data obtained following the inverse PCR and sequencing of the DNA obtained from 
17e, where a Sau 3A1 site was observed at 85 bps upstream of the integration site of 
the left terminus, giving any band obtained from that integration a size of 549 bps.  A 
Sau 3AI site was also observed 91 bps downstream of the integration site of the right 
terminus of the vector, giving any band resulting from that integration a size of 281 
bps. This tallies with the Southern blot data.  The sequence obtained from the Inverse 
PCR product using the primers for the left terminus is given below. 
 
GCAACATCACACTTCCGCCACACTACTACGTCACCCGCCCCGTTCCCAC
GCCCCGCGCCACGTCACAAACTCCACCCCCTCATTATCATATTGGCTT
CAATCCAAAATAAGGTATATTATTGATAAAACAAAGGGGCCGGGCGCG
GTGGCTCACGCCTGCAATCCCAGCACTTTGGGAGGCTGAGGCGGGCAGAC
CACGAGGTCAGGAGATCAAATGATATCAAAACGCCAACTTTGACCCGG
AACGCGGAAAACACCTGAGAAAAACACCTGGGCG 
 
NCBI BLAST search was used to align the sequence with the human genome and the 
integration was observed to have happened in the chromosome 20q13+3, in the 1st 
intron of the BTPD4 gene.  The last 4 bps of the Ad terminus were deleted.  The 
sequence was analysed in the ENSEMBL database to verify the location.  The 
location of the integration in the genome was mapped in the 61876780 bp (numbering 
based on the ENSEMBL database) of the chr 20.  
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Fig. 33: Analysis of the junction between HC-AdV DNA and chromosomal DNA: clone 17e. 
A. Sequence of the junction site.  B. Map of chr 20, showing the integration that took place in 20q13.3.  
C. Closer view of 20q13.3, showing the region where the vector had integrated.  D. Map of the BTBD4 
gene, showing the integration of the vector in the intron 1-2.  The sequence data from the right 
terminus too was used to obtain the picture. 
 
The sequences obtained from the Inverse PCR product using the primers for the right 
terminus is given below. 
 
 
 
 
A 
B
C
D 
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CATCACTCCGCCCTAAAACCTACGTCACCCGCCCCGTTCCCACGCCCCG
CGCCACGTCACAAACTCCACCCCCTCATTATCATATTGGCTTCAATCC
TGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGGCGCCTGCCACCACACC
TGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCA
AGATGGTCTCGATCGCGCCCCTAGGGGCCGGCCTTAATTAAATCAAGC
TTATCGATACCGTCGAGACC 
 
NCBI BLAST search was used to align the sequence with the human genome and the 
integration was observed to have happened in the chromosome 20q13+3.  The last 25 
bps of the right terminus of the Ad DNA were deleted.  The sequence was analysed in 
the ENSMBL database to certify the location, and the integration was mapped to bp 
61881299 in chr 20 q13.3, in the 1st intron of the BTBD4 gene, 4.5 kb downstream of 
the left terminus integration. 
 
Since all the bands observed in the Southern blotting (summarized in pg 92) can be 
accounted for, it can be assumed that there was only one event of vector integration in 
the cellular genome, and during the event, 4519 bps of the cellular DNA were deleted. 
 
IV.5.5.A HT1080 derived cell lines 
Clone 3a 
A deletion of 9 base pairs was observed in the terminus at the junction site.  The 
integration had taken place in the chromosomal location 7p21, at the 17859816 bp.  
However, a fusion of sequences from 4q22 was observed 75 bps downstream of the 
integration site. 
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Clone 3c 
A substitution of a G to C was observed in the terminus at the –3 bp location, where 
the last bp was missing.  The integration was mapped to chromosome 4p21 at the 
136793983 bp, but sequences different from those expected from the database were 
observed for the first 31 bps down stream of the junction site in the genomic region. 
 
 
When the sequences are analysed, it looked as if the DNA at the junction site had 
formed a hairpin structure. 
     3c left terminus 
     G 
   T-A 
   A-T 
    G-C 
     T-A 
     T-A 
     A-T 
     T-A 
     T-A 
                       5’-ATCA-TAT-’3  
Clone 4a 
The inverse PCR yielded three sequences, two from the left terminus and one from 
the right terminus of the integrated vector.   
 
Left terminus sequence 1: 
15 base pairs were observed to have been deleted from the terminus. The 
chromosomal location of the integration was 3p22, in the base pair 32977598.  
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The possibility of the DNA at the junction site forming a stem loop was also noticed 
in this junction site. 
4a left terminus I 
5’- CAAAGAGGCAAAGAAGGCTGCAATGACCTTATTTTGGATTGAA-‘3 
 
 
         
  Left terminus sequence 2  
A deletion of the last 7 bps of the terminus was observed and the integration was 
mapped to 13923835 bp in chromosome 5p15.2, in the DNAH5 (dynein, axonemal, 
heavy polypeptide 5) gene, in the 23rd intron.  
 
 
Right terminus sequence: 
The last 6 bps of the terminus was absent in the sequence and the vector had 
integrated into the 14466138 bp of the 5p15.1-p14, in the TRIO (triple functional 
domain, PTPRF interacting) gene, in the 33rd intron. The integration is at a site 
542303 bps downstream from that of the above-mentioned left terminus. 
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Clone 4b 
In the left terminus sequence, a deletion of the last 4 base pairs, and a possible 
duplication (underlined) of the last 10 base pairs of the terminus present in the 
junction, and a deletion of a C at the 4th bp from the genomic sequence, was observed. 
The integration site was mapped as the 125388250 bp of the chromosome 11q 24.2 
into the CDON (cell adhesion molecule-related/down-regulated by oncogenes) gene, 
in the 7th intron. 
 
In the right terminus sequence, a deletion of the last 3 bps of the terminus, a 
duplication (underlined) of the last 8 bps of the terminus present in the junction, and 
the introduction of two novel base pairs in the junction site, was observed. The 
integration had taken place in chromosome 11q24 in the124920889 bp, 467361 bps 
upstream of the left terminus. 
 
Clone 4c 
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In the left terminus sequence, the 4th bp from the end of the terminus was 
deleted and 4 novel bps were inserted in that site. The integration site was mapped as 
the 149348992 of the Xq28, into the intron 4-5 of the CXorf6 gene.  In the vector Ad 
SLS11, this corresponded to bp 29081, located in the c346 cosmid derived stuffer 
DNA. 
In the right terminus sequence, the last 14 base pairs of the terminus were deleted. Of 
the 64 genomic DNA bps obtained during sequencing, the first 40 bps matched 100% 
with cDNAs from 11 different genes, with 2 of the genes located in 14 q 23-24 region, 
the remaining 24 bps did not find matches during BLAST searches. Sequence analysis 
in Ensembl suggests that the integration took place in chromosome 14 q23, in 
66874487 bp in the ATP6V1D gene, and the “unmapped” 24 bps are from the 
136554664 bp from 6q23 in PDE7B gene.  
The first part matches also in part (17/29) with 130035841 bp in chromosome 6q22.3.  
 
      
Clone 4d 
The left terminus sequence had a deletion of the last 17 base pairs. The site of 
integration was mapped into chr 2p24, into non coding area in the 14295915 bp. 
 
The right terminus sequence had a deletion of the last 68 base pairs. The site of 
integration was mapped into chr 2p24, into non coding area in the 14311184 bp, 20 
bps upstream of the left terminus integration. 
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Comparison of the junction site 
 
 
 
Clone 6a 
The last 6 base pairs of the left terminus were found to be deleted and the integration 
was observed to have happened in the chromosome 17q24, bp 68279602, in the 
SLC39A11 solute carrier family 39 (metal ion transporter), member 11 in the 8th  
intron. 
 
The last 6 base pairs of the right terminus were missing and the integration was 
observed to have happened in the chromosome 17q24, in the bp 68326313 bp, in the 
SLC39A11 solute carrier family 39 (metal ion transporter), member 11 in the 8th 
intron, 46711 bps upstream of the left terminus. 
 
 
When the sequences are analysed, it looked as if the DNA at the junction site had 
formed a hairpin structure, possibly in the manner depicted below. 
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Clone 6b 
The last 3 bps of the left terminus was missing.  A substitution was noticed at the 
position +3 of the integrations. The integration was mapped to chromosome 18q24 in 
bp 74665084, located in non coding area. 
 
The last 2 bps of the right terminus was absent and the G at –2 position was 
substituted by a C.  Novel 9 bps were introduced at the junction. The integration was 
mapped to non coding region of chromosome 18q11, in the bp 20386721. 
 
  
When the sequences are analysed, it looked as if the DNA at the junction site had 
formed a hairpin structure, possibly in the manner depicted below. 
 
   A  
 C-G 
 T-T 
 A-A 
 G-C 
 T-A 
 T-A 
 A-T 
 5’- ATT-ATG-‘3 
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Clone 6c 
In the left terminus, the last bp was missing.  The novel 4 (or possibly 7 bps) bps at 
the junction of the viral and genomic sequences might be a duplication (underlined) of 
bps from –12 position relative to the junction.  The integration took place the 4325726 
bp of chromosome 3p26.1 in the SET domain and mariner transposase fusion gene, in 
the 1st intron. 
 
 
Clone 6e 
The entire left terminus was present. The integration was mapped to chromosome 
11q22.1, in the 100761198 bp. 
 
 
The last 10 bps of the right terminus were absent in the integration that took place in 
chromosome 21q in the 39152777 bp, located in non coding region. 
 
 
Clone 6f 
The last 7 bps of the left terminus was deleted and the integration was mapped into 
alpha satellite DNA.  A substitution was observed at +3 bp in the genomic DNA in 
the junction. 
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A deletion of the last 29 bps of the right terminus, and in the junction site sequences 
derived from the genomic DNA, and two substitutions at bp +5 and +10 were 
observed. The integration was mapped into the 65543774 bp in chromosome 9q12. 
 
Clone 7a 
The last 6 bps of the left terminus were deleted. The vector was found to have been 
integrated into the 67405840 bp of the chromosome 18q22.3. 
                                                       
The last 22 bps of the right terminus were missing.  The sequence showed similarity 
to three separate loci, all in chromosome 16p11 region, one in non-coding region 
(29461478 bp), and two in the same gene (30201478 bp and 29359713 bp).                                               
 
  
Clone 7b 
Left terimus sequence I. 
The last 80 bps of the left terminus was missing and the integration had taken place in 
the 121699946bp of Chr 10q25. 
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In the second sequence obtained from the left terminus, the last 21 bps of the terminus 
were missing.  The location of the integration in the genome was mapped in the 
58075708 bp of the chromosome 15q22.2 
 
The entire right terminus was observed to be present.  The integration had taken place 
in the chromosome 15q24, in an Alu repeat region in between coding genes at 
53144052 bp of the chromosome, 4931656 bps downstream of the observed left 
terminus. 
 
Clone 7c 
A deletion of 81 bps of the left terminus was observed the integration, which was 
mapped into chromosome 3p11 at 68177382 bp, in the FAM 19A1 gene, in the 1st 
intron. 
 
The right terminus integration was mapped in the same locus as the left terminus, 598 
bps upstream of the left terminus integration. The last bp of the terminus was missing 
 111
 
Clone 7e 
In the left terminus, the last 3 bases were found missing.  The integration was mapped 
into 13q14.11 in the NP_001009814.1 gene into 24th intron in the 41194735 bp. 
 
A deletion of the last 20 bps of the right terminus were observed.  The integration 
occurred at the 109261928 bp in chromosome 12q24.11. 
 
Clone 7g 
The last 26 bps of the left terminus were observed to be deleted in junction site, and 
the integration was localised possibly to chromosome 14q24 into the ATP6V1D gene 
in the 66874695 bp in exon 9. 
 
In the right terminus sequence, a deletion of the last 14 bps was observed. The 
integration was in 14q24 into the ATP6V1D gene in the 66874458 bp. 
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IV.5.5.B C32 derived cell lines 
 
Clone 8a 
The last 26 bps of the left terminus were missing and the integration was mapped to 
chromosome 8q24 into 144983689 bp 
 
The last 49 bps of the right terminus were missing and the integration had taken place 
in the 136554715 bp of 6q22.3 into exon 13 of the PDETB gene. 
 
Clone 17a 
The last 3 bps of the first left terminus were missing and the integration was mapped 
to chr Xq26.2 into the 133321215 bp, in the 1st intron of HPRT gene, which also 
corresponds to the bp 1723 of the Ad SLS 11 vector used in the study. 
 
In the second left terminus band the presence of the full terminus, with a substitution 
of a T to C at bp -6 from the junction, was observed. At +18 bps into the genomic 
sequence from the junction, an A was substituted by a G.  The integration had 
occurred in 24908960 bp of chr 6p22.2. 
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The last 49 bps were found deleted in the right terminus, and the integration was 
mapped to Chr 10, in repetitive DNA. 
 
Clone 17c 
The last 7 bps of the left terminus were missing and the integration was mapped to the 
44962757 bp in chr 16q11.2, a novel A was inserted at the junction site 
 
 
Clone 17d  
Two bands were sequenced from the left terminus. 
Left terminus sequence, band I: 
The last 17 bps of the terminus were deleted and the integration was mapped to 
133320237 bp chr Xq26.2, in the 1st intron of the HPRT gene, which also corresponds 
to the bp 709 of the Ad SLS 11 vector used in the study. 
 
Left terminus sequence, band II  
The last 49 bps of the terminus were found missing and the integration had taken 
place in 170477721 bp of chr 1q25.1in the KLHL20 gene, in the 10th intron. 
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Clone 22a 
The last 24 bps of the right terminus were deleted and the integration was localized to 
sequences similar to satellite 3 mRNA. 
 
Clone 22b 
The entire left terminus was present in the integration, which had taken place in 
175256298 bp in Chr 3q26+3, in the NLGN1 gene, in the 5th intron. 
 
103 bps of the right terminus was deleted and the integration was mapped to Chr 
3q26.3 in the bp179409396.  
 
 
Clone 22c 
The last 2 bps of the left terminus were deleted and a novel T was inserted in the 
junction, which was mapped to the 89017534 bp in Chr 11q15. 
  
Clone 22d 
The last 23 bps of the left terminus were deleted and the integration was mapped to 
the 70744517 bp of Chr 7q11, in the 3rd intron of the CALN1 gene. 
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Two sequences were obtained from the right terminus. 
 
The last 3 bps of the Ist right terminus were deleted and the integration was localized 
to an Alu Y repeat element at the 194954088 bp of Chr 3q29. 
  
The last 28 bps of the IInd right terminus were deleted and the integration was 
localized to an alphoid repetitive DNA region.  
 
 
 
Clone 22e 
A deletion of the last 17 bps of the left terminus and the substitution of an A to G in 
the genomic DNA, at the +10 bp from the junction, were observed and the integration 
was mapped to Chr 3q13 to the 117218961 bp, in the 3rd intron of the LSAMP gene. 
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Clone 22f 
The full left terminus was observed to be present and the integration occurred in chr 
7q31 in the bp 111008662 in the 34th intron in the DOCK4 gene.  
 
 
The last 57 bps of the right terminus were missing and the integration was in bp 
110989851 of chr 7q31, in intron 39-40 of the DOCK4 gene, 18811 bps upstream of 
the left terminus, in the event that both of the integrations taken place in the same 
chromosome. 
 
Clone 22 g 
Two sequences were obtained from the left terminus.   
In the first left terminus sequence, the last 27 bps were found deleted and the 
integration had occurred in Chr Xp11.1-11.4 in 45359319 bp. An A to T substitution 
at bp +1 in the genomic DNA at the junction site was also noted. 
  
The last 16 bps of the IInd left terminus were deleted and the integration was mapped 
to the 144984259 bp of Chr 8 q24+3. 
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The last 5 bps of the right terminus were missing and the integration was mapped to 
Chr. 8q23, integration in 108870353 bp. 105 bps downstream of the junction site, the 
sequences were from Chr 9q12.  Owing to the strange nature of the junction, this was 
reconfirmed by inverse PCR using two different enzymes. 
 
 
Clone 22h 
The presence of the entire left terminus and the introduction/substitution of 1 bp at the 
junction site were observed and the integration was mapped to Chr 9p12 in the 
43592419 bp. 
  
 
The full right terminus was present and 2 substitutions, G to T at +1 bp and a C to G 
at +25 bp from the junction site in the genomic sequence, were observed.  The 
integration has taken place in chr 9p12 at position 42373494, in a novel predicted 
gene.          
 
 
Clone 22i 
Two sequences were obtained from the left terminus.  
The last 15 bps of the Ist left terminus were missing and the integration was mapped 
to 44947706 bp of Chr 22q 13, in the 6th intron of the PPARA gene.  
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A deletion of 43 bps was observed in the IInd left terminus and the integration had 
taken place in Chr Xq26.2  in the bp 133321664, corresponding to Hprt 1st intron, and 
the 2136 bp of the vector used.  
 
 
 
The last 59 bps of the right terminus were deleted and the integration was mapped 
into the 141523423 bp in Chr 7q35 in a novel gene. 
 
Clone 22k 
 
The last 17 bps of the left terminus were deleted and the integration had taken place in 
Chr 20p12.1 in the 14643087 bp. A T to C substitution was observed -28 bps 
upstream of the junction site in the viral terminus. 
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The full right terminus was present and the integration had taken place in the 
integration had taken place in Chr 20p12.1 in the 14643056  bp, 81 bps downstream 
of the left terminus, had both of the integrations taken place in the same arm. 
 
 
The locations of the HC-AdV termini integrated into the cellular genome are mapped 
here in Fig. 34. 
 120
 
Fig. 34: locations of the HC-AdV termini integrations in the cellular genome.  The approximate 
location of each integration as obtained from the sequence data was mapped on to a map of the 
genome. 
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The results obtained in the above section were summarised in Table 8. 
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3a L 7p 21 
17859816 bp  
Å 11 N Integrated in a junction of 4q22 and 7p 21 
3c L 4 q 28 
 
136793983 bp   
Æ 1 N A G to C substitution at –3 of the terminus, 
rearrangements in the first 31 bps downstream of the 
integration. 
4a L 3p22 
 
32977598 bp 
Å 15 N  
4a L 5p15.2 
13923835 bp 
Å 7 Y DNAH5 gene, 3’ 
4a R 5p15 
14466138 bp 
Æ 7 Y TRIO gene, 3’ 
4b L 11q24.2 
125388250 bp 
Æ 4 Y CDON gene, MID. Deletion in +3 from the terminus in 
the genomic sequence. 
4b R 11q24 
124920889 bp 
Æ 3 N  Last 8 bps duplicated, 2 additional bps introduced. 
4c L Xq28 
 
149348992 bp 
 
Å  0 Y 4 bp insertion at the junction. 
CXorf6 gene 
4c R 14 q23 
66874487 bp 
Æ 14 Y 14q23-6q23 junction from +40 bps onwards.ATP6V1D 
gene 
4d L 2p24 
14295915 bp 
Æ 17 N  
4d R 2p24 
 
14311184 bp 
 
Å 68 N  
6a L 17q24 
68279602 bp, 
44670 bps 
away 
Å 6 Y SLC39A11  solute carrier family 39 gene 
6a R 17q24 
68326313 bp 
Æ 6 Y SLC39A11  solute carrier family 39 gene 
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6b L 18q24 
74665084 bp 
Æ 3 N -2 to -6 of terminus duplicated 
6b R 18q11 
20386721 bp 
Å 2 N -3 from terminus is substituted, 9 unknown bps at 
junction 
6c L 3p26.1 
4325726 bp 
Å 1 Y 4 unknown bps in the junction. SETMARgene 
6e L 11q21 
100761198 bp 
Å 0 N  
6e R 21q22 
39152777 bp 
Å 10 N  
6F L Alpha satellite 
repeated DNA 
NA 7 N 3 novel bps introduced in the junction. 
6F R 9q12 
65543774 bp 
Æ 29 N 2 substitutions in the genomic region 
7a L 18q22.3 
67405840 bp 
Å 6 N  
7a R 16p11 Æ 22 ? In –3 position, an A to G substitution. Integration in 3 
different loci possible (2 active genes). 
7b L 10q25 
121699946 bp 
Æ 80 N  
7b L 15q26 
58075708 bp 
Æ 21 N  
7b R 15q24 
53144052 bp 
Æ 0 N  
7c L 3p11 
68177382 bp 
Æ 81 Y FAM19A1 
7c R 3p11 
68176784 bp 
Å 1 Y FAM19A1 
7e L 13q 14.11 
41194735 bp 
Å 3 Y NP_001009814.1 gene 
7e R 12 q24.11 
109261928 bp 
Æ 20 N  
7g L 14q24 
66874695 bp 
Æ 26 Y  
ATP6V1D gene 
7g R 14q24 
66874458 bp 
Å 14 Y ATP6V1D gene 
8a L 8q24 
144983689 bp 
Å 26 N  
8a R 6q22.3 
136554715 bp 
Æ 49 Y PDE7B 
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17a L X q26.2 
133321215 bp 
Æ 3 Y HPRT 
17a L 6p22.2 
24908960 bp 
Æ 0 N A T to C and A to G substitutions in –5 and + 18 
positions, respectively. 
17a R 10 ? NA 49 ? Repetitive  DNA 
17c L 16q11.2 
44962757 bp 
Å 7 N A novel A introduced at the junction site. 
17d L X q26.2 
133320237 bp 
Æ 17 Y HPRT 
17d L 1q24 
170477721 bp 
Å 49 Y KLHL20 
17e L 20q13+3 
61876780 bp 
Å 4 Y BTBD4  gene 
17e R 20q13+3 
61881299 bp 
Æ 25 Y “, 4519 bps downstream of the L 
22a R ? NA 24 Y Satellite mRNA 
22b L 3q26+3 
175256298 bp 
Å 0 Y A novel G introduced at the junction site. NLGN1 gene 
22b R 3q26+3 
179409396 bp 
Å 105 N  
22c L 11q15 
89017534 bp 
Æ 2 N A novel A introduced in the junction. 
22d L 7q11 
70744517 bp 
Å 23 Y CALN1 
22d R 3q29 
194954088 bp 
Å 3 N Part of integration into an Alu Y region 
22d R ? NA 28 N Alphoid repetitive DNA 
22e L 3q13 
117218961 bp 
Æ 17 Y A T-C substitution in + 10 bps. LSAMP gene. 
22f L 7q31 
111008662 bp 
Æ 0 Y DOCK4  
22f R 7q31 
110989851 bp 
Å 57 Y “18811 bps upstream of the left terminus 
22g L Xp11.1-11.4 in 
45359319 bp 
Å 27 N A T-A substituion at Bp +1. 
22g L 8 q24+3 in 
144984259 bp 
Æ 16 N  
22g R 8q23 
108870353 bp 
Å 5 N* Chromosomal joining into chr 19 (into a LOC388526 
gene, 105 bps downstream of the junction site) 
22h L 9 p 12 in Æ 0 N Deletion of 2 bps at +2 bp from junction. 
 124
43592419 bp 
22h R 9 p12 
42373494 bp 
Å 0 Y A C to A substitution at +2 bp from the junction. Novel 
gene. ENST00000355214 
22i L 22q13 
44947706 bp 
Æ 15 Y PPARA 
22i L X q26.2 
133321664 bp 
Æ 43 Y HPRT 
22i R 7q35 
141523423 bp 
Å 59 Y Novel gene 
ENSG00000197962 
22k L 20p12.1 
14643087 bp 
Å 17 N A T to C substitution at -28 bps 
22k R 20p12 
14643056 bp 
Æ 0 N  
 
Table 8: Table listing the integration of the vector, the direction of the integration with respect to the 
chromosome, and the consequences thereof to the cellular and viral DNA.  The BLAST searches on 
NCBI and ENSMBL databases were performed on the sequence obtained from the Inverse PCR. 
 
The HC-AdV Ad SLS 11 appeared to integrate in a random manner in the 
chromosomal DNA.  In all chromosomes, except Chr 19, integrations of the vector 
were observed. 
 
IV.5.5.C Sequence from both termini of the vector molecule 
As mentioned in pg 90, the bands observed in the Southern blots conducted on clone 
17e can be correlated with the sequence data obtained from the same clone via Inverse 
PCR.  The sequence data on some other clones suggest that both of the termini of the 
same molecule have been sequenced.  These “probable both termini”, observed when 
the left and the right termini of the vector were found in the same chromosome, are 
given in the table below, Table 9.  
 
Clone Left Terminus 
integrated in bp 
Right terminus 
integrated in bp 
Probable deletion in the 
genomic DNA in bp 
4a 5p15.2, 13923835 5p15, 14466138 542,303  
4b 11q24.2, 125388250 11q24, 124920889 467,361 
4d 2p24, 14295915 2p24, 14311184 15,269 
6a 17q24, 68279602 17q24, 68326313 46,711 
6b 18q24, 74665084 18q11, 20386721 54,278,363 
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7b 15q26, 58075708 15q24, 53144052 4,931,656 
7c 3p11, 68177382 3p11, 68176784 598 
7g 14q24, 66874695 14q24, 66874458 237 
17e 20q13+3, 61876780 20q13+3, 61881299 4519 
22b 3q26+3, 175256298 3q26+3, 179409396 4,153,088, possible concatomer 
22f 7q31, 111008662 7q31, 110989851 18,811 
22g 8q24+3, 144984259 8q23, 108870353 36,113,906 
22h 9p12, 43592419 9p12, 42373494 1,218,925 
22k 20p12.1, 14643087 20p12, 14643056 31 
 
Table 9: Data showing the probable integration of both the left and right termini of the vector into the 
same chromosome.  
However, it is not possible to state dogmatically that the sequence obtained did come 
from both of the termini of the same vector molecule instead of two individual termini 
from two different vectors, due to the fact that the bands cannot be corroborated 
totally by the Southern blot data and in the absence of FISH data.  So it must be 
interpreted with caution. 
 
IV.5.5.D Integration of the vector DNA into genes 
Of a total of 61 clones from which the data is presented, 29 integrations were in genes 
(chromosomal regions identified as genes in the ENSEMBL database), 30 integrations 
were in non-coding region and the sites of 2 integrations could not be determined.  
The data was plotted on the following Pie diagram, Fig. 35. 
This suggests that HC-AdV integrated in both coding as well as non coding genetic 
regions, and there seemed not to be any specific preference to either of them. 
 
IV.5.5.E Integration of the vector DNA into common insertional sites 
The genes in which the integrations had taken place were compared against the 
known Common Insertional Sites (CIS) for Retroviral Vectors in the mouse genome 
to analyse whether HC-AdV preferred integration into certain genes that were 
commonly targeted by retroviral vectors, given that the genes had the same names in 
both human and mice genomes.  Individual genes were searched for matches the CIS 
in the Copeland Database http://rtcgd.ncifcrf.gov/ . No matches were found to the CIS 
in the mouse genome to the genes in which integrations of HC-AdV had taken place. 
 126
 
Fig. 35:  Pie diagram showing the distribution of integration sites of HC-AdV in the cellular genome.  
The ENSMBL database was used to verify whether the integration had taken place in a gene or a non 
coding region 
 
IV.5.5.F Integration of the vector DNA into genes of any particular ontology 
To check if the HC-AdV DNA favoured integrations into genes of any particular 
function, the molecular ontology of the genes involved were analysed using the Swiss 
prot tool found at http://ca.expasy.org/sprot/ or the ENSEMBL database.  The gene 
ontology of any gene is subdivided into molecular function, biological process and 
cellular function and the individual results were rechecked using the GO tool at 
http://www.geneontology.org/GO.doc.shtml.  The two insertions into genes from the 
in vivo data given in pg 145 are also included in table 10.  
 
Gene Molecular functions Biological processes 
DNAH5 i. Microtubule motor activity. i. Microtubule-based 
movement. 
TRIO i. Guanyl-nucleotide exchange  
  factor activity. 
ii. Protein serine/threonine kinase         
   activity 
i. Transmembrane receptor 
protein tyrosine phosphatase 
signaling pathway 
ii. protein amino acid 
phosphorylation 
Diagram showing the distribution of integration 
sites in the genome
48%
49%
3%
Genes
Non coding region
Undetermined
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CDON i. Protein binding i. Cell adhesion 
ii. Positive regulation of 
myoblast differentiatio 
Cxorf6 ? ? 
ATP6V1D i. Hydrogen-transporting ATPase activity 
ii. Rotational mechanism 
i. Vacuolar acidification 
ii. ATP biosynthesis 
SLC39A11 i. Metal ion transporter activity i. Metal ion transport 
SETMAR i. DNA binding 
ii. Histone-lysine N-   
    methyltransferase activity 
iii. Zinc ion binding 
i. Chromatin modification 
ii. Regulation of transcription 
FAM19A1 ? ? 
NP_001009814.1 i. ATP binding 
ii. Hydrolase activity, acting on   
    acid anhydrides. 
 
PDE7B i. 3',5'-cyclic-AMP phosphodiesterase 
activity 
i. Signal transduction 
ii. Synaptic transmission 
HPRT i. Hypoxanthine 
phosphoribosyltransferase activity 
i. Purine ribonucleoside salvage 
ii. Behavior 
KLHL20 i. Actin binding 
ii. Protein binding 
i. Cytoskeleton organization and 
biogenesis 
BTBD4 i. Nucleic acid binding 
ii. Protein binding 
iii. Zinc ion binding 
i. Transcription 
ii. Regulation of transcription 
NLGN1 i. Carboxylic ester hydrolase activity 
ii. Neurexin binding 
i. Calcium-dependent cell-cell 
adhesion 
ii. Neuronal ion channel 
clustering 
iii. Protein targeting 
iv. Regulation of neuron 
differentiation 
v. Synaptic vesicle targeting 
vi. Synaptogenesis 
CALN1 i. Calcium ion binding  
LSAMP i. Protein binding i. Nervous system development 
ii. Cell adhesion 
DOCK4 i. Guanyl-nucleotide exchange factor 
activity. 
ii. GTP binding 
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iii. GTPase binding 
ENST00000355214 ? ? 
PPARA i. Protein binding 
ii. Transcription factor activity 
i. Fatty acid metabolism 
ii. Lipid metabolism 
iii. Transcription from RNA 
polymerase II promoter 
ENSG00000197962 ? ? 
Bfsp2 i. Structural molecule activity 
ii. Structural constituent of eye lens 
i. Cytoskeleton organization and 
biogenesis 
Gmeb2 i. DNA binding 
ii. Transcription regulatory function 
i. Transcription 
 
Table 10: List of the molecular ontology of the genes where the HC-AdV integrations had taken place.   
 
The aim of conducting this part of the study was to determine whether the HC-AdV 
favoured integration into genes of any particular molecular function or biological 
process.  There was a special interest to determine whether AdV preferentially 
integrates into genes that are protooncogenic or those genes that might have 
oncogenic potential, like the ones involved in cell cycle.  In the molecular ontology of 
the genes analysed, no integration was observed in such genes (two integrations were 
observed in genes involved in transcription), and HC-AdVs did not seem to exhibit 
any obvious affinity to integrate into genes of any given ontology. 
 
IV.5.5.G Influence of genes on the integration of the vector DNA into non-coding 
region 
To determine if the integrations of the HC-AdV DNA into the non coding region of 
the genome was influenced by the presence of neighbouring genes, the site of 
integration was analysed for the distance between it and the closest gene. Two 
parameters were selected.  The integrations were mapped for 10 kb upstream and 
down stream and then for 25 kb upstream and downstream of the integration site. 10 
(32.3 %) of the integrations that had taken place into the non-coding region, had taken 
place within 25 kb of genes, 5 integrations (16.2 %) had taken place within the 10 kb 
window. In three cases (viz 8a L, 22g L, and 17a L), integrations had taken place in 
regions of gene clusters where there were four, four and two genes within the 25 kb 
window.  The data was formulated into table 11. 
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Clone Neighbouring gene Distance (in Kb) 
3a L PRPS1L1 20.13 
4a L CCR4 6.2 
4b R E124 23 
6f R Novel ENSESTG00000033857 11 
7b L SEP32IP 8.3 
7b L FOXB1 8.7 
7e R ANAPC7 2.9 
8a L ENST00000327830 
NRBP32 
NP_510965.1 
SCRIB 
11.2 
12.5 
12.7 
14.3 
17a L Q5VV38 
GMNN 
5.7 
14.7 
22g L ENST00000327830 
NRBP32 
NP_510965.1 
SCRIB 
11.1 
12.4 
12.8 
14.4 
 
Table 11: List of the genes located within a 30 kb window of the integration of the HC-AdV into the 
non coding region of the genome. 
 
This study was carried out to check if in the case of integrations in the noncoding 
region of the genome, whether the integration would have any possible effects on the 
transcription of any genes.  33% of the integrations in the “harmless” regions of the 
genome had occurred within 25 kb of coding regions.  
 
IV.5.5.H Deletions in the adenoviral terminus 
The deletions in the terminus were studied, and of the 61 junction sites observed, 
14.76 % (n = 9) had no deletions in the termini. In 68.9 % (n = 42) the termini had 
deletions in the region between 1 and 30 bps, and in 9.8 % (n = 6), the termini had 
deletions between 31 to 60 bps.  In 4.9 % (n = 3), the termini had deletions between 
61 and 90 bps. Only one single terminus with a deletion of 105 bps was observed.  
The deletions from the termini sequences were plotted as Fig. 36. 
From the data analysed, it was observed that in the majority of HC-AdV integrations, 
the vector integrated through the viral termini.  The viral terminus seemed to have had 
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undergone random integration into the chromosomal DNA in the region of the first 30 
nucleotides. 
 
 
Fig. 36: Graph comparing the number of junction sites to the deletions in the Ad terminus in those 
junctions. 
 
IV.5.5.I Role of homologous sequences in the random integration of the vector 
DNA into chromosomal DNA 
The role of “patchy homologies/ micro homologies” [eg. (Wronka et al., 2002)] in the 
integration of the vector DNA into chromosomal DNA was analysed.  Four 
integrations were observed to occur in a homology mediated manner, three in the 
HPRT gene, and one in the c346 cosmid region.  In 36/61 junctions (59 %), patchy 
homologies between the termini and the genomic DNA of 3 bps or above were 
observed. The homologies were calculated only from the sense strand. In many cases, 
overlaps between individual “patchy homologies” were observed.  Only homologies 
to 3 or more bps within the first 30 bps in the junction have been presented as “patchy 
homologies” (Table 12). 
No. of junction site with deletions in the termini
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The sequence obtained from the left terminus of the HT1080 derived cell line 6c is 
given as an example (Fig. 37). 
 
 
Fig. 37: Patchy homologies between AdV terminus DNA and chromosomal DNA in the junction site in 
the HT1080 based cell line 6c. 
 
Junction site 
Id 
Homologous patches in number 
of bp 
Distance of the beginning of the patch from 
the junction 
3a L 3, 4, 4 3, 6, 15 
4a L 4 3 
4a R 3, 4 0, 11 
4a L 3, 4, 3, 4, 3, 3 1, 7, 9, 12, 15, 24 
4b L 7, 4, 4 1, 3, 8 
4b R 4, 3,  7,5 
4c L 3, 3, 3, 3 1, 10, 15, 20 
4d R 3, 3, 3, 4, 3 0, 2, 12, 18, 22 
6a L 3, 4 0, 2 
6b L 3, 5 4, 7 
6b R 3,3 7, 10 
6c L 3, 4, 5, 6 25, 20, 7, 1 
6e L 4, 7, 3, 4 18, 9, 4, 1 
6f R 3, 5 2, 9 
7a L 4, 4 4, 9 
7b L 4, 4, 4 1, 5, 15 
7b L (II) 3, 3 0, 5 
7c L 5 13 
7c R 4 13 
7e L 4, 3, 2 0, 8, 14 
8a L 3 8 
8a R 4 0 
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17a L 3, 5 0, 14 
17a L (II) 3 13 
17a R 5 16  
17d L 5 2 
17e L  3 2 
17e R  4, 4 0, 4 
22b L 3, 3 1, 7 
22 b R 4 5 
22d R 5 1 
22f L 5 3 
22g L 3, 3, 3 2, 5, 11 
22g L (II) 4, 3, 4 6, 1, 8 
22 h R 3 1 
22i L 3 2 
 
Table 12: List of microhomologies between the Ad5 terminus and the site in the cellular genome where 
the integration had taken place. 
 
From the data analysed, it was observed that the HC-AdV DNA, like wt Ad DNA, can 
use limited homologies of up to 7 bps between the terminus and the genomic DNA 
sequence during integration. The homologous patches could be right at the junction 
site or up to 24 bps away from it.  
Three integrations were observed in the Hprt gene, two (22gL and 8aL) in different 
loci in chr 8q24, three (4cR, 7gL and 7g R) were found integrated in different loci in 
the ATP6V1D gene in Chr 14q24.  In the last case, it is possible that the integrations 
in 7gL and 7gR are from both the arms of one single vector molecule, though in the 
absence of FISH analysis, this can only be postulated and not proved. Apart from that, 
no particular site in the genome was targeted more than once during integration by the 
vector.  
 
IV.5.5.K Mutations observed at the junction sites of the vector DNA into the 
chromosomal DNA 
To determine whether mutations were associated with the integration of the HC-AdV 
vector into the genome, the sequences of the terminus and the genomic DNA were 
studied. By convention, the sequences found in the databases were taken as that for 
the genomic DNA of HT 1080 and C 32 cells.  The deletions in the terminus exactly 
at the junction site, which occurred during the integration of the vector into the 
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genome were not considered as mutations in this study.  In the sixty one junction sites 
analysed, there were twenty two junctions with mutations associated either in the part 
of the viral terminus DNA that had integrated or in the cellular DNA.  Eight of these 
mutations were observed in the genomic region (including those three clones where 
chromosomal joining was observed), nine had taken place in the junction of the 
integration and five were observed in the termini.  Three junctions had mutations in 
both the terminus derived sequences and the genomic sequences, and two had 
mutations in the terminus derived sequences and the junction derived sequences.  The 
data was plotted on to the following Pie diagram (Fig. 39). 
 
 
Fig. 39: Pie diagram showing the mutations in the junction site of the region where the HC-AdV had 
integrated into the genome. 
 
From the data, it was clear that vector DNA integrated in 64% of the cases without 
causing any mutations.  Though no experiments were carried out to eliminate the 
possibility that some or many of the mutations observed may have been a result of the 
chromosome instability of the cell lines and may have nothing whatsoever to do with 
the vector, and should the case be that the mutations were all induced by the 
integration of the vector, no evidence was seen in the present study to suggest that the 
mutations observed during vector integration was any different than those described 
during the non homologous end joining of DNA. 
Mutations in the junction site
64.2
14.7
8
13.1
no mutations
mutations in the
junction
mutations in the viral
terminus
mutations in the
genomic sequence
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IV.5.5.L Conclusions reached from the study of the junction sites isolated after 
the random integration of HC-AdV DNA into the chromosomal DNA 
The aim of these set of experiments was to determine the nature of the integration of 
the HC-AdV in vitro. Following the molecular analysis of the clones, the following 
conclusions were reached.  
 
i. Despite the 1 moi used, more than one vector copy had integrated in some 
(up to 38 %) of the clones studied. 
ii. The vector had integrated mainly as a full intact vector molecule (93.3 %), 
in the studied clones. 
iii. The integration of the vector seemed to have taken place through the 
termini. 
iv. The vector did not show any preferential integration into genes of any 
particular molecular function or biological process. 
v. The vector utilized “patchy homologies” during the integration (in 60.7 % 
of the integrations). 
vi. In 6.6 % of the integrations, the event was “homology mediated”. 
vii. In the ATP6VID gene in Chr 14q24, and Chr 8q24, more than one 
independent integration of the vector DNA into the gene was observed.  
viii. The termini were present either in total, or had deletions up to 105 bps. 
When deletions had taken place in the termini during integration, 80.7 % 
of them had occurred within the first 30 bps of the terminus.  No specific 
relationship was observed between the deletions in the terminus and the 
integrations into active genes. 
ix. In 37.7 % of the studied junction sites, mutations in the host genomic 
sequences or in the termini or right at the junction site were observed.  
x. Integrations had taken place in both active as well as non active genes, 
with no apparent preference. 
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IV.5.6.A Vitality curve of the 6TG resistant cell lines in medium supplemented 
with HAT 
This series of experiments were carried out to analyze if there was a reversion in the 
homologous recombination that had taken place and to reconfirm that the 
recombination was genuine.  
1x105 cells of each of the 6TG resistant cell lines based on both HT1080 and C 32, 
were plated in 6 well plates and were maintained in α MEM medium supplemented 
with 1 X HAT supplement. HAT supplement is comprised of hypoxanthine, 
aminopterin and thymidine. Aminopterin (C19H20N8O5) is a folic acid antagonistic 
that blocks the de novo synthesis of purine, and hypoxanthine and tymidine are purine 
analogs.  6TG resistant cells were expected to die in medium containing HAT 
supplement while revertants were expected to survive. Cell count using Trypan Blue 
staining was taken once in three days and the numbers of the viable cells, counted 
using a Haemocytometer were plotted in a graph (Fig. 39).   
Based on these results it was concluded that no revertants were present in the number 
of cells used in the selection experiments and that in these cells, the homologous 
recombination between the vector and the genomic DNA was likely to be a genuine 
one. 
 
IV.5.6.B Reconfirmation of the homologous recombination using PCR 
These experiments were carried out to reconfirm the events of homologous 
recombination that had taken place between the vector and the genomic DNA.  The 
DNA isolated from the 6TG resistant clones was used as the template for PCR 
reactions with primers SSHPRT1 and SSHPRT2 and the product size was expected to 
be 558 bps.  The PCR products were digested with the restriction endonuclease Eco 
RV (fragments of 82 and 476 bps expected) and were run on a 2% 1X TAE gel.  The 
enzyme was expected to cut in the novel Eco RV site that had been generated due to 
homologous recombination between the vector and the genomic DNA. In the case of 
homology mediated insertional recombination, then the digested and the undigested 
forms of the product was expected. Plasmid p STK129 that had the original 
unmutated exon 2 of Hprt was used as the negative control (p2) (Fig. 40). 
In these experiments, the earlier results obtained about the 6TG resistant cell lines 
were reconfirmed. It was evident that the recombinations were all of the classic 
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replacement type, formed by two recombination events, one upstream and one 
downstream of exon 2. 
 
IV.5.6.C Nucleotide sequence of the corrected region 
The PCR products obtained in the above-mentioned experiments were cloned on a 
TOPO plasmid and were sent for sequencing and were checked against the controls. 
In the sequences analysed, the replacement of the wild type exon 2 with the mutated 
form was observed.  The sequence of one of the 6TG mutuants is compared below 
with the parental control. 
 
2a sequence 
CGCCCTTGTATCCTGTAATGCTCTCATTGAAACAGCTATATTTCTTTTTCAG
ATTAGTGATGATGAACCAGGTTATGACCTTTGATATCTTTTGCATACCTAA
TCATTATGCTGAGGATTTGGAAAGGGTGTTTATTCCTCATGGACTAATTAT
GGACAGGTAAGTAA                       
 
HT1080 sequence 
CGCCCTTGTATCCTGTAATGCTCTCATTGAAACAGCTATATTTCTTTTTCAG
ATTAGTGATGATGAACCAGGTTATGACCTTGATTTATTTTGCATACCTAAT
CATTATGCTGAGGATTTGGAAAGGGTGTTTATTCCTCATGGACTAATTATG
GACAGGTAAGTAA                     
 
Sequence legend: 
Standard font: hprt sequence 
Bold font: T insertion and novel Eco RV site/ corresponding bps in parental cell 
Underlined font : Topo TA vector 
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Fig. 39: Vitality curve of 6TG resistant HT 1080 (A) and C32 (B) based clones in HAT medium.  Cells 
were grown in 6 well plates in medium supplemented with HAT, and cell count was taken and plotted 
on to the graph above.  
 
A 
B 
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Fig.40. Scheme (A) and the gel electrophoresis photo of the PCR to confirm the event of homologous 
recombination of the HC-AdV DNA with the cellular genomic DNA.  DNA from HT 1080 derived 
6TG resistant cells (B) or C 32 derived 6TG resistant cells (C) were amplified with the primers 
SSHPRT1 and SSHPRT2 and the products were purified, digested with Eco RV and run on a 2% gel. 
M- marker, p1- p SLS 11 DNA (positive control), p2- p STK 129 DNA (negative control), HT- 
HT1080 DNA, c32- C32 DNA, 1a to 9a- DNA from HT1080 derived 6TG resistant clones, 10a to 13e- 
DNA from c32 derived 6TG resistant clones 
A 
B 
C 
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This experiment was carried out to confirm the recombination at the sequence level 
and from the obtained sequences, it was evident that the cases of recombination of the 
vector DNA with the Hprt locus were genuine events. 
 
IV.5.6.D Conclusions reached from the molecular analysis of clones obtained 
through the homologous recombination events of HC-AdV DNA with the Hprt 
locus 
The aim of these experiments was to analyse homologous recombination of the vector 
DNA with the chromosomal DNA a molecular level. From the results, it was 
concluded that 
 
i. The cases of homologous recombination observed were all genuine and of 
the classical double cross over replacement type instead of the single event 
insertion type. 
ii. No terminus of the vector DNA was present in the genome (pg 92). 
iii. The sequences downstream of the hprt stuffer, in particular, the HygEGFP 
expression cassette, were not present in the integrated molecule. (pg 92). 
iv. No revertants back to the hprt +ve state were observed. 
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IV.6 Analysis of the homologous and heterologous rcombination of 
vector DNA into chromosomal DNA following HC-AdV mediated 
gene transfer in vivo 
 
IV.6.1 Determination of the amount of viral vector particles reaching 
the mouse liver after a given dose 
As a requirement to determine recombination frequencies of HC-AdV DNA in 
hepatocytes, an accurate determination of the amount of vector DNA present in the 
hepatocytes following a given dose into the tail vein was essential and this experiment 
was carried out to determine the amount of viral particles that reach the hepatocytes 
following the injection of a given dose into the tail vein 
As reviewed in (Kuzmin et al., 1997, Overturf et al., 1997, Stein et al., 1998, Wolff et 
al., 1997, Worgall et al., 1997), the vast majority of the vector injected fails to reach 
the liver since they are phagocytocised by Kupffer cells and macrophages. So the 
rationale was that, after injecting a HC-AdV into mice, harvesting the liver 10 days 
p.i. should allow only the vector molecules present in the hepatocytes to be detected.  
The HC-AdV Ad SLS 16, carrying the murine FAH cDNA in a RSV promoter BGH 
poly A cassette was used for the study. Vector was injected via the tail vein into 
FahΔexon5 mice in doses ranging from 1x1010 to 5x108 inf. units per mouse, and the 
subjects were sacrificed 10 days post injection.  A total of 13 mice were used for the 
study (including the control).  The livers were harvested, the DNA was extracted and 
the vector DNA load was titered per 3µg and 6µg of DNA using the slot blot method 
(Fig. 41). 
The results are summarised in Table 13.  A diploid mouse cell has 6 pg of DNA and 
so the number of cells used was calculated from the amount of DNA used. 
 
Dose Slot blot value No: cells No: of copies reaching each nucleus 
1x1010 10.4 x106 1x106 10 
2x109 3.2 x 106 1x106 3.2 
1x109 1.1 x 106 1x106 1.1 
5x108 0.45 x106 1x106 0.45 
1x108 N.D. 1x106 N.D. 
 
Table 13: Data showing the number of copies of HC-AdV per hepatocyte as per Slot blot method 
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Fig.41. Schematic representation of the experiments carried out to determine the number of HC-AdV 
molecules reaching the liver following tail vein injection.  Mice were injected with different amounts 
of the vector, sacrificed, the livers harvested and the DNA isolated.  Viral load was measured using the 
Slot blot procedure. 
 
The aim of this experiment was to determine the exact number of HC-AdV vector 
molecules reaching each hepatocyte following the injection of a given dose, so as to 
facilitate the calculation of the frequencies of integration and homologous 
recombination of the HC-AdV in vivo.  From the experiment, it was evident that the 
amount of vector reaching the liver is dose dependent and ranges from 10 copies per 
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hepatocyte following and injection of 1x1010 inf. Units (in contrast to the expected 
300 copies) to 1 copy in 2 hepatocytes following an injection of 5x108 inf. units.  
 
IV.6.2 Determination of the rate of random recombination of HC-
AdV in vivo and molecular analysis of the junction sites of integration 
 
VI.VII.1. Determination of the rate of integration of the vector 
 
 
This experiment was carried out to determine the rate with which the HC-AdV 
integrates into the genome in vivo.  
ITR ψ stuffer       FAH cDNA expression cassette stuffer       ITR
RSV mFAH  BGH
        cDNA   poly A  
Fig. 42: Diagram of Ad SLS 16 
The vector used in this study was Ad SLS16, which expresses the murine FAH cDNA 
from the RSV promoter (Fig. 42).  The FahΔexon 5 knockout mouse was used as the 
model in which the vector was tested. The full details of the cloning of the vector are 
given in the Materials and Methods section. 
As explained in the Materials and Methods section, the production of the fumaryl 
acetoacetate hydroalse transgene was expected to confer resistance to the hepatocytes 
where the vector would be present.  The vector, which remained as an episome, was 
expected to be gradually lost during the turn over of the hepatocytes.  However, on 
the event of the integration of the vector into the genome, the FAH +ve cell would 
have a growth advantage in the liver, and given the regenerative capacity of the liver, 
would give rise to a nodule of Fah +ve cells, which could be visualized following 
immunohistochemical analysis of the mouse liver with a Fah specific antibody. When 
such a mouse liver containing a mixture of Fah +ve and negative cells was perfused 
and the isolated hepatocytes transplanted onto a second recipient, the above-
mentioned Fah +ve cells from the donor, were expected to have the growth advantage 
and repopulate a part of the recipient liver, provided the vector integrated into the 
genomic DNA. 
Fah Δ exon 5 strain mice (n = 10, including control) were injected with Ad SLS 16 via 
tail vein injection. Pilot studies with varying doses of the vector had shown that the 
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optimal amount of vector required to count the Fah +ve nodules was 5x108 inf. units 
and so that dose was favoured. 
 The mice were allowed to recover after the injection and were kept for 2 weeks off 
NTBC.  NTBC was then added to the drinking water at a concentration of 7.6 
mg/litre, and the mice were kept on the diet for a further two weeks and were 
sacrificed at predefined time-points, unless specifically mentioned. For the mice 
predestined for the immunohistochemical analysis of the liver alone, the animals were 
sacrificed by cervical dislocation and the livers were harvested and fixed in 10% 
phosphate buffered formalin (Fig. 43).  The tissues were dehydrated in 100% ethanol 
and embedded in paraffin wax and sliced using a microtone.  Four-micron sections 
were selected and rehydrated.  The sections were stained with haemotoxylin and eosin 
and with a polyclonal rabbit antibody to rat FAH, and viewed through a Zeiss 
Axiovert 135 microscope (Fig. 44 & 45).   
A collection of cells in an ellipsoidal block was taken as a Fah +ve nodule (Fig. 46), 
and number of nodules and the number of cells per nodule was noted. The slides 
containing the sections were scanned on a flat bed Canon scanner along with a size 
standard at 300 dpi resolution, the images were opened with NIH image J programme 
and the surface area of the sections was calculated and in accordance to the methods, 
the total number of hepatocytes per slide was calculated as in (Wang et al., 2002). The 
number of viral vector genome per hepatocyte after the mouse was given a particular 
dose was calculated as mentioned in section VI.VI.  The rate of integration of the 
vector DNA into the chromosomal DNA was calculated as on pg 57. The rate of 
integration of the viral vector was calculated on the basis of vector molecules as 
4.0275x10-5 (S.E.M = 1.76 x10-5) in n = 9 mice (Table 14). 
 
No: of mice 
injected 
Dose of Ad SLS 
16, inf. units 
Rate of integration (mean, corrected to the number of 
vector molecules reaching the hepatocytes) 
6 5 x108 6.2075 +/- 2.49, x10-5 
2 2 x108 3.335 +/- 1.185, x10-5 
1 1 x109 2.54 x 10-5 
 
Table 14: The data obtained from the experiment for calculating the rate of random integration of the 
HC-AdV into the cellular genome in vivo. 
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Fig. 44: Schematic representation of the experiments carried out to determine the rate of random 
integration of HC-AdV in vivo.  Mice were injected with different amounts of the vector, cycled on and 
off the NTBC diet to allow them to recover and were sacrificed.  The livers were harvested and the 
immunohistochemistry carried out with an anti-Fah antibody. 
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Fig. 44: Liver sections from mice that had been injected with a dose of 1x109 inf. units of Ad SLS 16 
 
 
 
 
 
 
 
 
 
 
 
Fig. 45: Liver sections from mice that had received a dose of 5 x108 inf. units of Ad SLS 16. 
 
The FAH +ve nodules can be visualized more clearly in these liver sections. 
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Fig. 46: Liver sections from mice that had received a dose of 5 x108 inf. units of Ad SLS 16. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 47: Liver sections from mice that had received the serial transplantation injections of hepatocytes 
from the mice injected with Ad SLS 16. 
 
In the serial transplantation experiments (Fig. 47), the mice were anaesthetised, and 
two lobes of the liver were tied off from the rest, cut out and treated as in the ones 
mentioned above. The remaining part of the liver was perfused using collagenase, and 
the prefused liver was filter sterilized and 1x106 viable hepatocytes were isolated.  
Recipient mice were anaesthetized, and the isolated hepatocytes were injected into the 
spleen, the flesh and the skin were stitched back, and the mice were allowed to 
recover with NTBC containing drinking water.  The mice were sacrificed at set times, 
the livers were harvested and the DNA was isolated. Standard PCR was carried out to 
confirm the presence of the vector derived DNA in the recipient liver DNA.  Inverse 
PCR was carried out and the PCR fragments were cloned into TOPO cloning vector 
and were sequenced.  
This series of experiments were carried out to calculate the rate by which the HC-
AdV integrates randomly into the genome in vivo. This was found out to be 4.0275 x 
10-5 (S.E.M = 1.76 x10-5) in n = 9 mice, based on the number of infectious units of 
HC-AdV per cell. 
 
IV.6.2.A PCR to test for the presence of the transgene in the liver of the 
experimental animals 
The DNA obtained from the adenovirus injected and serially transplanted mice were 
analysed using PCR. A primer pair was used whereby P1 was designed from the RSV 
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promoter sequence and the P2 from the mFah CDNA.  A band of 481 bps was 
expected to be amplified only in the presence of the entire cassette (Fig. 48 & 49).  
 
ITR ψ RSV mFAH                     ITR   Chromosomal
         cDNA                                DNA
481 bps
P1   P2
 
 
Fig. 48: Scheme of the PCR to test for the presence of the RSV-FahcDNA cassette in the serially 
transplanted liver. 
 
The DNA bands were cut out and cloned into a TOPO TA cloning vector and the 
DNA sequences were detemined. The sequences were as expected, showing the RSV 
promoter sequence and the murine FAH cDNA sequence. 
 
 
Gel i.d. Mouse i.d comments Gel i.d. Mouse i.d comments 
1 16.2 Serial transplant 11 Serial 23 Serial transplant 
2 16.3 Serial transplant 12 Serial 24 Serial transplant 
3 410 injection 13 Serial 511 Serial transplant 
4 410 (hep) injection 14 Serial 524 Serial transplant 
5 411 injection 15 16#2 Serial transplant 
6 412 injection 16 Fah-/- control 
7 412 (hep) injection 17 Wt control 
8 415 injection 18 p SLS 16  10000 copies 
9 416 injection 19 p SLS 16 1 copy 
10 Serial 21 Serial transplant 20 H2O water 
 
Legend: Serial transplant: subjects that received the serial transplantation 
10000 copies: 10000 copies of the vector molecule/mouse genome, spiked in mouse 
DNA 
1 copy: 1 copy of the vector molecule/mouse genome, spiked in mouse DNA. 
 
A 
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Fig. 49: A. Table with details about the samples used in the PCR.  B. PCR experiment carried out on 
the liver extracted from the liver of mice injected with Ad SLS16 or serially transplanted with viable 
hepatocytes that had been transduced by that vector.  The DNA was amplified with the primers and run 
on a 2 % 1XTAE agarose gel.  See 49.A for details about the samples in each lane. 
 
AATTCGCCCTTGACAGGTCTGACATGGATTGGACGAACCACTGAATTC
CGCATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACAATAAAC
GCCATTTGACCATTCACCACATTGGTGTGCACCTCCAAGCTAATTCCG
TAGGGGGCTCTGCTGCCCGGTGCTCGTCAGCATGTCCTTTATTCCAGTGGC
CGAGGACTCCGACTTTCCCATCCAAAACCTGCCCTATGGTGTTTTCTCCAC
TCAAAGCAACCCAAAGCCACGGATTGGTGTAGCCATCGGTGACCAGATCT
TGGACCTGAGTGTCATTAAACACCTCTTTACCGGACCTGCCCTTTCCAAAC
ATCAACATGTCTTCGATGAGACAACTCTCAATAACTTCATGGGTCTGGGTC
AAGCTGCATGGAAGGAGAAGGGCGAATT 
 
Sequence code: 
Standard font: TOPO TA vector, Bold font: RSV promoter,  
Underlined font : FAH cDNA 
 
This PCR reaction and the related sequencing reaction were carried out to check for 
the presence of the transgene in the DNA of the liver of the injected and the serially 
B 
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transplanted test animals, and the results confirm its presence.  However, the vector 
was lost in some of the serially transplated mice.  This was also expected, since the 
NTBC diet was restored to the experimental animals once they started appearing 
unhealthy, and so, though under the experimental conditions the mice with FAH 
positive cells had a selective advantage, mice with FAH negative livers could also 
survive. 
 
IV.6.2.B Sequence analysis of the junction sites between the Ad SLS 16 DNA and 
the chromosomal DNA  
In the serial transplantation experiments, the mice were anaesthetized, and a part of 
the liver was harvested and fixed for immunohistochemical staining.  The remaining 
part of the liver was perfused using collagenase, the perfused liver was filter 
sterilized, 1x106 viable heptocytes were isolated and injected into the spleen of Fah -/- 
recipient mice, which were then allowed to recover with NTBC containing drinking 
water.  The mice were sacrificed at set times, the livers were harvested and the DNA 
was isolated.  Inverse PCR was carried out using the restriction endonuclease Tsp 
509L and the PCR fragments were cloned into TOPO cloning vector followed by 
sequencing.  
 
Sequence of the junction site from mouse 16#2 
Mouse 16#2 had received a splenic injection of 1x106 viable hepatocytes from mouse 
41, which had been injected with 5x108 inf. units of Ad SLS 16, and had been allowed 
to recover from the injection with one cycle on and off NTBC.  Mouse 41 was 
sacrificed 4 weeks after the injection.  Mouse 16 too was kept on one round on and off 
NTBC and was sacrificed 4 weeks after it was injected. 
 
  
A deletion of 31 bps in the right terminus and a T to C substitution was observed at 
the -9 bp of the terminus. Though the location of the sequence was found to originate 
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from a clone that contained the preribosomal RNA gene, the exact location is not yet 
available in the database 
 
Sequence of the junction site from mouse 511 
Mouse 511 had been injected with 5x108 inf. units of Ad SLS 16, had been allowed to 
recover from the injection with one cycle on and off NTBC and was sacrificed 8 
months after it was injected.  
 
 
The last 15 bps were found deleted from the left terminus and the integration was 
mapped to the 63673236 bp of Chr 5 C.3 in a non coding region. 
 
Sequence of the junction site from mouse 327 
Mouse 3 had received a splenic injection of 1x106 viable hepatocytes from mouse 41, 
which had been injected with 5 x108 inf. units of Ad SLS 16, and had been allowed to 
recover from the injection with one cycle one and off NTBC (4 weeks post injection).  
Mouse 3 was kept on one round on and off NTBC and was sacrificed 4 weeks after it 
had received the hepatocytes. 1x106 viable hepatocytes from the perfused liver were 
injected into mouse 327 via the spleen.  After a cycle on and off NTBC, mouse 327 
was sacrificed, the liver harvested and the DNA prepared. 
 
  
The last bp of the left terminus was missing in the integration event that was mapped 
to the 37088008 bp in chromosome 10B1. 
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The entire right terminus was present in junction site that was located in the 
103407545 bp of Chr 9, corresponding to the 5th intron of the beaded filament 
structural protein 2, phakinin (Bfsp2). 
 
Sequence of the junction site from mouse S21 
Mouse S21 had received a splenic injection of 1x106 viable hepatocytes from mouse 
410, which had been injected with 5x108 inf. units of Ad SLS 16, and had been 
allowed to recover from the injection with one cycle one and off NTBC.  Mouse 410 
was sacrificed 4 weeks after the injection.  Mouse S21 was kept on one round on and 
off NTBC and was sacrificed 4 weeks after it was injected.  
 
 
The last 10 bps of the right terminus were missing and the integration was mapped to 
bp 89372401 in chr 2E1. 
 
Sequence of the junction site from mouse S23 
Mouse S23 had received a splenic injection of 1x106 viable hepatocytes from mouse 
410, which had been injected with 5x108 inf. units of Ad SLS 16, and had been 
allowed to recover from the injection with one cycle one and off NTBC.  Mouse 410 
was sacrificed 4 weeks after the injection.  Mouse S23 was kept on one round on and 
off NTBC and was sacrificed 4 weeks after it was injected.  
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The last 64 bps were found deleted from the left terminus in the integration which had 
taken place in the 2nd intron of the glucocorticoid modulatory element binding protein 
2 (Gmeb2), in the 180986861 bp of chromosome 2H1. 
 
 
In the integration that took place in the 107788894 bp of Chr 12 in a predicted gene, 
the last 16 bps of the right terminus was found deleted. 
 
Sequence of the junction site from mouse S24 
Mouse S24 had received a splenic injection of 1x106 viable hepatocytes from mouse 
410, which had been injected with 5x108 inf. units of Ad SLS 16, and had been 
allowed to recover from the injection with one cycle one and off NTBC.  Mouse 410 
was sacrificed 4 weeks after the injection.  Mouse S24 was kept on one round on and 
off NTBC and was sacrificed 4 weeks after it was injected.  
 
The last 78 bps of the right terminus were deleted in the integration that took place in 
a non coding region of Chr 18 d4 in the bp 60650359 bp. 
 
The results have been summarized in Table 15. 
 
Mouse 
ID 
Terminus Integration 
in  
chr 
Direction of the 
vector in relation 
to the chr 
Deletion 
from the 
termini 
Integration in 
gene 
Comments 
16.2 R  ? ? 31 ? Deletion at –9 
bp 
511 L  5c 
636732361 
bp 
Æ 15 N . 
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327 L 10B1 
37088008 
bp 
Å 1 N  
327 R 9 
103407545 
Æ 0 Y 
Bfsp2 
 
S21 R 2E1 
89372401 
bp 
Æ 10 N  
S23 L 2H1 
18098686 
bp1 
Æ 64 Y 
Gmeb2 
 
S23 R 12 
107788894 
bp 
Å 16 Y 
predicted 
 
S24 R 18D4 
60650359 
bp 
Å 78 N  
 
Table 15 Table listing the integration of the vector, the direction of the integration with respect to the 
chromosome. 
 
This series of experiments was carried out to directly demonstrate integration events 
in the mouse liver by determining the sequences of the junctions of integration 
between vector and cellular DNA.  
 
IV.6.3 Determination of the rate of homologous recombination of 
HC-AdV in vivo 
This experiment was carried out to determine the rate with which the HC-AdV 
recombines with genome in vivo via homologous recombination. 
The vector used in this study was Ad SLS 14 (Fig. 50), which carries a 12.3 kb 
fragment of the murine Fah gene spanning the region between the 1st intron and the 
10th intron.  The Fah Δexon5 knockout mouse was used as the model in which the vector 
was tested.  The full details of the cloning of the vector are given in the Materials and 
Methods section. 
 
ITR ψ Murine FAH gene, Ist intron to 10th intron       Hprt stuffer     ITR
    E2   E3  E4         E5     E6 E7         E8  E9  
Fig. 50. Diagram of the HC-AdV SLS 16 
 154
As explained in the introduction, the Fah enzyme was not produced in the liver of the 
knockout mice.  Since the vector lacks the promoter and exons 1, 10, 11, 12, 13 and 
14, it would not confer any selective advantage on the cells where it remained as an 
episome.  However, in the event of the homologous recombination of the vector with 
the Fah locus, and the subsequent correction of the mutated exon 5 (Fig. 51), the Fah 
+ve cell would have a growth advantage in the liver, would give rise to a nodule of 
Fah +ve cells, which could be visualized following immunohistochemical analysis of 
the mouse liver with the Fah specific antibody. As in the work with Ad SLS 16, when 
such a mouse liver containing a mixture of Fah +ve and negative cells was perfused 
and the isolated hepatocytes transplanted onto a second recipient, the above-
mentioned Fah +ve cells from the donor were expected to have a growth advantage 
and repopulate a part of the recipient liver, provided the vector integrated into the 
genomic DNA. 
The FahΔ exon 5 strain mice (n = 10, including control) were injected with Ad SLS 14, 
via the tail vein. Pilot studies with varying doses of the vector had shown that the 
optimal amount of vector required to count the Fah +ve nodules was 2x109 inf. units 
and so that dose was favoured.  The mice were allowed to recover after the injection 
and were kept for 2 weeks off NTBC and the rest of the experiment [treatment of 
animals and immunohistochemistry (Fig. 53)] was exactly as in the earlier experiment 
with Ad SLS 16 (Fig. 52).  The same method was used to determine the rate of 
homologous recombination which was calculated on the basis of vector molecules as 
5.651x10-7 (S.E.M = 1.7x10-7) in n = 11 mice (Table 16). 
 
    E2    E3 E4        E5       E6 E7        E8  E9
                
E1    E2   E3   E4       E5      E6  E7       E8  E9        E10 E11     E12  E13         E14
E1    E2   E3   E4       E5      E6  E7       E8  E9        E10 E11     E12  E13         E14
12.3 kb homology
Neo cassette insertion in E5
Corrected E5
Ad SLS 14
Fah locus
with neo 
insertion in E5
Fah gene
corrected
following
HR with
Ad SLS 14
 Fig. 51: Schematic representation of the homologous recombination of HC-AdV DNA with the Fah 
locus in thechromosomal DNA of the  FahΔexon 5 mouse to generate a Fah +ve cell.  
 
 155
Cycle on 
and off NTBC
Livers 
harvested
Immunohistochemical analysis
1x10E10 to 
4x10E8 inf. Units
Ad SLS 14
Ex 2 3 4     5   6 7     8 9 Ad SLS 14
Ex1  2 3 4     5* 6 7   8 9   10 11 12 13  14
Ex 1  2 3 4     5   6 7    8  9  10 11 12 13 14
Fah locus with
neo insertion in 
exon 5
Corrected gene
following HR
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Fig.52. Experimental animals were injected with different doses of vector and maintained on a diet 
with and without NTBC supplement to allow them to recover.  They were sacrificed, the livers 
harvested and immunohistochemical analysis was carried out with Fah antibody. 
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Fig. 53: Liver sections from mice that had received the dose of 1x1010 inf. units of Ad SLS 14  
 
No: of mice 
injected 
Dose of Ad SLS 14, 
inf. units 
Rate of integration (mean, corrected to the number of 
vector molecules reaching the hepatocytes) 
2 1 x1010 7.34 +/- 1.95, x10-7 
7 2 x109 4.99 +/- 2.9, x10-7 
2 1 x109 6.24 +/- 0.23, x 10-7 
 
Table 16: The data obtained from the experiment for calculating the rate of homologous recombination 
of the HC-AdV with the Fah locus in vivo.   
  
Taken together, the in vivo rate of homologous recombination was found to be  
5.7x10-7. 
 
IV.6.3.A PCR to confirm the correction of exon 5 in the mice 
The serial transplantation of the hepatocytes was carried out as described in the earlier 
experiment with Ad SLS 16.  The immunohistochemical analysis revealed the 
presence of Fah +ve cells and to confirm the correction of exon 5 in the Fah locus of 
the mice following homologous recombination between the vector DNA and 
chromosomal DNA, DNA extracted from Ad SLS 14 injected and serially 
transplanted mice were analysed using PCR. The primers used in the reaction were as 
follows: Fah A was designed from the 4th intron sequence, Fah B from the neomycin 
cassette, and Fah C from the Fah exon 5 sequence downstream of the site of the neo 
insertion.  A band of 243 bps was expected to be amplified between Fah A and Fah B 
primer pairs, and a band of 187 between Fah A and Fah C primer pairs in the presence 
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of the corrected band or the episome.  No product was expected between primer pairs 
Fah A and Fah C in the non corrected liver under the conditions used (Fig. 54) 
 
 
Gel i.d. Mouse i.d Comments 
1 401 injection 
2 403 injection 
3 406 injection 
4 14 serial1 Serial transplantation 
5 14 serial 2 Serial transplantation 
6 14 serial 3 Serial transplantation 
7 14 serial 4 Serial transplantation 
8 14 serial 5 Serial transplantation 
9 16#2 Serial transplantation 
10 25.505 Injection, Ist generation AdV Ad SLS25 
Fah - Mouse - Control, Fah -/- Knockout mouse 
p P SLS 14 Control, Vector plasmid 
fah  + Mouse + Control, Wt mouse, 129 strain 
fah+* Mouse + Control, Wt mouse, C57/Bl6 strain. 
-ve H20  
-ve H20  
 
 
Fah locus
Knocked out gene                    Corrected gene
Fah A  Fah B       Fah C Fah A   Fah C
251 bp 135 bps  
 
 
 
 
 
 
A 
B 
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Fig. 54: A. Table detailing the samples used in the PCR.  B. The scheme of the PCR.  C. The PCR 
experiment carried out on the DNA extracted from the liver of mice injected with the Ad SLS 14.  
DNA was amplified with the three primers and run on a 2 % TAE agarose gel.   
 
Sequence from the 135 bp band (corrected band) 
 
AATTCGCCCTTCTAGGTCAATGGCTGTTTGGGGTGTTCCCTCTGCAGG
AGACTACACGGACTTCTACTCTTCTCGGCAGCATGCCACCAATGTTGG
CATTATGTTCAGAGGCAAGGAGAATGCGCTGTTGCCAAATTGGTATG
TCCAAGGGCGAATT 
 
Sequence from the 251 bp band (non corrected) 
 
AATTCGCCCTTTAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTC
ATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTG
GGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTG
AGGCGGAAAGAACCAGCTGGGGCTCGAGATCCACTAGTTCTAGCCTCGAC
C 
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CACCAATGTTGGCATTATGTTCAGAGGCAAGGAGAATGCGCTGTTGC
CAAATTGGTATGTCCAAGGGCGAATT 
 
Sequence code: 
Standard font: CMV 
 Bold font: Fah gene 
Underlined font : TOPO TA vector  
 
This PCR was carried out to confirm that the Fah exon 5 had been corrected in the 
serially transplanted mice.  Though the chances of the 135 bp band arising from the 
episomal Ad SLS 14 could not be totally ruled out, it was unlikely after the multiple 
cell divisions arising from the serial transplantation process and therefore, taken 
together with the immunohistochemical data, it can be safely concluded that the 
vector had corrected exon 5. 
 
IV.6.4 Conclusions reached from the in vivo experiments 
 At the time of the preparation of the manuscript, the mouse genome has been 
sequenced, but the data that is available in the database is not as much as compared to 
the human genome.  The following conclusions have been reached from this study. 
i. In this experiment, HC-AdV genome underwent integration in vivo with 
the chromosomal DNA at a rate of 4.0275x10-5. 
ii. From the available data, it can be stated that HC-AdV display no specific 
predisposition (37.5 %) to integrate into genes in vivo, similar to the results 
obtained in vitro. 
iii. As in the in vitro data, deletions were observed in the termini of the AdV.  
50 % of the deletions took place within the first 30 bps of the ITR. 
iv. In this experiment, HC-AdV genome underwent homologous 
recombination in vivo with the chromosomal DNA at a rate of 5.651x10-7.  
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V Discussion 
 
At the time the project has started, no study had been performed on the fate of high 
capacity adenoviral vectors.  The risk posed of insertional mutagenesis of the vectors 
became visibly apparent only after the ill-fated trial in France (Li et al., 2002).  By the 
time of the completion of the lab work, no work had been published on the site of 
integration of HC-AdV in the genome and as of date, no work has been published 
about the rate of integration of HC-AdV in vivo.   
 
V.1 Selection of the models 
In the experiments involving the fate of the HC-AdV genome following gene 
thransfer in vitro, it was of paramount interest to select a system that was very well 
characterized.  The Hprt model has been successfully used since the mid 1980s to 
study site directed mutagenesis events [for example, see (Lin et al., 1985)], and the 
positive and negative selections using 6TG and HAT mediums have been very well 
studied [for example, see (Sharp et al., 1973)], and so that model was chosen.  At the 
time of the experiments, the FAH-/- mouse model was a more characterized knockout 
model than the urokinase-/- mouse model [reviewed in (Michalopoulos & DeFrances, 
1997)] and so it was selected.  The drawback of the model was that surgical extraction 
of single FAH+ve nodules from a FAH-ve liver, without any contamination 
whatsoever, was not technically feasible; to circumvent this, the system of serial 
transplantation of the hepatocytes into FahΔexon5 mice, was utilized to select for a 
subset of the Fah+ve cells in the donor mouse’s liver, and was carried out with the 
intention of elucidating some of the sequences of the sites of integration between the 
vector genome and the mouse genome.  Also, when the rate of random integration of 
the vector was tested, the proof for a case of integration was taken as a clear 
ellipsoidal Fah +ve nodule.   
 
V.2 Recombination rates of HC-AdV DNA with chromosomal DNA in vitro 
Cell types may vary with respect to their permissivity for adenoviral infection and that 
was the rationale behind the testing of the permissivity of the cell types to adenovirus 
vector transduction.  Two of the cell lines used in the study described here, viz., HeLa 
and HT1080 were used in a similar study in which the rates of integration of HC-AdV 
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and Ist Gen AdV were compared (Harui et al., 1999).  The rate of integration of HC-
AdV in HeLa was between 2.6 and 0.5x10-4, and that of HT1080 was between 1.8 and 
0.29x10-3, at 10 moi per cell.  Ist Gen AdV integrated at slightly higher rates.  The 
rates of HC-AdV integration, observed for the same cell lines in this present study 
were 3.01x10-4 and 4.6x10-4 respectively.  In the above mentioned work involving 
KB, CHO, CV-1, cells, the authors had observed HC-AdV DNA integration at rates 
between 1 to 0.01x10-2, at a moi of 10. (Hillgenberg et al., 2001) had published that 
the rate of integration of HC-AdV DNA into the genomic DNA of U87-MG cells was 
1.6x10-4 at a moi of 0.1, as opposed to the rates observed in current study between 5 
to 0.1x10-3 at a moi of 1 in different cell lines.  In the study by (Hillgenberg et al., 
2001), the permissivtiy of the cells to AdV was not tested.  The authours had also not 
observed any instances of homologous recombination of the vector into the genome.  
However, as observed in the experiments described here, the rate of HR is three logs 
lower than the rate of NHEJ, and so they might have not noticed it.  (Ohbayashi et al., 
2005) report that in experiments with male ES cells transduced by HC-AdV at a moi 
of 10, the rate of homologous recombination of the vector DNA into the chromosomal 
DNA was between 2 to 0.67x10-3, and the rate of random integration of the vector 
DNA into the chromosomal DNA was between 1.5 to 0.5x10-3.  In the experiments 
described in this study, the rate of homologous recombination of the vector into the 
genome ranged from 2 to 0.1 x10-5 at a moi of 1.  The differences between the cell 
types might be the reason behind the higher rate of homologous recombination 
reported by that group.  Human cells are reported to be 30-100 times less tolerant of 
integrations of exogenous DNA into their genome as compared with rodent cells 
(Colbere-Garapin et al., 1986, Hoeijmakers et al., 1987, Lohrer et al., 1988, Mayne et 
al., 1988), though in the case of established cell lines, there was no significant 
difference between the rates of integration of the vector in human and non human 
cells (Harui et al., 1999).  The integration patterns of DNA in normal cells are simpler 
than in transformed cells (Hoglund et al., 1992), though it remains to be seen whether 
this would result in a significant difference in the rates of homologous recombination.  
In work involving targeting of the Hprt locus using AAV vectors, Russel et.al. 
(Russell & Hirata, 1998) report that the rate of integration of the vector in HT1080 
was 2x10-4 at a moi of 50,000 and the rate of spontaneous mutation of the Hprt gene 
was 2x10-5.  The rate of homologous recombination of HC-AdV in HT1080 cells 
observed in this present study was 1.1x10-6, and in the experiments involving early 
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passage cells that were either infected with Ad SLS 21 or PBS treated, no 
spontaneous mutation was observed under the conditions used.  This contrast may be 
due to the difference of protocols between the labs.  Since due to genomic instability 
(Hanson & Caisander, 2005) the expression level of the proteins involved in cellular 
DNA repair mechanism can vary between cell lines (Wang et al., 2005), the range in 
the difference of random integration of the vector into the genome can also be 
expected.  HC-AdV do not code for any proteins involved in DNA repair and 
recombination and so are dependent on the cellular machinery to carry out the 
process.  Recombination via homologous or non homologous end joining (NHEJ) can 
be linked to the levels of Rad family proteins and Ku70/Ku80, which compete for the 
broken ends of the DNA to channel them into the respective pathways (Haber, 1999).  
The inverse correlation between the rates of random integration and homologous 
recombination of the HC-AdV DNA observed in this present study in HT1080, C32 
and FF-95 cells seem to suggest this.  The progression into cell cycle also determines 
where DNA repair takes place by HR or NHEJ; genes coding for HR machinery are 
more expressed during the G2 and S phase of the cell cycle, whereas those supporting 
NHEJ are present throughout the cycle [reviewed in (Takata et al., 1998, Wurtele et 
al., 2003)].  The HT1080 cell line grows much faster than the C32 and FF-95 cells 
and have to be passaged more often (see Materials and Methods), and so the 
difference in the rates of recombination in these cell lines may be linked to the cell 
cycle.  The plans in this study to test for the expression of these proteins were 
hindered by time constraints.  
 Earlier work done on the Hprt model using plasmid transfection had suggested 
that the rate of random integration of plasmid DNA into the genome is 10-4 to 10-5 and 
the rate of HR is 10-6 to 10-8, and the greater the amount of homology, the higher the 
rate of HR (Doetschman et al., 1987, Lin et al., 1985, Thomas & Capecchi, 1987, 
Thomas et al., 1986).  The rates at which DNA molecules reach the nuclei are low, 
being less than 10% in the CaPO3 method (Orrantia & Chang, 1990) and only     1 % 
and 0.1 % in the case of  the DNA complexed with polyethylenimine and cationic 
lipids respectively (Pollard et al., 1998), and even after that, a large proportion of the 
DNA gets degraded (Liang & Jasin, 1996).  So the amount of DNA used for 
transfection cannot be directly correlated with the rate of integration as was done in 
(Harui et al., 1999), but nevertheless, the recombination rates of AdV seem to be 
higher than that of plasmid DNA.  The precursor terminal protein coupled to the ends 
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of the Ad termini is a DNA binding protein.  Two pTP molecules can bind co-
operatively to short DNA duplexes in a sequence independent manner. pTP also binds 
to ssDNA without sequence dependence, and simultaneous interaction of two DNA 
binding regions within a pTP molecule too has been demonstrated (de Jong et al., 
2003) but it remains to be seen if the smaller TP may have similar properties and 
serve not only in protecting the ends of the DNA, but also in tethering it to specific 
regions in the genome.  TP-linked Adenviral genomes have been used in other studies 
(Hartigan-O'Connor et al., 2002) and it would be very interesting to determine the 
rates of recombination of TP-linked Ad genomes, after calculations have been done to 
determine the number of DNA molecules reaching the nuclei, by Slot Blot Analysis of 
the transfected nucleii isolated using Hirt’s method, and compare them with the rates 
obtained in this study. 
 
V.3 Southern blot analysis of the clones 
 The Southern blot data obtained in this study demonstrated that in up to 38% 
of the clones, more than 1 copy of the vector was present and that in 21% of the 
clones, there were more Ad termini than expected from the number of transgenes 
integrated.  This agrees with the data presented in (Hillgenberg et al., 2001), where, 
though in 50 % of the clones both the Ad termini were observed, in 19 % of the 
clones descrepancies between the number of termini and integrated transgene were 
observed.  However, the Southern data that is presented in this study is handicapped 
by the fact that the adenoviral left terminus was used the probe.  The larger part of the 
probe hybridised with the packaging signal, but the probe had also cross-hybridised to 
a lesser extent with the adenovirus right terminus too.  In the paper mentioned above, 
the vector had a RSV-LacZ-SV40Poly A cassette at the right terminus and so in that 
case, unlike the study described here where a DNA fragment of the cosmid c346 
bordered the right terminus, it was possible for the researchers to perform a Southern 
blot exclusively for the right terminus of their vector using the SV40 PolyA probe.  
Discrepancies between the number of transgenes and the vector terminus were also 
reported in (Harui et al., 1999), where possible DNA rearrangements, including 
internal ones in the vector genome, were observed, also in agreement with the data 
presented in this present study.  The above mentioned study also reported that the 
integrated vector underwent rearrangements over time.  Chromosome instability has 
been reported in cell lines once past the Hayflick limit [reviewed in (Effros, 2004, 
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Hanson & Caisander, 2005)] and this might explain some of the data observed.  
Though 6TG resistant/ Hyg resistant clones were isolated from the primary cell lines 
FF-95 and HRPE, they failed to survive long enough to generate enough DNA needed 
for Southern blot and Inverse PCR protocols used in this study.  However, the 
developments of mini southern blot (Lan et al., 2002) and LAM PCR (Schmidt et al., 
2003), both of which need far less amount of DNA than that needed in conventional 
methods, can be used in any future work using primary cells to obtain the result.  The 
Southern blot data obtained in this study has demonstrated that in the clones where the 
HC-AdV DNA had undergone HR into the genome, viral termini or non homologous 
sequences such as the transgene were absent. This, along with the data obtained from 
the PCR analysis of the clones, demonstrates that the HR resulted in a proper 
exchange of the exon 2 of the Hprt gene and not in an insertion of the homologous 
sequences.  Nevertheless, FISH data on the clones could have pinpointed the data 
obtained from the Southern blot. 
 
V.4 Sequence analysis of the clones 
V.4.1 Mutations in the cellular genome 
In the experiments described here, the protocol of Inverse PCR was developed for use 
in the adenoviral integration system, where the entire Ad terminus may or may not be 
present.  Currently other PCR methods of determining the sequence of the junction of 
recombination, such as LAM PCR, PCR with various types of linkers, Alu PCR etc 
do exist, but the best results were obtained using Inverse PCR in the study.  However, 
under normal conditions, PCR tends to amplify the smaller fragments in a pool of 
DNA fragments of different sizes, and so not all of the junction sites could have been 
sequenced.  In work on HC-AdV DNA recombination into chromosomal DNA 
published by other labs using Adapter ligated PCR (Ohbayashi et al., 2005), 
sequences were obtained from both ends in two (possibly 3) out of the twenty clones 
analysed, and three out of forty three clones when Inverse PCR and Lam PCR were 
used (Wang et al., 2005).  In the work presented here, only in one clone, 17e, it can be 
stated that the sequences from all of the Ad termini detected in it using Southern blot, 
have been accounted for.  Even in this case, it would not be possible to rule out 
integrations of the adenoviral termini where extensive deletions had taken place, 
thereby nullifying the chances of detecting it in the Southern Blot.  Wt. AdV have 
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been reported as forming concatamers and repeats during integration into the genome; 
deletions of up to 175 bps have been reported in the termini of integrated wt AdV 
[reviewed by (Doerfler et al., 1984)].  The cell lines themselves were known to have 
gross chromosomal irregularities and rearrangements in the karyotype, including 
deletions, additions and translocations in the chromosomes (Chen, 1978, Chen, 1983, 
Chen & Shaw, 1973, Rasheed et al., 1974).  Therefore it is plausible that two 
independent vector DNA integration events are being coupled as one, when the 
sequence data from both the left and right termini of the integrated vector in one 
individual clone comes from the same region of the same chromosome.  In the 
absence of FISH data and of individual karyotyping of the cell lines both at the start 
and the close of the experiment, a dogmatic assertion cannot be made.  The 
integration events in these clones cannot be pinpointed by the Southern data due to 
unresolved bands.  Nevertheless, the chances of two separate vector DNA integrations 
taking place in very close regions are at least 1/6x10-9 (based on the size of diploid 
human and mouse genome).  However, it has also been demonstrated that it was 75 to 
470 fold more likely for one integration event to take place in a preintegrated locus 
(Merrihew et al., 1996), and the Southern blot data from this study has shown that in 
spite of using a low moi, multiple integrations can take place in the same clone.   So it 
must be treated with caution when the results from 7 clones (4d, 6a, 7c, 7g, 17 e, 22f 
and 22k) suggest that during the course of integration of the vector, deletions ranging 
from 31 bps to 46 kb (15 kb, 47 kb, 598 bp, 237 bp, 4.5 kb, 18 kb and 31 bp, 
respectively), were observed in the chromosomal DNA.  Should that be the case, it 
would not be a novel discovery.  Deletions of up to 1.6 kb in the genomic DNA have 
been reported during integration of Wt AdV (Schulz & Doerfler, 1984).  Deletions of 
14, 24 and 567 bps (Wang et al., 2005), 21 bp and at least 20 kb (Ohbayashi et al., 
2005) in the genomic DNA have been reported during integration of HC-AdV.  In the 
first paper cited above, possible larger deletions were observed in another three 
clones, though for reasons not published, the authors had determined that the 
individual 5’ and 3’ termini interspaced by larger deletions to those mentioned above, 
found integrated in same chromosome in these three clones did not come from the 
same vector DNA molecule. 
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V.4.2 Mutations in the vector genome 
Work done on wt AdV revealed that during the process of integration, mutations 
(deletions, insertions and substitutions) did frequently occur in the viral genome, 
especially in the termini. In this present study, the vast majority (68 %) of the 
deletions took place within the first 30 bps of the termini, and 15 % had no deletions 
in the termini.  In the study by Mitani et. al, (Ohbayashi et al., 2005) 86 % (18/21) of 
the vector termini had deletions up to 30 bps and 9.5 % (2/21) had no deletions in the 
termini, whereas in the work by Lieber et. al. (Wang et al., 2005), the data from their 
first series of experiments suggest that 82 % (19/23) had up to the first 30 bps and 14 
% (3/21) had no deletions in the termini.  The evidence for the use of patchy 
homology (micro homology) between the recombination partners was evident.  This 
has been reported for wt AdV (Doerfler et al., 1984, Doerfler et al., 1989) and for HC-
AdVs (Ohbayashi et al., 2005, Wang et al., 2005).  The crucial role played by Mre 11 
and the microhomology between the recombination partners during NHEJ has been 
well established (Paull & Gellert, 2000, Roth & Wilson, 1986), and so it is plausible 
that AdV DNA too may use cellular NHEJ pathways during integration into the 
genome. 
 
V.4.3 Is HC-AdV DNA mutagenic? 
In this present study, it was observed that in 64 % of the cases, HC-AdV DNA 
integrated without causing any mutations (deletions in the termini sequences are not 
included).  However in 14.7 % of the junction sites studied, mutations were present at 
the junction site in the form of insertions or substitutions.  In 13 % of the junction 
sequences, mutations were introduced in the genomic DNA. Deletions, insertions, 
duplications and chromosomal translocations too were observed and are consistent 
with the data from wt AdV DNA integration sites where mutations in and around the 
site of integration have been reported in genomic and viral DNA (Doerfler et al., 
1984, Schulz & Doerfler, 1984). Translocations of genomic DNA were also noticed in 
integration sites of HC-AdV (Ohbayashi et al., 2005).  Transposition of genomic 
DNA in 3 extra integration sites has been observed in integration of HC-AdV-AAV 
hybrid vector DNA into chromosomal DNA, at the AAV ITR, suggesting that those 
68 bps might be involved in the amplification and transposition of the vector copies 
during DNA replication (Wang et al., 2005).   
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Such aberrations in the DNA following integration are not unique to AdV.  Deletions 
of genomic DNA, chromosomal translocation, insertion of novel DNA at the junction 
site, deletions in the vector and the association of the integration site with 
chromosomal breaks have all been reported for AAV DNA integration (McCarty et 
al., 2004, Miller et al., 2004, Miller et al., 2002, Miller et al., 2005, Nakai et al., 
1999), and HBV DNA integration (Koike et al., 1983, Mizusawa et al., 1985, Tokino 
et al., 1987, Wang et al., 2001).  During integration by HPV DNA into the 
chromosomal DNA, deletions were observed in the HPV DNA (Kalantari et al., 2001, 
Luft et al., 2001, Yoshinouchi et al., 1999), translocation of the chromosomal DNA 
observed during EBV DNA integration (Debiec-Rychter et al., 2003) and integration 
of SV40 DNA into the genome can be accompanied by deletions in both viral and 
cellular DNA (Strayer et al., 2002, Strayer, 1999, Wallenburg et al., 1987).     
In fact, the modifications of the recipient chromosomal locus and of the integrating 
DNA are all hallmarks of NHEJ.  Point mutations, deletions, concatamer formation 
and rearrangements have been observed in the integrating DNA (Calos et al., 1983, 
Wake et al., 1984, Wilson et al., 1982).  Although the integration may not change the 
locus at which the event took place (McFarlane & Wilson, 1996), rearrangements 
including deletions, duplication, insertions and translocations have been reported 
(Covarrubias et al., 1986, Covarrubias et al., 1987, Hamada et al., 1993, Kato et al., 
1986, Mahon et al., 1988, Mark et al., 1992, Robins et al., 1981, Wilkie & Palmiter, 
1987).  Stem-loop and hairpin configurations of DNA at junction sites observed in 
this present study is in agreement with the data that had been observed during studies 
on wt Ad DNA integration into chromosomal DNA (Doerfler et al., 1984, Knoblauch 
et al., 1996), other viral DNA integration into chromosomal DNA (Bullock et al., 
1984, Romani et al., 1990) and other non homologous recombination events 
(Krawinkel et al., 1986, Nalbantoglu et al., 1988, Nicholls et al., 1987).  So, it can be 
stated that, as is expected, AdV DNA behaves like any other part of free DNA and the 
NHEJ mechanism treats it like any other part of the DNA to integrate it into the 
genome. 
 
V.4.4 A small level of selectiveness during random integration by the vector DNA 
into the chromosomal DNA? 
The study carried out revealed that the integration of HC-AdV DNA in the 
chromosomal DNA took place in a random manner.  However four individual 
 168
integrations had occurred in a homology mediated manner, three in the Hprt fragment 
DNA region, and one in the c346 stuffer DNA region of the X Chr of the vector 
AdSLS 11.  However, this is in agreement with existing data.  In the experiments 
involving a HC-AdV with stuffer DNA from human Chr X (Wang et al., 2005) 2/23 
integrations were in Chr X.  Interestingly in the above paper, the clone 18/2 integrated 
in the CXorf6 gene in Chr X, 49 kb upstream of the integration site observed in clone 
4c.  However, the CXorf6 gene may not point out to any hotspot for HC-AdV 
integration, since the sequences correspond to the c346 cosmid sequences present in 
Ad SLS 11 and so it might just be coincidence that both vectors integrated 
independently in the same gene. 
 
V.4.5 Integration of HC-AdV DNA into genes 
An important question is whether HC-AdV integration takes place into genes.  
According to the latest ENSEMBL release (Aug 2006) there are 22,205 known genes 
in 3,253,037,807 bps in a human haploid genome and 21,839 known genes in 
3,377,887,556 bps in a mouse haploid genome (for more details, visit 
http://www.ensembl.org/index.html).  The average gene length is conserved in 
eukaryotes (Kiang et al., 2006) and it can be calculated that genes may account for 
333,075,000 bps (1/9) of the human genome, based on the calculation that  the 
average size of a human gene is 10-15 kb ( for more details, visit 
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hmg.table.686).  The DNA of the 
active genes is present in the unbound form and so may be more accessible to foreign 
DNA.  As reviewed in the introduction, retroviral, lentiviral and AAV gene transfer 
vectors tend to integrate in active genes.  Papillomavirus, and possibly HBV tend to 
integrate into active genes.  43.5 % (23/46) of the HC-AdV integrations had occurred 
in active genes in the study conducted by (Wang et al., 2005).  In contrast to this, 
(Ohbayashi et al., 2005) have reported that only 28 % of the 18 junction sites of the 
HC-AdV integrations look place in active genes.  The in vitro data from this study 
agrees with the former paper; 48 % (26/61) of the integrations had taken place in 
genes.  The in vivo data suggested that the rate of integration was 37.5 % (n = 8).  No 
gene of any specific ontology was targeted.  However, another 16.4 % (10/61) 
integrations had taken place within 30 kb of active genes.  Nevertheless, it is 
interesting to observe that about half of the integrations took place in noncoding 
regions of the genome, though the active genes are present in the unbound form and 
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should be more accessible to the vector.  In the paper by (Ohbayashi et al., 2005), 44 
% (8/18) of the integrations had taken place within this frame, though only 28% had 
actually integrated into active genes.  In contrast to the data by (Wang et al., 2005), no 
integrations were observed in oncogenes.  The rate of integration of HC-AdV DNA 
into the chromosomal DNA is low compared to retroviral vectors and AAV vectors, 
and of those vector molecules that do integrate, only half of them integrate in genes.    
In other viral vector gene transfer systems in use, the rate of integration of the vector 
DNA into genes are much higher and the overall rate of integration of the vector DNA 
into the chromosomal DNA too is much higher than the rate of integration of HC-
AdV vector DNA into the genome. Taken together it can be concluded that HC-AdV 
shows less predisposition to integrate into genes than the other vector systems 
currently in use.  But data from more integration sites such as those published in (Wu 
et al., 2003) and (Mitchell et al., 2004) would be necessarybefore a dogmatic assertion 
can be issued about the chances of HC-AdV vector DNA integration in to genes.  
Though a read-through from the transgene through the gene where the 
integration has taken place, as in the case of retro and lentiviral vectors is unlikely due 
to the presence of the poly A in the HC-AdV construct, it may still be a reason for 
concern.  Perturbations of genome wide methylation patterns have been reported with 
wt AdV integration (Heller et al., 1995, Remus et al., 1999). Since promoter 
methylation can result in variations of gene expression (Bestor, 1998), this may have 
adverse results during the integration in and around active genes.  The limited 
promoter and enhancer activity of the ITR of certain Ad types have been published 
(Hatfield & Hearing, 1993, Matsumoto et al., 1989, Miralles et al., 1989, Xing & 
Tikoo, 2005).  It would be very interesting to investigate if the insertion of HC-AdV 
DNA at or near a gene can cause fluctuations in the gene expression.     
 
V.5 HC-AdV DNA recombination into chromosomal DNA in vivo 
As of date, this study furnishes the first proof of random integration and homologous 
recombination of HC-AdV DNA into chromosomal DNA in vivo.  There have been 
publications that on injecting 5x109 PFU of Ist gen AdV via tail vein, 14-28 copies 
were present per hepatocyte (Vrancken Peeters et al., 1996), and after and injection of  
2x109 PFU, 1-100 copies were present in the hepatocyte nuclei, with an average of 20 
copies (Schowalter et al., 1997).  This is contradictory with the data from this study, 
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where 10 copies reached the liver following an injection of 1x1010 infectious units of 
HC-AdV.  In the papers mentioned above FISH using the vector plasmid was carried 
out to determine the number of vector genomes per hepatocyte, and in the present 
study, slot blot procedure was used to calculate the amount of vector DNA reaching 
the hepatocytes and this could be one of the reasons for the differences in the results.  
The differences in the results could also be due to the differences in the methods in 
which the experiments were carried out. 
Every effort was made to be certain that when measuring the rate of random 
integration of the vector into the genome, only nodules resulting from an integration 
(circular, spherical shape) were counted.  This may have resulted in some genuine 
cases of integration that did not have the “correct” shape to be discarded as a clump of 
Fah+ cells.  It is quite possible that in some cases, the microtone had sliced off the 
nodule just at the top, leaving a few Fah+ve cells, that were not counted as an instance 
of HC-AdV integration.  However, it was better to err on the side of caution and as of 
date, this mouse model has the best phenotype that can be used in such an 
investigation.  The rate of random integration of HC-AdV DNA into the chromosomal 
DNA in vivo was calculated as 4x10-5 and the rate of homologous recombination of 
the vector DNA into the genome as 5.6x10-7.  Though serial transplantion of the 
corrected hepatocytes resulted in sufficient expansion so as to enable the sequencing 
of the junction sites, the sensitivity of the experiment had to be sacrificed.  More 
cycles of serial transplantion may finally result in single clonal repopulation of the 
liver, enabling the use of Southern blot experiments, but until then PCR must suffice 
to provide the evidence for the homologous recombination.  As of date, no proof has 
been presented about the rate of homologous recombination of Ist Gen AdV in vivo 
(Ino et al., 2005), though integration of the vector has been shown (reviewed in the  
introduction).  The limited data obtained from the junction sites suggest that the 
nature of integration of the HC-AdV DNA into chromosomal DNA in vitro is no 
different from that in vivo, with the same indifference to integration into genes, and 
with the introduction of mutations into the vector and chromosomal DNA.  Large 
mutations (such as chromosomal translocations and large deletions) were not 
observed in the integration sites in the work done in vitro. 
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V.6 Synopsis 
Taking everything in account, it is very tempting to propose that a picture is starting 
to emerge of HC-AdV integration into the genome. The TP might play a role in 
protecting the Adenoviral DNA termini and when broken DNA fragments are present, 
the NHEJ repair apparatus of the cell might treat the HC-AdV as any other fragment 
of cellular DNA and start the mechanisms ending in the integration of the vector into 
the genome. 
 Though Ad 12 has been implicated in the formation of tumours in rodents, 
Ad5 has not displayed any tumorigenic tendencies so far. The expression levels of of 
MHC class I (Nielsch et al., 1991), peptide transporter Tap-2, chaperone Tapasin, and 
the immunoproteosome complexes MECL-1, PA28-α, and PA28-β (Vertegaal et al., 
2003) were observed to be highly suppressed in Ad 12 than in Ad 5, and this may be 
one of the reasons contributing to the oncogenic potential of Ad 12.  In any case, the 
HC-AdV used in the current study is based on Ad 5 and so there is only low concern 
regarding the oncogenic potential with vectors based on this serotype.  
 So, from all of the data presented in the study, it has been demonstrated HC-
AdV does not remain only as an episome, it rarely integrates in vitro and in vivo in the 
genome.  Yet, of all the gene therapy viral vector systems that are currently available, 
it seems to be the safest option, seemingly unaffected by the presence of genes in the 
target DNA.  The mutations observed during the integration are to be expected in any 
case of NHEJ repair of DNA, and the viral vector, by itself, does not seem to induce 
any of them.  No evidence was observed for any preferred integration into potentially 
dangerous genes such as oncogenes, tumour supressors or those involved in the cell 
cycle.  To conclude, no signs of great risks due to HC-AdV vector DNA integration 
into the chromosomal DNA, compared to those posed by the other viral gene transfer 
vector systems currently in use, were detected during this work and this thesis 
suggests that HC-AdV may have potential to be a safe gene transfer vector system of 
low mutagenicity. 
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VI Outlook 
 As of date, this work is the first instance where HC-AdV integration in vivo 
has been well characterised and has the largest number of junction sequences of HC-
AdV in vitro.  It would be very interesting to see the characteristics of HC-AdV 
integration in primary cell lines.  The 1 moi /cell used in this study may not be 
feasible in real clinical gene therapy and so it would be worth examining the rates and 
nature of HC-AdV integration at much higher mois. 
 The rate of integration of the vector is not as high as that reported for other 
gene therapy vectors, but to establish this, it is essential to calculate the exact amounts 
of targeting molecules reaching the nucleus following transfection and then to 
compare the rates of recombination and integration following HC-AdV infection and 
transfection of the plasmid in the same cell line.  The role of the TP in the integration 
could also be examined in this study. 
 According to the current knowledge, the HC-AdV utilises the cellular repair 
pathway to undergo homologous recombination or random integration into the 
genome.  This could be further characterised and the effects of the key gene products 
on the rate and nature of integration can be examined. 
 Though the current work indicates that HC-AdV integrates without resulting 
in large deletions in the genomic DNA, to state dogmatically that HC-AdV integrates 
either with or without deletions in the genomic DNA, FISH of the cellular genome of 
the clones is a necessity.  Maybe the future work in the field could utilize the 
technique. 
 Following a single or double rounds of serial transplantation of the transduced 
hepatocytes into recipient subjects, it was possible to isolate the Ad-mouse junction 
sites.  However, the number obtained in this study was not sufficient for detailed 
statistical analysis of the results.  So it would be interesting, from a point of clinical 
gene therapy, to obtain more junction sites and also try to serially transplant the 
FAH+ve hepatocytes for more rounds, untill the repopulation of a liver from a single 
integration event can be obtained. 
 To conclude, the advantage of the HC-AdV viz that it does not seem to be as 
predisposed as other viral vector systems to integrate into the genome is also its bane.  
So it would be worthwhile to develop methods of making the vector more suitable so 
as to make it conform to the idea of the ideal gene therapy vector: to make the vector 
 173
undergo homologous recombination at the exact location in the genome where the 
researcher wants it to.  The knowledge in the pathways of integration and homologous 
recombination can be utilized for this.  If the vector can be made to undergo a much 
higher rate of homologous recombination in vivo, for example, by cloning cassettes 
expressing those genes outside the region of homology in the vector, then it can be 
used in the treatment of inherited genetic diseases and indeed can come closer to 
becoming the ideal vector for gene therapy. 
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VII.1 Summary 
Gene therapy trials using adenoviral vectors for gene delivery are currently underway. 
A clinical trial based on retrovirus-mediated gene transfer resulted in the development 
of leukaemia in some of the subjects due to insertional mutagenesis. This experience 
highlights the importance of an evaluation of the biosafety of gene transfer vectors 
prior to their use in humans. The overall aim of this research was to quantitatively and 
qualitatively analyse recombination between vector DNA and chromosomal DNA in 
vitro and in vivo following HC-Ad vector-mediated gene transfer.  
To study the rates, at which HC-AdV DNA underwent homologous recombination 
with chromosomal DNA following gene transfer in vitro, the Hprt model, a classical 
system in recombination studies, was utilized.  A vector was designed to target exon 2 
of the human Hprt gene by introducing a stop codon upon homologous 
recombination. In these experiments, which were performed in primary cells and in 
established cell lines, the frequency of homologous recombination of the HC-AdV 
DNA with the HPRT locus was found to be, depending on the cell type, between 
2x10-5 to 1.2x10-6. In a different set of experiments and using a selection marker 
strategy, the rate at which HC-AdV DNA integrated randomly into the chromosomal 
DNA was determined to be between 5.4x10-3 to 1.1x10-4. 
To more closely mimic the situation following therapeutic gene transfer, in vivo 
experiments were performed. The use of the FahΔexon 5 knockout model allowed to 
study homologous and heterologous recombination events following in vivo gene 
transfer to the liver. Correction of the pathological phenotype was achieved either by 
targeting exon 5 with an HC-AdV carrying a 12.3 kb targeting sequence (homologous 
recombination) or by measuring integration frequencies following gene transfer with 
an HC-AdV expressing the FAH cDNA (heterologous recombination). The targeting 
frequency of exon 5 was estimated to be 5.6x10-7, and the rate of random integration 
was found to be 4x10-5.  This study is the first to document evidence of recombination 
between HC-AdV DNA and chromosomal DNA in vivo.   
The analysis of the vector integrates following transduction of primary cells and cell 
lines indicated that HC-AdV DNA integrated as an intact molecule and via the termini 
in most cases.  About half of the vector DNA integrations took place inside genes and 
none were observed in protooncogenes.  Analysis of the junction sequences suggested 
that the HC-AdV DNA had integrated in a random manner throughout the genome 
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without an obvious preference for any particular chromosomal regions. Patchy 
homologies between the vector termini and the chromosomal DNA were observed at 
the site of integration.  Though the majority of the integrations had occurred without 
causing any mutations in the chromosomal DNA, cases of substitutions and insertions 
of nucleotides too were observed.  This study has established quantitative data on in 
vitro and in vivo recombination frequencies of adenoviral vector DNA with genomic 
DNA and has provided a molecular characterization of observed integration events. 
These results may contribute to a risk-benefit assessment of adenovirus-mediated 
gene transfer. 
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VII.2 Zusammenfassung 
Gentherapieversuche mit adenoviralen Vektoren befinden sich zurzeit in der 
klinischen Testphase. Nach Retrovirus-vermitteltem Gentransfer kam es bei einigen 
Probanden durch Insertionsmutagenese zur Entstehung von Leukämien. Diese 
Erfahrung unterstreicht die Bedeutung präklinischer Untersuchungen zur biologischen 
Sicherheit von Gentransfervektoren. Zielsetzung der vorliegenden Arbeit war die 
quantitative und qualitative Analyse von Rekombinationsereignissen  zwischen 
Vektor und chromosomaler DNA in vitro und in vivo nach HC-Ad Vektor-
vermitteltem Gentransfer. 
Zur Bestimmung der Häufigkeit homologer Rekombination zwischen HC-Ad Vektor 
DNA und chromosomaler DNA wurde das häufig in Rekombinationsstudien 
eingesetzte HPRT-Selektionsmodell verwendet. Ein adenoviraler Vektor wurde 
konstruiert, der das menschliche HPRT Gen durch Einführung eines Stop Codons in 
Exon 2 mittels homologer Rekombination inaktivierte. In primären Zellen und in 
etablierten Zellenlinien wurden zelltypabhängig Häufigkeiten homologer 
Rekombination zwischen 2x10-5 bis zu 1,2x10-6 ermittelt. Die Frequenz zufälliger 
Integrationsereignisse wurde durch HC-Ad Vektor-vermittelte Zelltransduktion unter 
Verwendung eines Selektionsmarkers ermittelt und lag innerhalb eines Bereiches von 
5,4x10-3 und 1,1x10-4. 
Zur besseren Nachahmung der klinischen Situation wurden in vivo Experimente in der 
Labormaus durchgeführt. Die Verwendung des FahΔexon 5 Modells erlaubte die 
Untersuchung homologer und heterologer Rekombinationsereignisse nach in vivo 
Lebergentransfer. Die Korrektur des pathologischen Phenotyps wurde erreicht 
entweder durch das Targeting von Exon 5 mit einem HC-Ad Vektor, der eine 12.3 kb 
Targetingsequenz trug (homologe Rekombination) oder durch Bestimmung der 
Integrationshäufigkeit nach Gentransfer mit einem die FAH cDNA exprimierenden 
HC-Ad Vektor (heterologe Rekombination). Die Targetinghäufigkeit des Exon 5 
wurde mit 4,6x10-7  bestimmt, die Häufigkeit der zufälligen Integration mit 4x10-5. 
Dies ist die erste Untersuchung, die in vivo Rekombination zwischen HC-Ad Vektor 
DNA und chromosomaler DNA dokumentiert. 
Analyse der Vektorintegrate nach Transduktion von primären Zellen und von 
Zelllinien ergab, dass in den meisten Fällen die HC Ad-Vektor DNA als intaktes 
Molekül und über die viralen Enden integrierte. Ungefähr die Hälfte der 
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Integrationsereignisse fand innerhalb von Genen statt. Keine Integration wurde in 
Protoonkogenen beobachtet. Die Analyse der Junktionssequenzen ergab, dass die HC-
Ad Vektor DNA zufällig im Genom integrierte und ohne offensichtliche Präferenz für 
bestimme chromosomale Regionen. Am Ort der Integration wurden häufig 
Mikrohomologien zwischen den Vektorenden und der chromosomalen DNA 
beobachtet. Obwohl die meisten Integrationen nicht zu Mutationen in der 
chromosomalen DNA führten, wurden einige Fälle von Nukleotidsubstitutionen und 
Insertionen beobachtet.  
In dieser Untersuchung wurden quantitative Daten bezüglich der Häufigkeit von in 
vitro und in vivo Rekombination zwischen adenoviraler Vektor DNA und 
genomischer DNA erhoben und die Integrationsereignisse wurden auf molekularer 
Ebene charakterisiert. Diese Ergebnisse tragen zu einer Risiko-Nutzen Abwägung 
nach Adenovirus-vermitteltem Gentransfer bei. 
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